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Abstract 
20S proteasomes are large, multisubunit complexes that display a number of different peptidase 
activities. A series of di- and tripeptidyl boronic acids were shown to be t1ght-binding 
inhibitors of the liver 20S proteasome chymotrypsin-like activity. Time course experiments 
suggested that these peptidyl boronic acids cause inhibition of the chý'motrypsin-like activity 
through an apparent slow-binding mechanism. Other liver 20S proteasome activites e. g. 
trypsin-like and PGPH were also inhibited to a lesser extent. Inhibition of 20S proteasome 
activities by peptidyl boronic acids was slowly reversed during dialysis. Kinetic studies showed 
that inhibition of the chymotrypsin-like activity only followed ideal competitive behaviour, 
between 0 and 2-3xKi inhibitor concentrations. Ki values determined over these inhibitor 
concentrations, were between 15 and 120 nM for the most effective peptidyl boronic acids. 
These included peptidyl boronic acids containing Phe-boroLeu or Leu-boroLeu structures e. g. 
Bz-Phe-boroLeu and Cbz-Leu-boroLeu. Tri-leucine peptidyl boronic acids were shown to be 
the most effective inhibitors of the liver 20S proteasome trypsin-like activity. Spleen 20S 
proteasomes are predominantly assembled with EFN-y-inducible catalytic subunits whereas liver 
20S proteasomes are constructed with a mixture of constitutively expressed and IFN-y- 
inducible catalytic subunits. Broadly sirrular effects were observed when the peptidyl boronic 
acids were tested with spleen 20S proteasomes. The most effective inhibitor of the 20S 
proteasome chymotrypsin-like activity, Bz-Phe-boroLeu, was also shown to potently inhibit 
the chymotrypsin-like activity of 26S proteasomes and 20S proteasomes activated with 0.02% 
SDS. Peptidyl boronic acids were found to cross the plasma membrane of cultured human or 
mouse cells. Because of the slow release of bound inhibitor from 20S and 26S proteasomes, 
it xvas possible to demonstrate their inhibition in immunoprecipitation experiments. 20S 
proteasornes, but not 26S proteasomes, remained inhibited following gel filtration of an extract 
prepared from cells treated with a peptidyl boronýic acid. IC50 values for the chymotrypsin-like 
activity of 20S or 26S proteasomes immunoprecipitated from cells treated with peptidyl 
boronic acid, were similar to the Ki values determined for the same activity of purified 20S 
proteasomes. 
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Chapter I- Introduction 
Chapter I 
Introduction 
1.1 - Protein degradation 
The breakdown of short-lived, long-lived and abnormal/misfolded proteins occurs within all 
organisms. Degradation of proteins is an essential process that removes damaged and 
misfolded proteins. The selective degradation of proteins is also IMPortant for effective control 
of cellular metabolism. For example B-type cyclins bind to and modulate the activity of cyclin- 
dependent protein kinases. These cyclins are degraded during the metaphase-anaphase 
transition of the cell cycle before accumulating in the S and G2 phases (Brandeis & Hunt, 
1996). Protein degradation is thought to occur in all cellular compartments. The predorninant 
pathway in the cytosol and nucleus is known as the ubiquitin-proteasome pathway. UbIquItin 
is a 76 amino acid protein found in eukaryotic cells (Hilt & Wolf, 1996). Attachment of 
multiple ubiquitin chains to substrate proteins marks them for degradation by the 26S 
proteasome (Wilkinson, 1995; Rock et al., 1994). ATP hydrolysis is required to drive the 
degradation of proteins by the 26S proteasome and substrates for the pathway include the cell 
i and the tumor suppressor protein p5' cycle regulators Mos, the retinoblastoma (Rb) protem 1 -1 
(Ishida et al., 1993, Boyer et al., 1996, Dietrich et al., 1996). Regulators of transcription and 
signal tranduction are also degraded by this pathway for example, the Ga protein, protein I 
kinase C-(x, the MAToC repressor, Gcn4, c-Jun, c-Fos and STAT I (Hilt & Wolf 1996; Lee 
et A, 1996, Tsurumi et al., 1995, Fuchs et al., 1996; Kim & Maniatis, 1996). 
The substrate proteins are cut progressively, yielding 6-12 an-ýno acid peptides. These 
peptides are thought to be hydrolysed to amino acids by exopeptidases (Mitch & Goldberg, 
1096). S-9 arruno acid peptides displaying) C-terrrunal hydrophobic or basic residues, are also 
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transported into the endoplasmic reticulum for expression on MEC class I molecules (Joyce 
et al., 1994; Gaczynska et al., 1993). Recent studies have suggested that the MF-KB p105 
--Y*%, e 
the mature p5O precursor protein is co-translationally processed by the 26S proteasome to c 
subunit (Lin et al., 1998b). It was not clear whether ubiquitin played any role in this reaction, 
that may be required for the precursor processing of other proteins. 
Non-ubiquitinated proteins can also be degraded by the 26S proteasome. The best 
characterised example of this is the degradation of ornithine decarboxylase (ODC), a key 
enzyme in polyamine biosynthesis. Polyarnines induce the synthesis of the protein antizyme 
that inhibits ODC. The association of antizyme with ornithine decarboxylase stimulates the 
degradation of ornithine decarboxylase by the 26S proteasome (Hayashi & Murakami, 1995, 
Li. et al., 1996b). The N- and C-terminal regions of antizyme were proposed to be important 
for interacting with 26S proteasomes and ornithine decarboxylase respectively. 
1.2 - Ubiquitination of proteins 
Attachment of ubiquitin molecules to substrate proteins requires the action of three types of 
enzyme. EIub iqu itin- activating enzymes catalyze the formation of a thiol ester between the 
C-tet-minus of ubiquitin and a cysteine residue of the EI enzyme. This reaction requires the 
expenditure of one ATP (Wilkinson, 1995). E2 ubiquitin-conjugating enzymes catalyse the 
transfer of ubiquitin from EI to a cysteine residue on the E2 protein. Some larger E2 enzymes 
catalyse the direct transfer of ubiquitin to the substrate protein or growing ubiquitin chain. In 
other cases an E3 ubiquitin-ligase assists the transfer of ubiquitin from the E2 enzyme to the 
substrate protein (Wilkinson, 1995). The covalent linkage of ubiquitin molecules in 
polý, ubiqtiitin chains is usually through the C-ternunal carboxyl group of one ubiquitin and the 
1) 
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F, -amino group of Lys-48 on the next ubiquitin. Human E2EPF -was shown to catalyze the 
formation of Lys- II linked polyubiquitin chains, in the presence or absence of an E3 ligase 
(Baboshina & Haas, 1996). tn the absence of E3 ligase, the yeast E2 enzyme RAD6 catalysed 
the formation of Lys-6 linked multiubiquitin chains on the substrate protein histone HIM. In 
the presence of E3 ligase and using bovine serum albumin as substrate, the linkage specificity 
was shown to change fi7om Lys-6 to Lys-48. Hence linkage specificity for some E2 enzymes 
is sub strate/co -factor dependent. 
Ubiquitin carboxy-terminal hydrolases (UCHs) cleave ubiquitin from e. g. peptides, lysine, 
glutathione or small proteins. Ubiquitin-specific processing proteases cleave ubiquitin groups 
from ubiquitinated proteins. Both classes of enzyme catalyze the disassembly of polyubiquitin 
chains (Wilkinson, 1995; Wilkinson, 1997). The UCH enzymes cleave the covalent bond 
between the undegraded peptide and the C-temunus (proXiMal end) of the polyubiquitin chain 
(Hochstrasser, 1995; Wilkinson, 1995). Ubiquitin- specific processing proteases e. g. Ubp I 4p 
in yeast or isopeptidase T in mammalian cells, then release single ubiquitin. molecules from the 
proximal end of the ubiquitin chain (Wilkinson, 1997). 
1.3 - The 20S proteasome - the catalytic core of the 26S proteasome 
The -16S proteasome is a 
large multisubunit complex which is constructed from the 20S 
proteasome and two 19S regulatory particles that fit onto the ends of the 20S proteasome 
(Demartino et al., 1996). The 20S proteasome is a 700 kDa complex, composed of four 
seveii-membered subunit rings. These rings are stacked together to form a barrel-shaped 
StRICtUre approximmely II ni-n in diameter and 15 nm in length (Hegerl et al., 1991 -. Wenzel 
tX., Baunicister, 1995. Kopp et al., 1995). The Thermoplasma acidophilum 20S proteasorne is 
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composed of two subuffits. The molecular masses of the cc and P subunits are 26 and 231 kDa 
respectively. Immuno-electron nucroscopy in conjunction with subunit- specific antibodies, 
have been used to show that the outer protein rings of the proteasome are composed of (x- 
subunits. The two juxtaposed inner rings are composed of P-subunits (GrzIwa et al., 199 1). 
The central channel of the 20S proteasome has three large cavities. Two of the mities are 
located at the interface between the ot and 0 rings, and the third is between the 0 rings (Lbwe 
et al., 1995). The minimum diameter of the cavity is 13A which means that only unfolded 
polypeptides can pass through the channel. 
Thermoplasma (x-subunits expressed in the absence of P subunits, spontaneously form into 
heptameric rings that did not possess peptidase activity (ZwIckl et al., 1994). Loose 
aggregates of mature 0 subunits, expressed in the absence of (x subunits, were shown to exhibit 
moderate peptidase activity compared to 20S proteasomes. P precursor proteins expressed 
in the absence of u-subunits exhibited virtuaRy no proteolytic actiVity. Hence it was proposed 
that autocatalytic processing of the P-subunits occured during 20S proteasome assembly. 
This would ensure that the catalytic activity of the P-subunits was not activated, until the 
proteasome was assembled (Zwlckl et al, 1994). 
1.3.1 - The structure of eukaryotic 20S proteasomes closely resembles prokaryotic 20S 
proteasomes 
Yeast 20S proteasomes are composed of 14 different subunits that have molecular weights of 
10-'14 kDa (Heinemeyer et al., 1994). These subunits are encoded by genes of a single gene 
family The subunits can be divided into two groups, based on their similarity to the 
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archaebacterial (x or 0 subunits. The two outer rings of the complex are composed of a-type 
subunits. The two juxtaposed inner rings of the complex are composed of P-type subunits 
(Groll et al., 1997). Figure I. IA shows the arrangement of subunits in the yeast 20S 
proteasome. Higher eukaryotic organisms express 7 ot-type and 10 P-type subunits with 
molecular weights of 20-34 kDa (Hilt & Wolf, 1996; Hisamatsu et al., 1996). Figure 1.1 B 
shows the arrangement of subunits in the human 20S proteasome. The expression of the 
mammalian 0 subunits LNT2, LNW7 and MECLI is upregulated by the cytokine IFN-y 
(Hisamatsu et al., 1996). Several studies have shown that increased expression of IFN-y 
inducible subunits, causes a greater proportion of these subunits to be incorporated into iiew 
20S proteasomes (Hisamatsu et al., 1996; Froh et al., 1994; Akiyama et al., 1994; Belich et 
al., 1994). This occurs at the expense of three constitutively expressed P-subunits Y/6, 
X/MB I and Z, that exhibit a high degree of identity to the LFN-y inducible subunits. 
Experimental data did not suggest that IFN-y directly suppressed the expression of the 
constitutive proteins. Instead it was proposed that the IFN-y inducible subututs were 
preferentially incorporated into newly synthesiZed 20S proteasomes (FrUh et al., 1994; Belich 
et al., 1994). 
The crystal structure of the yeast 20S proteasome shows the entrance to the inner chambers, 
being blocked by the N-ternunal regions of five a-type subunits al/C7, a2/Y7, O/YI3, 
ot6/PRE5 and O/C 1. Substantial movements of these subunits were proposed to be required 
for entry of unfolded polypeptides (Groll et al., 1997). These movements may occur during 
the ATP-dependent attachment of regulatory particles to the ends of the 20S proteasome. 
N ai-roN\ (-10. diameter) openings in the side of the complex, particularly near the Interface 
between the ct- and were observed. Small pept'de substrates and longer unfolded 
polypeptides may gain access to the catalNiic sites through these entrances (Groll et al, 1997). 
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Figure 1.1 - Arrangement of subunits in yeast and human 20S proteasomes 
Panel A illustrates the arrangement of subunits in yeast 20S proteasomes determiried through 
the crystallisation of the complex. The figure was reproduced from the report of Groll et al. 
(1997). Panel B illustrates the arrangement of subunits in human 20S proteasomes as 
determined by Kopp et al. (1997) and Dahlmann et al. (1999). The IFN-y inducible subunits 









1.4 - Peptidase activities of 20S proteasomes 
Fluorogenic peptide substrates have been used to investigate the catalytic activites of 
eukaryotic, 20S proteasomes. Degradation of peptide substrates by 20S proteasomes occurs 
in an ATP-independent manner. Distinct activities responsible for cleavage on the carboxyl 
side of basic (e. g. Arg), hydrophobic (e. g. Leu, Tyr and Phe) and acidic (e. g. Glu) arnino acids 
were initially identified. These activities were referred to as trypsm-fike, chymotrypsin-like and 
peptidylglutamyl-peptide bond hydrolase (PGPH) activities respectively (Table 1.1) (Wilk & 
Orlowski, 1980; Rivett et al., 1994). The archaebacterial 20S proteasome also catalyses the 
hydrolysis of chymotrypsin-like, trypsin-like and PGPH substrates (Akoplan et al., 1997). 
Further eukaryotic 20S proteasome activities were subsequently characterised (Table 1.1). 20S 
proteasomes isolated from rat liver were shown to possess two distinct PGPH activities when 
assayed with Cbz-LLE-0-naphthylamide (NAP) (Djaballah & Rivett, 1992). The higher- 
affinity LLE I activity (assayed with 0-0.1 mM Cbz-LLE-NAP), was shown to obey Nfichaelis- 
Menten kinetics with a K.. value of approx. 100 ýM. The lower-affinity LLE2 activity 
(assayed with 0.4-0.6 mM Cbz-LLE-NAP) exhibited sigmoidal kinetics. This could be 
explained either by allosteric activation of the proteinase at a second site or the involvement 
of multiple catalytic sites which display positive cooperativity. The two activities could be 
ditTerentiated by their response to KC1, selected dIvalent metal ions, the proteasome Inhibitor 
3,4-dichloroisocouniarin (DCI) and heat treatment. 
The existence of both acidic and neutral chymotrypsin-like activities was shown for bovine 
pituitary '_OS proteasomes (Figu eiredo -Pereira et al., 1995). The cleavage of most 
chytilotrypsin-like substrates e. (-,. Suc-LL\Y-, AI, \IC occurs optimally at a neutral or slightl\ 
[)ýislc pli. The cleavage of the substrate Boc-%E. NL- NAP at the L-NA bond vvas shown to 
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occur optimally at pH 5.5 and 45'C The two chymotrypsin-like activities could be 
differentiated by their responses to sodium and calcium ions and selected proteasome Inhibitors 
e. g. Cbz-GGL-al. 
Two other chymotrypsin-like activities have been described for bovine pituitary 20S 
proteasomes (Orlowski et al., 1993). The first of these activities was named 'branch-chain 
amino acid preferring' (BrAAP) that preferentially cleaves on the carboxyl side of branched 
chain amino acids e. g. leucine. The BrAAP activity was stimulated by DO that inhibits the 
chymotryp si n- like activity. The second activity, named 'small neutral anuno acid preferring' 
(SNAAP) preferentially cleaves on the carboxyl side of small neutral amino acids e. g. glycine 
and alanine. This activity was not inhibited by the aldehyde inhibitors chymostatin and Cbz- 
LLF-al but was inhibited by DO and N-ethylmaleirnide. Further work showed that the identity 
of the residues preceding the cleavage site e. g. third (M) residue from the cleavage site, 
regulates the passage of a substrate to a particular chymotryp si n- like active site (Cardozo et 
al., 1994). Cardozo and coworkers (1996) showed that the BrAAP actiVity caused hydrolysis 
of substrates on the carboxyl side of Pro and Glu residues. The cleavages were assigned to 
the BrAAP activity on the basis of inhibition by the BrAAP inhibitor Cbz-GPFL-al, 
competition by a BrAAP substrate and activation of both cleavages by DCI. These results 
show that the BrAAP activity exhibits a broad PI specificity. 
9 
Chapter I 
Table 1.1 - Peptidase activities of the 20S proteasome 






Acidic chymotrypsin-like Boc-VEAL-NAP 
Branch-chain amino acid preferring (BrAAP) Cbz-GPAL-G-pAB 
Cbz-GPAL-A-pAB 
Abz-GPAL-A-Nba 






Peptidylglutamyl peptide hydrolase (PGPH) 
Cbz-LLE-NAP 
LLE I activity 
Cbz-LLE-pNA 
_V 




Abbreviations: Suc, N-succinyl; ANIC, 7-amino-4-methylcoumarin; Cbz, benzylox-), carbonyl; 
, pAB, p nobe oate pN, 
A, p-nitroanifine, Boc, tert-butoxycarbonyl, NAP, naphthylarrude, -ami nz 
Abz, 2-aminobenzoyl; Nba, 4-nitrobenzylarmde; SBzl, thiobenzyl. 
The hydrolysis of the leaving group in these substrates is generally monitored by measuring the 
fluorescence of the solution at defined excitation and emission wavelengths or through a 
diazotization procedure (FLivett et al., 1994; Orlowski et al., 1993). Cleavage of the pAB 
group in the BrAAP and SNAAP substrates is usually very slow unless an amiinopeptidase e. g. 
aminopeptidase N is present in the assay solution. 
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1.5 - Protease inhibitors have been used to gain a greater understanding of the 20S 
proteasome activities 
A variety of protease inhibitors and effectors have been employed to study 20S proteasome 
activities. In one of the first studies on 20S proteasomes a number of compounds e. g. p- 
chloromercurib enzo ate, N-ethylmaleimide, iodoacetanude and inorganic salts such as ZnC12 
and NaCl caused inhibition of peptidase activities (Wilk & Orlowski, 1980). Most of these 
compounds caused inhibition of the chymotrypsin-like activity vAth some inhibiting the trypsin- 
like and PGPH activities. Similar results were obtained in other studies using e. g. palnutic acid 
but these inhibitors were used at millimolar concentrations and gave no clear indication of the 
number or type of catalytic sites being affected (Orlowski & Mchaud, 1989; Dahlmann et al., 
1985). A number of senne protease inhibitors were tested against mammalian 20S proteasome 
activities. One of these was 3,4-dichloroisocoumarin (DCI) that causes irreversible inhibition 
of serine proteases e. g. human leukocyte elastase, cathepsin G and human factor D (Harper 
et al., 1985). Several studies showed that DO was most effective at inhibiting the 
chymotrypsin-like activity measured with the substrates Cbz-GGL-pNA, Cbz-GGF-pNA, 
AAF-AMC or Suc-LLVY-AMC (Table 1.2; pages 16 and 17) (Orlowski & Nfichaud, 1989, 
Cardozo et al., 1992; Orlowski et al., 1993-, Orlowski et al., 1997; DjabaHah et al., 1992). The 
SN. -kAP, trypsin-like and PGPH actiVities of 20S proteasomes were inhibited using suitable 
concentrations of DCI (Orlowski et al., 1993; Orlowski et al., 1997). Low concentrations of 
DCI sometimes caused stimulation of the trypsin-like and PGPH activities (Djaballah et al., 
1992, Oi-loxvski et al., 1993). For example 20 ýM DCI stimulated the hydrolysis of 0.1 mM 
Cbz-LI E-NAP (Djaballah & Rivett, 1992). Stimulation of these activities could result from 
inhibition of one type of catalytic site, causing conformational changes that stimulate the 
actkity at other sites. DO N\,, as also shown to stimulate the BrAAP activity of bovine pituitary 
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proteasomes (Orlowski et al., 1993). 
Relatively high (5 mM) concentrations of the serine protease inhibitor dilsopropyl 
fluoroPhosphate (DFP), inhibited the chymotrypsin-like activity of 20S proteasomes measured 
with the Cbz-GGL-pNA and Suc-LLVY-AMC substrates (Orlowski & Michaud, 1989, 
Djaballah et al., 1992). This irreversible inhibitor was also proposed to inlýiibit the trypsin-like 
and PGPH activities in one study (Djaballah et al., 1992). These results are in contrast to 
Mason (1990) who proposed that 25 mM DFP did not inhibit the Cbz-GGR-AMC actiVity of 
liver 20S proteasomes. 
Peptidyl chloromethanes and peptidyl diazomethanes irreversibly inhibit serine or cysteine 
proteases by modifying active site residues (Table 1.2) (Mason, 1990). YGR-CH2Cl was 
found to be an effective inhibitor of the liver 20S proteasome chymotrypsin-like and trypsin- 
like activities (Reidlinger et al., 1997). AAF-CH2CI and Cbz-FGY-CfIN2were shown to 
'no aci inhibit the 20S proteasome chymotrypsin-like activity. Other aml id combinations gave 
rise to less effective inhibitors (Savory et al., 1993; Mason, 1990). It was observed that either 
YGR-CH2CI or AAF-CH2Cl inhibited the hydrolysis of the chymotrypsin-like substrate Suc- 
LLVY-AMC, to a much greater extent than AAF-AMC using either liver 20S or 26S 
proteasomes (Reidlinger et al., 1997). This effect was also observed in another report 
investigating the antitumor drug Aclacinomycin A (Figueiredo-Pereira et al., 1996). 
fl \cLicinoinycin ., \ (100 ýiM) inhibited the 
20S proteasome chymotrypsin-fike activity measured 
with Sue LLVY-AMC or Cbz-EE. AL-pNA by 36% and 45% respectively. The hydrolysis of 
another chymotrypsin-like substrate Cbz-GGL-pNA was inhibited by 26% using the same 
concentration of -Aclacinomycin A (Figueiredo-Pereira et al., 1996). These differences in 
inhibition ilia), indictate that each chymotrypsin-like substrate is hydrolysed to some extent by 
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other catalytic sites. The nature of the P2, P3 and P4 residues as well as PI will affect -,,, -hich 
catalytic site(s) predon-iinantly hydrolyse the substrate (Stein et al., 1996). 
1.5.1 - Peptidyl aidehydes are effective inhibitors of 20S proteasome activities 
Peptidyl aldehydes have proved to be one of the most effective classes of 20S proteasome 
inhibitor. In one study Cbz-PGAL-al was shown to be the most effective inhibitor of the 
chymotrypsin-like actiVity measured with the Cbz-GGL-pNA substrate (Vinitsky et al., 1994). 
The Ki value for inhibition of this activity was 16.4 ýM with corresponding Ki values of 36.7 
ýM for the SNAAP activity (cleavage of Cbz-GPAGG-pAB at the G-G bond) and 104 ýM 
for the BrAAP activity (cleavage of Cbz-GPALG-pAB at the L-G bond). Another inhibitor 
Cbz-GPFL-al was most effective against the BrAAP and SNAAP activities with Ki values of 
1.5 and 2.3 ýM respectively. Ac-LLn-L-aI or Cbz-LLnV-al effectively inhibited the rabbit 20S 
proteasome chymotrypsin-like and PGPH activities (Rock et al., 1994). The Ki values for 
inhibition of Suc-LLVY-AMC hydrolysis were 0.14 and 0.021 ýM for Ac-LLnL-al and Cbz- 
LLnV-aI respectively. The corresponding Ki values for inhibition of Cbz-LLE-NAP hydrolysis 
were 1.2 and 0.66 ýM. These Ki values were obtained using an assay buffer containing 
0.035% SDS. SDS (0.01-0.02%) is known to activate the chymotrypsin-like and PGPH 
activities ot 20S proteasomes (Rivett, 1989, Arribas & Castaho, 1990). The tiypsin-like 
activity ývas either inhibited or stimulated depending on the substrate used and the precise 
assay conditions. SDS was proposed to stimulate the peptidase activities by inducing 
conforniational changes and greater conformational flexibility in the complex. Higher 
micewratioi-is of SDS e. (-,. 0.1% inhibited the peptidase actiVities of 20S proteasomes (Arnbas 
, S- Castaflo, 1990). Rock and coworkers ( 1994) determined similar Ki values for the effect of 
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Ac-LLnL-al and Cbz-LLnV-al on the rabbit 26S proteasome chymotrypsin-like and PGPH 
activities. This confirmed that the catal,, ilc activities of both 20S and 26S proteasomes xý,, ere 
effectively inhibited by the peptidyl aldehydes. 
Peptidyl aldehydes have played an important role in defining and specifically inhibiting the 
activities of mammalian 20S proteasomes. The hydrolysis of Boc-VEAL-NAP at the L-NAP 
bond was found to occur optimally at pH 5.5 (Figueiredo-Pereira et al., 1995). This is in 
contrast to other chymotrypsin-like substrates e. g. Cbz-GGL-NAP that are optimally 
hydrolysed in neutral or slightly basic buffers. Cbz-GGL-al (286 ýM) was shown to inhibit the 
hydrolysis of Cbz-GGL-NAP by 84%. The same concentration of inhibitor caused only 14% 
inhibition of the acidic chymotrypsi n- like activity measured with Boc-VEAL-NAP. Cbz-LLE- 
al and Cbz-GPFL-al were used in one report to show that the 20S proteasome BrAAP activity 
can cleave after Pro and Glu residues (Cardozo et al., 1996). This study increased the known 
substrate specificity of the BrAAP activity from the previously defined post-Leu cleavage. 
Leupeptin (Acetyl-LLR-al) has been shown to specifically inhibit the trypsin-like activity of 
mammalian 20S proteasomes (Wilk & Orlowski, 1980; Savory & Rivett, 1993). Hydrolysis 
of the chyrnotrypsin-like substrates Cbz-GGL-pNA, Cbz-GGYA-pNA, Cbz-GGYS-NAP, 
AAF-AMC or the PGPH substrate Cbz-LLE-NAP was not sigrUficantly inhibited, using 
leupeptin concentrations that caused substantial inhibition of the trypsin-fike activity measured 
with Cbz-i)(, -\)LR-NAP, Bz-FV-R-pNA or Boc-LSTR-AMC. 
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Table 1.2 - Categories of proteasome inhibitor 
Type of compound General comments References 
Isocournarin derivatives Selective irreversible inhibitor of serine Orlowski & 
e. g. proteases; micromolar e. g. 50 ýM DCI causes Michaud, 
3,4-dichloroisocoumarin irreversible inhibition of the chyrnotrypsin-like 19891 
(DCI) and SNAAP activities and stimulation of the Djaballah et 
BrAAP activity; inhibits or stimulates the al., 19 9 2; 
trypsin-like and PGPH activities depending on Orlowski et 
concentration used and assay conditions. al., 1997. 
Peptidyl diazomethanes Irreversible inhibitors of serine and cysteine Savory et 
e. g. proteases; compounds are irreversible al., 19 9 3; 
C'bz-FGY-CHN2 inhibitors of the chymotrypsin-like activity, Reidlinger 
other activities are less effectively inhibited, et al., 1997. 
effects depend on the amino acids in the 
compound; need to be used at e. g. 100 ýiM 
concentrations. 
Peptidyl chloromethanes Irreversible inhibitors of serine and cysteine Savory et 
e. g. YGR-CH2C1, proteases; compounds irreversibly inhibit the al., 1993, 
AAF-CH2Cl chymotrypsin-like, trypsin-like and PGPH Reidlinger 
activities, effects depend on the amino acids in et al., 1997. 




Peptidyl aldehydes Compounds cause reversible inhibition of 
Rock et 
e. g. Ac-LLnL-al, chymotrypsin-like, acidic chymotrypsin-like, 
al., 1994 
Cbz-LLnV-al (MG1 15), trypsin-like, PGPH, BrAAP and SNAAP 
Vinitsky et 
Cbz-LLL-al (MG132) activities; some compounds are potent al., 
1994. 
inhibitors of the chymotrypsin-like activity 
with e. g. 0.02 ýM Ki values, compounds 
inhibit calpains and cathepsin B. 
Lactacystin and clasto- Lactacystin inhibits the chymotrypsin-like, Fenteany et 
lactacystin P-lactone trypsin-like, PGPH and BrAAP activities, al., 1995, 
chymotrypsin-like activity is most effectively Dick et al., 
inhibited; the inhibition is slowly reversed; 1996. 
clasto-lactacystin P-lactone is readily formed 
from lactacystin at pH 8 and is the sole 
species that inhibits proteasomes; lactacystin 
inhibits a platelet cathepsin A-like activity, 
generally used at 10-100 ýM concentration 
Peptidyl vinyl sulphones Irreversible inhibitors of chymotryp sin- like, Bogyo et 
e. g. trypsin-like and PGPH activities; effects al., 19 9 7; 
Cbz-LLL-(CH)2SO2M e depend on the amino acids in the compound-, Bogyo et 
(Z-LLL-VS) one compound NIP-LLL-VS is known to al., 1998. 




1.5.2 - Lactacystin -a particularly specific proteasome inhibitor 
Peptidyl aldehydes have been used in many in vivo studies, to imply a role of proteasome 
complexes in the degradation of proteins. Cbz-LLL-al (MG- 132) in particular has been used 
to imply a role of 26S proteasomes in degrading the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein and the retinoblastoma (Rb) protein. Inhibition of 
proteasome complexes by Cbz-LLL-al was also proposed to lead to the the induction of heat 
shock proteins (Jensen et al., 1995; Boyer et al., 1996; Lee & Goldberg, 1998). However, 
peptidyl aldehydes are known to inhibit other proteases e. g. calpains and cathepsins (Rock et 
al., 1994). Investigators have attempted to overcome this problem by using less effective 
peptidyl aldehydes and other protease inhibitors to show that effective inhibition of proteasome 
complexes correlates with effective inhibition of protein degradation (Palombella et al., 1994). 
Lactacystin is a streptomyces metabolite that inhibits the cell cycle and induces neurite 
outgrown in neuroblastorna cells (Fenteany et al., 1995). Figure 1.2 shows the structure of 
lactacystin and the mechanism by which it decays to clasto-lactacystin P-lactone (P-lactone) 
and N-acetyl-L-cysteine. The P-lactone is then slowly hydrolysed to a dihydroxy acid (DHA). 
Experiments in which ['H] lactacystin or [3 H] P-lactone were incubated with crude extracts 
of Neuro-22a cells or bovine brain, showed that 20S proteasomes were the only radiolabelled 
cellLilar target (Fenteany et al., 1995). The chymotryp si n- like activity of purified 20S 
proteasornes was effectively inhibited by 10 ýM lactacystin or I ýM P-lactone. The k,. bA 
values measured with the Suc-LLVY-AMC substrate were 194 and 3059 M-ls-l respectively 
(Feriteany et al., 1995). Lactacystin exhibited kobJlvalues of 10 and 4 M-ls-1 for the trypsin- 
like and PGPH activities. Lactacystin was initially thought to irreversibly inhibit the catalytic 
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I showed that the inhibi activities of 20S proteasomes. However, later studies ii ition x,,, as sloiý ly 
reversed, at a rate that was dependent on the source of 20S proteasomes (McConnack et al., 
1997). Results from another report showed that P-lactone was the sole species that inhibited 
proteasome activities (Dick et al., 1996). Conditions that stabillsed lactacystin and inhibited 
the production of P-lactone, greatly reduced the effectiveness of lactacystin as a proteasome 
inhibitor. Although lactacystin is a remarkably specific inhibitor of proteasomes, a recent study 
showed that 1-5 ýM lactacystin could inhibit a human platelet cathepsin A-like activity 
(Ostrowska et al., 1997). This inhibition was dependent on incubation of lactacystin at pH 8.0 
for 10 n-unutes to allow the production of the P-lactone species, before conducting the assays 
at pH 5.5. 
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Figure 1.2 - Mechanism of aqueous hydrolysis of lactacystin 
The streptomyces metabolite lactacystin breaks down to clasto-lactacystin P-Jactone (P- 
lactone) and N-acetyl-t. -cysteine (NAC) (Dick et aL, 1996). The reaction occurs rapidly at pH 
80 but reducing the pH to 63 caused lactacystin to become stable. The P-lactone is the sole 
species that inhibits the 20S proteasome. The P-lactone is slowly hydrolysed to the inactive 





















Recent studies have developed a new substrate 2-aminobenzyl-(Abz)-GPALA-4- 
nitrobenzylamide-(Nba) for assaying the BrAAP activity of mammalian 20S proteasomes 
(McCormack et al., 1998). Cleavage of this substrate occurs exclusively at the L-A bond to 
yield Abz-GPAL and A-Nba products. The fluorescence of the Abz group in the first product 
can be used to follow the reaction, without needing to use an armnopeptidase to release the 
pAB group of other BrAAP substrates (Table 1.1) (Orlowski et al., 1993). Inhibition of the 
20S proteasome BrAAP activity by compounds with the general structure Cbz-LL-Xaa-al, 
followed Michaelis kinetics when Xaa was Leu or norVal. Biphasic kinetic curves were 
observed if Xaa was Phe, Trp or (p-CI)Phe (McCormack et al., 1998). The peptidyl aldehydes 
that displayed simple kinetics were relatively potent inhibitors of the 20S proteasome 
chymotrypsin-like and PGPH activities. In contrast the peptidyl aldehydes that exhibited 
biphasic kinetics were effective inhibitors of the chymotrypsin-like activity and poor inhibitors 
of the PGPH activity. The effect of P-lactone on the BrAAP activity was assessed in an assay 
using 20S proteasomes and saturating amounts of the PA28 activator. This hexameric 
complex binds to the 20S proteasome and activates the chymotryptic, tryptic and PGPH 
activities (Kuehn & Dahimann, 1996). The results suggested that 2.5 mol P-lactone/mol 20S 
proteasome inhibited 90% of the chymotrypsin-like activity and also inhibited 60% of the 
BrAAP activity. In fbrther experiments the chymotrypsin-like activity of 20S proteasomes was 
selectively inhibited using a suitable concentration of P-lactone. The Ki values for inhibition 
of the BrAAP or PGPH actlVites by e. g. Cbz-LLL-al or Cbz-LLE-al, were under these 
circumstances identical. It v, -as therefore proposed that the BrAAP activity was catalysed by 
the active sites responsible for the chymotrypsi-n-like and PGPH actl,,,, Itles (McCormack et al., 
1998). This conclusion was not supported by Orlowski et al. (1993) who suggested that DCI 
cýiused inhibition of the chymotrypsin-fike and PGPH activities whilst stimulating the BrAAP 
act Iv It N, 
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1.6 - The active site nucleophile of 20S proteasomes is a threonine residue 
Early inhibitor studies from several groups suggested that the active site nucleophiles of 20S 
proteasomes were either serine or cysteine residues (Rivett, 1989, Mason, 1990). AJignment 
of Thermoplasma and human P-subunit sequences suggested that a conserved Ser- 129 or one 
of two conserved threonine residues Thr- I and Thr-2 could be the active site nucleophile 
(Seemýiller et al., 1995). The Ser- 129 residue could be mutated vAthout impairmg the catalytic 
activity of the resulting 20S proteasomes. In contrast deletion of Thr- I and Thr-2 or their 
mutation to Ala, yielded 20S proteasomes that were correctly folded and assembled but 
entirely inactive (Seemuller et al., 1995). Further experiments showed that deletion of Thr- I 
was sufficient to eliminate catalytic activity. In addition the mutation of Thr- I to Ser yielded 
tive to DCI. A conserved Lys-3 fully active 20S proteasomes that were 15 times more sensi I 
residue was proposed to play the proton acceptor/donor role in substrate hydrolysis (Seemuller 
et al., 1995). 
Analysis of Thermoplasma 20S proteasome crystals produced in the presence of Ac-LLnL-al 
identified the anuno-terrmnal threonine as the catalytic nucleophile (L6we et al., 1995). Ac- 
LLnL-al was bound to all 14 0-catalytic subunits with the aldehyde functional group located 
at the amino-terminal threonine. Lys-33 and Glu-17 were also located close to Thr-I 
suggesting that Glu- 17 may assist the proton acceptor/donor role of Lys-3 3. The (x and 0 
subunits were shown to fold in a very similar manner, With the notable exception of the extra 
N-terminal HO helix of a-subunits. This helix is important in the assembly of 7-membered (Y, 
Subunit rings and inay play a role in interacting with regulatory complexes of the 20S 
proteasonle (Lowe et al., 1995). 
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Analysis of yeast 20S proteasome crystals showed that Lys-3 3 and Asp- 17 were close to Thr- I 
of the catalytic P-subunits PI /PRE3, P2/PLJP I and P5/PRE2 (Groll et al., 1997, Dick et al 
1998). Yeast 20S proteasome crystals were subsequently prepared In the presence of Ac- 
LLnL-al or lactacystin. The Ac-LLnL-al aldehyde group was covalently bound to the hydroxyl 
group of Thr- I for all three catalytic P-subunits (Groll et al., 1997). Lactacystin was shown 
to covalently bind to the P5/PRE2 Thr-I residue. The mammalian homologue of 05/PRE2 is 
X/MB I that was shown to be labelled by 10 ýM ['H] lactacystin (Fenteany et al., 1995). In 
subsequent experiments 100 ýM [3 H] lactacystin was shown to label all six mammalian 
catalytic P-subunits X/MB 1, Y/6, Z, LMP7, LMP2 and MECL I of 20S and 26S proteasomes 
(Craiu et al., 1997). The arrangement of residues in the 05/PRE2 catalytic site, suggested that 
chymot ryp sin- like and trypsin-like substrates were likely to be hydrolysed by this site (Groll 
et al., 1997). The PI /PRE3 site was proposed to catalyse the PGPH activity. The P2/PUP I 
site was predicted to exhibit a broad substrate specificity. 
In subsequent work, two separate groups have mutated yeast catalytic threonine residues to 
alanine to determine which peptidase activities are catalysed at the different sites (Dick et al., 
1998; Chen & Hochstrasser, 1996; Arendt & Hochstrasser, 1997). Mutation of the P5/PRE2 
Thr- I to Ala or Lys-33 to Ala completely inhibited the chymotrypsin-like activity of purified 
20S proteasomes, measured with Cbz-GGL-AMC or Cbz-GGL-PNA. The trypsin-like activity 
measured Nvith e. g. Cbz-ARR-AMC or Cbz-ARR-4-methoxy-NAP was the same aswild-type 
"OS proteasomes. The PGPH activity measured with Cbz-LLE-NAP was either the same or 
oreater than xvild-type 20S proteasomes. Similar experiments finked mutation of the P2/PUPI Z, - 
Thr- I to Ala vAth complete loss of the trypsin-like activity. The near complete loss of PGPH 
activity was observed , vith 20S proteasomes containing the pl,, 'PRE3 Thr-I to Ala mutant 
" 
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subunit (Dick et al., 1998, Arendt & Hochstrasser, 1997). The mutations In either 02/PUP I 
or PI /PRE3 caused partial inhibition or stimulation of other proteasome activities. This 
suggested that mutation of one catalytic site causes conformational. changes that effect 
substrate hydrolysis at other catalytic sites. It was also proposed that stimulation of activity 
was due to overexpression of 20S proteasomes in mutant cells compared to wild-type cells 
(Arendt & Hochstrasser, 1997). The BrAAP activity of wild-type and mutant 20S 
proteasomes was investigated using the Cbz-GPALA-pAB substrate (Dick et al., 1998). These 
experiments suggested that the BrAAP activity was catalysed by the 01 /PRE3 catalytic site 
that also catalyses the PGPH actiVity. 01 /PRE3 Thr- I to Ala mutant 20S proteasomes were 
almost completely devoid of BrAAP activity measured with the chosen substrate. 
1.6.1 - Proteasome complexes are members of the N-terminal nucleophilic hydrolase 
family of enzymes 
Comparison of the subunit secondary structure of 20S proteasomes, the cysteine protease 
glutamine PRPP aiýnidotransferase and the serine protease penicillin acylase suggest that these 
enzymes belong to a new family named N-terminal nucleophilic hydrolases or Ntn hydrolases 
(Groll et al., 1997, Duggleby et al., 1995; Brannigan et al., 1995). The catalytic mechanism 
of penicillin acylase is proposed to involve a water molecule, that is hydrogen bonded to the 
(x-arnino group of the catalytic Ser- I residue. The water molecule in conjunction with the a- 
arnino group are thought to perform the proton acceptor/donor role in the catalytic mechanism. 
The arrangernent of a water molecule hydrogen bonded to the (x-amino group of Thr- 1, has 
been suggested as a proton acceptor/donor in 20S proteasome catalytic sites (Groll et al., =I II 
1997, Bi-minigan et al., 1995). However, yeast 20S proteasomes exhibitmg the P5/PRE2 Lys- 
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33 to Ala mutation were devoid of chyrnotrypsin-like activity (Dick et al., 1998). This result 
clearly indicated that the potential proton acceptor/donor residue Lys-33 is required for 
substrate hydrolysis. 
1.6.2 - Use of peptidyl vinyl sulphones to link mammalian 20S proteasome activities to 
particular catalytic sites 
Peptidyl vinyl sulphones have recently been employed to irreversibly inhibit the peptidase 
activities of recombinant Rhodococcus and mammalian 20S proteasomes (Bogyo et al., 1997, 
McCormack et al., 1997). Different combinations of amino acids give rise to compounds that 
preferentially inhibited one or more of the proteasome activities. For example 4-hydroxy-3- 
todo-2-nitrophenyl acetyl-LLL-(CH)2SO2Me (NLVS) inhibited the 20S proteasome 
chymotrypsin-like, trypsin-like and PGPH activities with k,, bs/lvalues of 13 500,10 and 24 
respectively (Bogyo et al., 1998). LLLL-vinyl sulphone (VS) was a relatively specific 
inhibitor of the trypsin-fike activity. A k,, b,, /l value of 1,500 Nf's-' was substantially larger than 
values of 240 for the chymotrypsin-like activity and 29 for the PGPH activity. Peptidyl vinyl 
sulphones are reported to be remarkably specific for proteasome complexes. [1251] NLVS was 
able to enter three different human cells and label either proteasome catalytic subunits or a 
protease that was identified as cathepsin S (Bogyo et al., 1997). The major labelled 
proteasoiiie P-subunits were LN1P2, LMP7 and X/MIBI. Proteasomes in yeast or 
Thermoplasma acidophilum cell extract could also be labelled. [125, ]NLVS labelled mutant 
Thermoplasma 20S proteasomes composed of Thr-I to Ser P-subunits. Other mutant 
Thermoplasma 20S proteasomes composed of Thr- I to Ala P subunits were not labelled. 
in one study the k-. b,, /l values for inhibition of the 20S proteasome chymotrypsin-like, trypsin- 
1) ý 
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like and PGPH activities were determined for II peptidyl vinyl sulphones (Bogyo et al., 
1998). Radiolabelled forms of some of the peptidyl vinyl sulphones were synthesiZed and used 
to label proteasomes in total cell lysates. The proteasome complexes were immunoprecipitated 
and then separated by SDS-PAGE, 2-D SDS-PAGE or non-equilibrium pH gradient 
electrophoresis followed by SDS-PAGE in the second dimension (Table 1.3). [ 125 1] NLN'S 
was shown to modify the LMP7 and X/MEB I subunits to a much greater extent than [1251] 
YLLL-VS. NLVS displayed a9 times higher kobAvalue for inhibition of the chymotrypsin- 
like activity measured with Suc-LLVY-AMC, compared to YLLLA'S. The relatively ýveak 
chymotryp si n- like inhibitor LLLL-VS, competed poorly against [125 1] YLLL-VS for binding 
to the LNIIP7 and X/NIIB I subunits when compared to the more effective chymotrypsin-like 
inhibitors NLVS and Bz-FLLL-VS. Hence LN/fP7 and X/NlEBI were proposed to 
predominantly catalyse the chymotrypsin-like activity. This assignment is in agreement with 
Reldlinger and coworkers (1997) who showed that ['H] acetyl-AAF-CH2CIprimanly mhibited 
the chymotrypsin-like activity of liver 20S and 26S proteasomes. This inhibitor was shown to 
predominantly label subunits LMP7 and X/MB I of 20S proteasomes. Also lactacystin 
preferentially inhibits the chymotrypsin-like activity of 20S proteasomes. ['H] lactacystin (10 
was shown to label subunit YJNIB I of 20S proteasomes (Fenteany et al., 1995). The six 
marnmalian catalytic subunits were labelled by 100 ýM ['H] lactacystin in a separate study 
(('raiu et al., 1997). Studies using 
[14C] DCI and a number of peptidyl aldehydes also 
concluded that inhibition of the pituitary 20S proteasome chymotrypsm-fike activity was linked 
to labelling of subunit X/MB I (Orlowski et al., 1997). However, this group suggested that 
inhibition of the spleen 20S proteasome chymotrypsin-like activity was associated with 
modification of the I N1112 suburut. The LMP7 subunit was tentatively assigned to the BrAAP 
ýIctjvitv Athough other studies have proposed that this activity is not catalysed by a separate 
site (McCormack et al., 1998, Dick et al., 1998). 
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Table 1.3 - Assignment of peptidase activities to mammalian catalytic P-subunits 
'- Results from Bogyo et al. (1998) 
b_ Results from Reidlinger et al. (1997) 
'- Results from Fenteany et al., (1995) 
d- Results from Orlowski et al., (1997) 
'- Results from McCormack et al., (1998) 
Peptidase activity I Assigned P- I Basis for assignment 
subunits 
Chymotrypsin-like LMP7, a) ["'I] NLVS modified LNIP7 and X/MB I subunits 
X/MB I to a much greater extent than [125 I]-YLLL-VS. NLVS 
(LNW2) I displayed a9 times higher kbAvalue for the 
chymotrypsin-like activity compared to YLLL-VS'. 
b) The relatively weak chymotrypsin-like inhibitor 
LLLL-VS competed poorly against [125 I]-YLLL-VS 
for binding to LNIP7 and X/MB 1. The more effective 
chymotrypsin-like inhibitor NLVS was a better 
competitor for LNIP7 and X/NIB I binding in similar 
experiments '. 
c) ['H] acetyl-AAF-CH2CI primarily inhibits the 
chymotrypsin-like activity of 20S and 26S 
proteasomes. This inhibitor predominantly labelled 
y subunits LNIP7 and I. 
b 
c) Lactacystin is much more effective at inhibiting the 
chymotrypsin-like activity than the trypsin-like or 
PGPH activities. [3 H] Lactacystin preferentially 
modifies the X/MB I subunit '. 
d) Studies using 
[ 14C ] DC1 and peptidyl aldehydes 
suggested that the chymotrypsin-like activity was 




Trypsin-like MECLIý Z a) ["51] Y-LLL-VS modIfied MEECLI and Z subunits 
to a much greater extent than ["51] NLN'S. Y-LLL- 
VS displayed a 56 times higher kobAvalue for the 
trypsin-like activity compared to NLVS 
b) The more effective trypsin-like inhibitors 
LLLL-VS and Bz-FLLL-VS, competed with [ 
12511 Y- 
LLL-VS for binding to MECL I and Z subunits, to a 
greater extent than YLLL-VS or NLVS 
a. 
PGPH (LLE I) LNV2, Y/6 a) [125 1] GLLL-VS-PhOH exclusively labelled the 
LNIP2 and Y/5 subunits. This inhibitor displayed 
relatively low kobs/lvalues for the chymotrypsin-like 
and trypsin-like activities 
a. 
b) NLVS displayed a similar kob)lvalue to GLLL-VS- 
PhOH for the PGPH activity. [1251] NLVS also 
labelled the LNU)2 subunit to a similar level as [1251] 
a GLLL-VS-PhOH 
PGPH (LLE2) Y/5 a) Studies using 
[ 14C] DCI and peptidyl aldehydes 
suggested that the PGPH activity measured with 0.64 
mM Cbz-LLE-NAP was catalysed by y/5 d. 
BrAAP a) LNIP7 a) Studies using 
[ 14C] DCI and peptidyl aldehydes 
lead to the tentative suggestion that the BrAAP 
activity was catalysed by the LMP7 subunit d. 
b) LNV7, b) Studies using lactacystin and peptidyl aldehydes 
XNEB 1, suggested that the BrAAP activity was catalysed by 
LNI? 2, Y/6 the active sites responsible for the chymotrypsin-like 






1 125 I]-YLLL-VS was shown to modify the MECLI and Z subunits to a much greater extent 
than ["'I] NLVS. YLLL-VS also displayed a 56 times higher kbA. value for inhibition of the 
trypsin-like activity measured with Boc-LRR-AMC, compared to NLVS. The most effecti%, e 
trypsin-like Inhibitors were LLLL-VS and Bz-FLLL-N'S with kobAvalues of 1,500 and 1,370 
M-'s-' compared to 560 M-'s-' for YLLL-VS. LLLL-VS and Bz-FLLL-VS were able to 
compete more efficiently against [125 I]-YLLL-VS for labelling of the MECL I and Z subunits, 
when compared to YLLL-VS and NLVS Hence MECL I and Z were proposed to 
predominantly catalyse the trypsin-like activity. 
1 125 11-GLLL-VS-PhOH was shown to exclusively label the LNIP2 and Y/6 subunits. The 
unlabeled form of this inhibitor displayed a relatively low kobAvalue for the chymotrypsin-like 
and trypsin-like activities. In contrast the kobA value for the PGPH activity was comparable 
to several other vinyl sulphones. NLVS displayed a similar kobAvalue to GLLL-VS-PhOH 
for the PGPH activity. In addition [125 1] NLVS labelled the LNT2 subunit to a similar extent 
as [125 1] GLLL-VS-PhOH. Therefore LNT2 and Y/8 were proposed to predominantly catalyse 
the PGPH activity. Orlowski and coworkers (1997) also linked inhibition of the PGPH activity 
with modification of the Y/5 suburut. This group measured the PGPH activity of 20S 
proteasomes using 0.64 mM Cbz-LLE-NAP. Hence the Y/6 subunit may be responsible for 
the LLE2 activity defined by (Djaballah & Rivett, 1992). This lower affinity activity, distinct 
tI rom the 
N( 
Yher affinity LLE I activity, was proposed to be responsible for the cleavage of the 




1.7 - Assembly of eukaryotic 20S proteasomes 
Archaebacterial 20S proteasome a-subunits spontaneously assemble into 7-membered rings 
that associate with P precursor proteins in the first stage of assembly (Zwickl et al., 1994). 
Eukaryotic (x-type subunits are proposed to associate together to form heptameric rings, 
containing all seven ot-type subunits in a specified arrangement (Figures 1.1 A and 1.1 B) (Groll 
et al., 1997; Schmidt & Kloetzel, 1997). The O-subunits 04/C7-1 and 03/C 10-11 along with 
the P2/Z proprotein are thought to associate with the ot-subunit rings to form the 13S 
intermediate complex (Frentzel et al., 1994; Nandi et al., 1997). ot-subunits are synthesized 
as mature subunits. The 04/C7-1 and P3/CIO-ll subunits are not synthesized with a 
prosequence and do not have an active site N-terminal threonine. The prosequence of P2/Z 
is slowly autoprocessed by the catalytic Thr- I residue (Schmidt & Kloetzel, 1997) (Figure 
1.3). The 06/C5 and P7/N3 proproteins, neither of which contain an active site, are then 
incorporated with the actiVe subunits 05 (X/MB 1) and PI (Y/6) bein I ig added last to yield the 
16S intermediate complex (Schmidt & Kloetzel, 1997). Two of the 16S 'half proteasome' 
complexes are suggested to associate together to form a complex dimer, where final processing 
of the P-propeptides occurs (Schmidtke et al., 1997; Kopp et al., 1993). Processing of P6/C5, 
P7/N'), P5 (X/NIIB 1) and PI (Y/5) was proposed to occur via a trans- auto catalytic reaction, 
in which active subunits cleave the propeptides of other active and mactive (06/C5 and 07/N3) 
subunits (Thornson & Rivett, 1996; Schmidt & Kloetzel, 1997). Molecular chaperones e. g. 
liscT'), UmpIp are present in the intermediate complexes and are proposed to assist the 
autocatalytic processing of the large (up to 80 residues) propeptides (Schn-iidtke et al., 1997; 




Figure 1.3 - Assembly of eukaryotic 20S proteasome complexes 
In the first stage the (x-subunits associate together in a specified arrangement to form seven 
membered rings (See Figure 1, IA and 1. IB). The P4/C7-1 and P3/CIO-H subunits that are not 
synthesized with a prosequence and do not have a N-term-inal threonine are then incorporated 
together with the prosequence of P2/Z. This prosequence is thought to be slowly 
autoprocessed by the catalytic Thr-1 residue (Schmidt & Kloetzel, 1997). The P6/C5 and 
P7/N3 proproteins, neither of which contain a catalytic threonine residue, are then 
incorporated into the 13 S complex with the active subunit proproteins P5 (X/MB 1) and PI 
(Y/6) being added last to yield the 16S intermediate complex (Schrmdt & Kloetzel, 1997). 
Two of the 16S 'half proteasome' complexes are suggested to associate together to form a 
complex dimer, where final processing of the P-propeptides occurs (Schmidtke et al., 1997, 
Kopp et al., 1993). 
al a2 0 ot4 (x5 ct6 ot7 
Iota C3 C9 C6 Zeta C2 C8 
Ot I u2 0 ct4 (x5 u6 ot7 
Iota C3 C9 C6 Zeta C2 C8 
(x I u2 0 u4 u5 ct6 ct7 
Iota C3 C9 C6 Zeta C2 C8 
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Iota C3 C9 C6 Zeta C2 C8 
ct I a7 ct6 ct5 ct4 0 a2 
Iota C8 C2 Zeta C6 C9 C3 
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The inducible subunit 02i/MECLI was reported to be incorporated into the assembling 
complex at the same early stage as 02/Z (Nandi et al., 1997). 051ALNIP7 was incorporated at 
the same late stage as 05 (X/MBI). In contrast OlifLNT2 was incorporated in the assembling 
complex at an early stage, whereas PI (Y/5) was incorporated at a late stage. Therefore the 
early incorporation of 01 i/LNW2 may assist the incorporation of the other EFN-y inducible 
subunits. This proposal was supported by the fact that P5i/LNtP7 and P2i/MECL I are only 
efficiently incorporated into the complex in the presence of 01 iALMP2 (Groettrup et al., 1996a, - 
Kuckelkorn et al., 1995). 
1.7.1 - Assembly of eukaryotic 26S proteasomes 
The 26S proteasome is formed by the association of two 700 kDa regulatory particles with 
the ends of the 20S proteasome. These complexes, also known as the 19S cap complex or 
PA700 complex are composed of 17-18 different subunits (Walz et al., 1998-, Glickman et al., 
1998). Six of these subunits are ATPases of the A AA (ATPases associated with various 
cellular activities) ATPase family. Studies in wl-iich HlS6-tagged versions of the ATPase 
subunits were expressed in yeast cells, suggested that each regulatory particle contains all six 
ATPases (Glickman et al., 1998). A model in which the ATPase subunits associate together 
in a six-membered heteromenc ring has been proposed (Walz et al., 1998). This ATPase ring 
inay associate with the (x-subunit ring and play an important role in regulating the passage of 
unfolded polypeptides, to the catalytic sites of the 20S proteasome. 
One of the human non-ATPase subunits, S5a, binds specifically to the polyubiquitin chains of 
Libiquitinated lysozyme. S5a Nvas also shown to bInd to polyublqultln chaIns contalning four 
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or more ubiquitin molecules (Deveraux et al., 1994). S5a and the yeast homologue 
SUN I /MCB I are proposed to exist free in the cytosol, presumably binding to ubiquitinated 
proteins and directing them to 26S proteasomes (Tanaka & Chiba, 1998). Disruption of the 
SUN I /MCB I gene did not cause lethality in yeast which suggested that other polyubiquitin 
receptor (pUB-R) proteins may be expressed. Recent studies had identified at least five 
different human pUB-R proteins that are generated from a single gene by alternative splicing 
(Tanaka & Chiba, 1998). The non-ATPase subunit Padlp has been suggested to catalyse the 
isopeptidase activity associated with the 26S proteasome (Lam et al., 1997). Both Pad Ip and 
the yeast homolog RpnI I are thought to exhibit isopeptidase activity, because they display 
sequences e. g. close to a possible cysteine nucleophile, that are conserved in deubiquitinating 
enzymes (Glickman et al., 1998, Wilkinson et al., 1997). 
The association of regulatory particles with 20S proteasomes occurs through an ATP 
dependent mechanism and causes activition of 20S proteasome activities (Chu-Ping et al., 
1994). Three-dimensional electron microscopy studies have suggested that the linkage 
between the regulatory particles and the 20S proteasome is flexible, allovAng a limited degree 
of movement (Walz et al., 1998). An approximately 300 kDa modulator complex has been 
shown to stimulate the attachment of regulatory particles to 20S proteasomes (Demartino et 
al., 1996, Adams et al., 1997). The modulator complex is constructed from three distinct 
subunits and stimulates the attachment of regulatory particles to 20S proteasomes and singly 
capped 20S proteasomes (Adams et al., 1997). 
1.8 - The PA28 complex 
The complex or IIS regulator is a ring shaped 180 kDa activator of 20S proteasomes 
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(Song et al., 1997). Two main forms of the PA28 complex have been identified. PA2.8(x and 
PA280 subunits associate together in the proposed hexameric ring structure((XP)3 (Song et 
al., 1996). This complex was suggested to be located mainly in the cytosol (Soza et al., 1997). 
PA28-y (Ki antigen) subunits are proposed to associate to form a hexameric (Y)6 structure that 
is predominantly locallsed to the nucleus (Tanaka & Chiba, 1998). These three proteins are 
all related, displaying -50% arnino acid sequence identity (Ahn et al., 1995). The 
PA28&PA28P complex has been shown to stiMUlate the chymotryp sin- like, trypsin-like and 
PGPH activities of 20S proteasomes (Kuehn & Dahlmann, 1996; Ustrell et al., 1995). Kuehn 
& Dahlmann (1996) reported that the level of stimulation was dependent on the amount of 
PA28 complex used, with a plateau being reached at 2 moles PA28 complex per mole 20S 
proteasome. Phosphorylation of the PA28a/PA28P complex was proposed to be required to 
produce the maximum stimulation of the 20S proteasome chymotrypsin-like activity (Li et al., 
1996a). 
PA28a is thought to predominantly combine with PA28P under physiological conditions, 
although X-ray crystallographic analysis of recombinant PA28ot showed that the subunits can 
combine to form a heptameric complex (Kuehn & Dahlmann, 1996; Knowlton et al., 1997). 
Recombinant PA28oc complexes can also stimulate the peptidase activities of 20S proteasomes 
(Ustrell et al., 1995). PA280 subunits do not readily combine to form homopolymeric 
complexes (Zhang et al., 1998). Recent studies show that particular residues in the PA28(x and 
PA28P subunits are important for binding and activating 20S proteasomes (Song et al., 1997, 
Zhang et al., 1998). In particular Arg-141 to Gly-149 of PA28(x are cntical for 20S 
proteasorne activation. Deletion or mutation of residues in the C-terminal region of PA28(x 
or PA-'SP also influence the ability of the PA28 complexes to bind and activate 20S 
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proteasomes. The precise role of PA280 is presently unclear. Some researchers suggest that 
this subunit cannot stimulate proteasome activity when expressed in the absence of PA28(x 
(Song et al., 1997). PA28P was suggested to influence the affinity of PA28 complexes for the 
20S proteasome. Another group suggested that PA28P can activate 20S proteasomes in the 
absence of PA28ct and both subunits are involved in binding and actl,,, ating 20S proteasomes 
(Zhang et al., 1998). The C2 mammalian (x-type subunit has been proposed to be an important 
contact site for PA28 complexes (Kania et al., 1996). 
Binding of PA28 complexes to the ends of the 20S proteasome has not been shown to 
stimulate the degradation of native, denatured or ubiquitinated proteins (Li et al., 1996a, 
Tanaka & Chiba, 1998). The PA28-20S proteasome complex has been implicated in the 
generation of antigenic peptides for presentation on MHC class I molecules (Groettrup et al., 
1996b). Expression of both the PA28cc and PA28P subunits is induced by IFN-y (Li et al., 
1996a). In one report recombinant PA28(x was expressed in fibroblast cells, expressing the 
murine cytomegalovirus pp89 protein. The overexpression of PA28cc lead to a marked 
eiihancement of recognition by pp89-specific cytotoxic T-ceHs. Sirnilar results were observed 
when control and PA28(x overexpressing ceffs were infected with a strain of influenza and then 
analysed using an influenza nucleoprotein specific cytotoxic T-cell line (Groettrup et al., 
1996b). These results could be explained by PA28-20S proteasomes functionally combining 
with 26S proteasomes, to cleave 1-2 amino acids fi7om the 9-10 amino acid peptides produced 
by the26S proteasome. The addition of PA28 complexes to 20S proteasomes was shown in 
a separate study to increase the diversity of peptides derived from synthetic 25 amino acid 
substrates (Groettrup et al., 1995). Cleavage of the pepticles by PA28-20S proteasomes may 
increase the production of peptides that end wl IIII ith hydrophobic or basic residues. These peptide 
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are selected for expression on MHC class I molecules (Gaczynska et al., 1993). 
Co-immunoprecipitation experiments have recently suggested that singly capped 20S 
proteasomes could bind to PA28 to form a hybrid proteasome (Hendil et al., 1998). Hybrid 
proteasomes might therefore be a second mechanism by which PA28 complexes increase the 
diversity of antigens and the level of cytotoxic T-cell recognition. 
1.9 - The 26S proteasome is responsible for degrading a wide variety of proteins 
The 26S proteasome has been implicated in the degradation of a large and expanding number 
of proteins, involved in a wide variety of cellular processes (Hilt & Wolf, 1996; Tanaka & 
Chiba, 1998). In this section I will briefly describe the role of proteasomes in selected areas 
of cell metabolism. The 26S proteasome is thought to be responsible for the degradation of 
most short-lived, long-lived and abnormal proteins in cells (Rock et al., 1994; Mitch & 
Goldberg, 1996). 26S proteasomes degrade various regulators of cell cycle progression e. g. 
B-type and GI cyclins. This topic has recently been reviewed by Tanaka & Chiba (1998). 
Immune and inflammatory response regulators are also proposed to be degraded by the 
ubiquitin-proteasome pathway. For example IKB proteins that inhibits NF-rcB p50-p65 
complexes, are ubiquitinated and degraded by the 26S proteasome (Alkalay et al., 1995, 
MaggirN\ar et al., 1995, Whiteside et al., 1995). Phosphorylation of Ser-32 and Ser-36 was 
proposed to induce the ubiquitination and degradation of IKB(x (Baldi et al. 1996). Recent 
studies have suggested that m-calpain also catalyses the degradation of 1KBct In human 
hepatocvtes (Han et al., 1999), 
Proteins that fail to correctly fold in the encloplasmic reticulum (ER) are proposed to be 
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transported out of the ER and degraded by 26S proteasomes localised to the ER membrane 
(Sommer & Wolf, 1997). This was shown to be the case for mutant forms of 
carboxypeptidase yscY (Fliller et al., 1996) and human cc- I -proteinase inhibitor (W'erner et al., 
1996). This pathway may also account for the degradation of incorrectly folded wild-type and 
AF508 cystic fibrosis transmembrane conductance regulator proteins (Ward et al., 1995; 
Jensen et al., 1995; Xiong et al., 1999). The human cytomegalovirus (HCNIV) exploits this 
degradation pathway to induce the degradation of MEC class I heavy chains (HC) (Wiertz et 
al., 1996a; Wiertz et al., 1996b). Both the US2 and US II proteins produced by HCMV, bind 
to glycosylated HC in the ER. This association stimulates the deglycosylation and retrograde 
transport of HC through the Sec6l. complex of the ER membrane. The deglycosylated HC is 
then degraded by 26S proteasomes. 
Other viruses are known to exploit the ubiquitin-proteasome pathway. For example the human 
papilloma virus-16 E7 protein induces the immortilization of mammary epithelial cells, by 
stimulating the degradation of the retinoblastorna protein (Rb) (Boyer et al., 1996). The Rb 
protein is a tumor suppressor protein that plays a critical role in controlling the G, phase of the 
cell cycle. The human immunodeficiency virus (HIV) type I proteins Env and Vpu stimulate 
the degradation of the helper T cell protein CD4, by 26S proteasomes (Fujita et al., 1997). 
CD4 is a cell surface protein that assists the attachment of helper T cell receptors to MEC 
class 11 molecules, on the surface of antigen-presenting cells. Another study showed that 
proteasomes form part of the cellular defense mechanism against HIV. I-HV infection of target 
cells was much more efficient in the presence of the proteasome inhibitors Cbz-LLL-al and 
lactacystin (SchNý, 'artz et al., 1998). Moreover in vitro assays showed that 20S proteasomes 
could degrade certain HIV proteins. 
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1.9.1 - Role of proteasome complexes in Alzheimer's disease 
Alzheimer's disease is a progressive neurodegenerative disorder which is characterised by the 
accumulation of ubiquitin conjugates in neurofibrillary tangles (Gregori et al., 1995; Gregori 
et al, 1997). Extracellular senile plaques also accumulate in the neural tissue. A principal 
component of these structures is the 4 kDa peptide P-amyloid (AP). AP peptides exhibit a 
length of 3 9-43 amino acids (Hamazaki, 1998). AP 1-40 is thought to be the major species that 
is produced, with the longer AP 1 -42 and AP 1-43 peptides being early and major components 
of the senile plaques in patients suffering from Alzheimer's disease and Down's syndrome. AP 
is derived from the amyloid precursor protein (APP), an integral type I membrane- spanning 
glycoprotein (Christie et al., 1999). AIPP is normally cleaved in the middle of the Ap amino 
acid sequence by an oc-secretase. This yields a soluble polypeptide termed sAPP(x. 
Alternatively 0- and y-secretase activities combine to produce AP and a different soluble APP 
polypeptide. The presenilin- I protein has been proposed to activate AP production by 
activating the y-secretase activity (Haass & Selkoe, 1998). The enzymes responsible for the 
(x-, P- and y-secretase activities have proved difficult to identify. Peptidyl aldehydes have been 
shown to inhibit the production of AD and are known to inhibit proteasome activities e. g. 
chymotrypsin-like activity (Christie et al., 1999). Other studies have suggested that 26S 
proteasome are localised close to senile plaques in cases of Alzheimer's disease and dementia 





- Aims of the project 
At the start of the project, very few effective and relatively specific proteasome inhibitors were 
available. Proteasome complexes are involved in many aspects of cellular metabolism and 
specific inhibitors of these complexes may prove useful in elucidating a greater understanding 
of various diseases e. g. arthritis, cystic fibrosis and Alzheimer's disease. These studies may 
lead to the use of the best inhibitors as novel therapeutic agents. Discussions with SmithKline 
Beecham lead to the proposal that a series of peptidyl boronic acids may prove to be highly 
effective inhibitors of proteasome activities. I therefore chose to characterise the effects of 
these compounds on the peptidase activities of purified 20S proteasomes. 20S proteasomes 
were purified from rat liver and rat spleen tissue and the specific activities for selected synthetic 
peptide substrates (Suc-LLVY-AMC, AAF-AMC, Cbz-GGL-AMC and Boc-LSTR-AMC) 
were determined. An initial screen of the effects of the compounds on liver 20S proteasomes 
was carried out, using the chymotrypsin-like substrate Suc-LLVY-AMC and the trypsin-like 
substrate Boc-LSTR-AMC. A kinetic analysis of the mechanism of inhibition was then 
performed using the most effective inhibitor, Bz-Phe-boroLeu. The structure-activity 
relationship of the peptidyl boronic acids for the liver 20S proteasome chymotrypsin-like 
activity was then investigated by determining the Ki values for a range of peptidyl boronic 
acids. Cornpanisons were made to the effects on the fiver 20S proteasome trypsin-like activity, 
to investigate whether the order of potency was maintained for other 20S proteasome 
activities. The effect of peptidyl boronic acids on the spleen 20S proteasome was subsequently 
investIL-yated. Spleen 20S proteasomes are constructed predominantly with IFN-y inducible 
catalytic P-subunits, whereas liver 20S proteasomes contain a mixture of constitutively 
expressed and IFN-y inducible catalytic P-subunIts. Any difference in effects nught suggest 
possible pi-cferential inhibition of subpopulations of proteasomes. The peptidyl boronic acid 
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inhibitors were also of interest because they are cell permeable. Studies were therefore carried 
out to investigate whether proteasome complexes are inhibited by these compounds in cultured 
cells. The slow release of bound inhibitor allowed direct demonstration that proteasomes are 
indeed a cellular target for several of the boronic acid inhibitors. Parallel studies were carried 
out at SmithKline Beecham to investigate the possible role of proteasomes in the generation 
of P-amylold. 
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Chapter 2- Materials and Methods 
2.1 - Materials 
Rats (Wistar) were obtained from B&K Universal Limited (Hull, U. K). Boc-LSTR-7- 
amid o -4 - methylcournarin (AMC) and Succinyl (Suc)-LLVY-AMC were purchased from the 
Peptide Institute (Osaka, Japan). AAF-AMC, Cbz-LLE-NAP, ATP, proteinA-agarose, 
bovine serum albumin and acetonitrile were obtained from Sigma Chemical Co. (Poole, U. K. ) - 
Cbz-GGL-AMC was obtained from Bachem (Bubendorf, Switzerland). Solutions for cell 
culture were obtained from Gibco BRL (Paisley, U. K. ) or Sigma Chemical Co. (Poole, U. K. ). 
Peptidyl boronic acids were synthesized by chemists at SmithKline Beecham using the general 
method of Kettner& Shenvi (1984) and Matteson& Sadhu (1981). [4- 3 H] Phenacetyl-(S)- 
Leu-(S)-Leu-(R, S)-boroLeu was prepared by palladium-catalysed tritiodehalogenation of 
parabromophenylacetyl-(S)-Leu-(S)-Leu-(F,, S)-boroLeu pinacol ester. The pinacol ester 
group was removed using NaIO4/acetone/ammonium acetate buffer to give the boronic acid. 
The resulting compound was 97.3% radiochemical purity by HPLC, 6.4 Ci/mmol specific 
activity. Cbz-LLL-vinyl sulphone was a gift from Dr Hidde Ploegh of the Dept. of Pathology, 
Harvard Medical School, U. S. A. The protein assay reagent for use in Bradford protein 
determinations was purchased from Bio-Rad (Hemel Hempstead, U. K. ). Ultrapure protogel 
was obtained from National Diagnostics (Atlanta, U. S. A. ). Sodium dodecyl sulphate (SDS) 
was purchased from United States Biochemicals (Cleveland, U. S. A. ). Collodion bags (75 IcDa 
cut-off) were obtained from Schleicher & SchUll (Dassel, Germany). MCP20 monoclonal ant'- 
proteasome antibody was a gift from Dr Klavs Hendil of the August Krogh Institute, 
iver proteasome) antibody Ab 186 was rai Copenhao-en, Denmark. The polyclonal anti-(rat li I 
in rabbits as described previously using dinitrophenol-modified proteasomes (Mason et al. 
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1996). Optiphase HiSafe 2 liquid scintillation cocktail was obtained from Fisons Chernicals 
(Loughborough, U. K. ). 
2.2 - Protein determination by the Bradford Method 
The method was essentially as described in (Bradford, 1976). Bovine serum alburnin (BSA) 
standards of 0-8 ýtg were set up in duplicate in a total volume of 0.1 ml. The BSA standards 
were diluted with Super Q water or appropriate buffer e. g. 50 mM Hepes/KOH, pH 7.5. 
Samples with an estimated protein content of 1-6 ýtg were diluted to 0.1 nil with Super 
water or appropriate buffer. The protein assay reagent from Bio-Rad was diluted 1: 5 with 
Super Q water. I ml of this diluted reagent was vortexed with each sample before incubation 
at room temperature for 10 minutes. The Absorbance (595 nm) of the standards and samples 
was then read using aI ml plastic curvette and a Pharmacia Ultraspec III spectrophotometer. 
These samples were read against the 0 ýtg BSA reagent blank. A typical standard curve is 
shown in Figure 2.1. 
2.3 - SDS-PAGE and Western blotting 
SDS-PAGE was conducted by the method of Laemmh (1970). Mni-gels were produced using 




Figure 2.1 - Standard curve for the determination of protein content by the Bradford 
method 
Samples of bovine serum albumin (0-8 4g) were processed in duplicate according to the 
Bradford method for protein content determination as described in section 2.2. The figure 


















Bovine serum albumin (BSA) (pg) 
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a) 6.30 ml of Ultrapure Protogel 
b) 1.55 ml of 3M Tris/HCI, pH 8.9 
c) 4.53 ml of filtered H20 
d) 0.125 ml of 10% SDS 
e) 8 ýd of TEMIED (N, N, N', N-Tetramethylethylenediarnine) 
f) 50 ýd of 10% ammonium persulphate 
A 4% stacking gel was prepared as follows- 
a) 0.5 ml of Ultrapure Protogel 
b) 0.276 ml of 0.5 M Tris/HCI, pH 6.8 
c) 4.104 ml of filtered water 
d) 50 [tl of 10% SDS 
e) 6 ýtl of TEMED 
0 20 ýtl of 10% ammonium persulphate 
The protein samples were prepared for electrophoresis by the addition of 24 mM Tris/HCI, pH 
6.8,1% (w/v) SDS, 7.6% glycerol, 0.02% (w/v) bromophenol blue and 10% 2- 
mercapto ethanol. Electrophoresis was conducted at 100 or II OV for approx. 90 n-ýnutes. The 
gels were either stained with Coomassie stain solution or electrophoretically transferred to 
nitrocellulose. Gels were mcubated with Coomassie stain solution (3 mM Coornassie Brilli Ii iant 
blue R-250,45% ethanol, 9% glacial acetic acid) for at least 30 minutes at room temperature. 
Gels were destained using a solution of 40% methanol and 10% glacial acetic acid in Super 
water. Electrophoretic transfer was conducted onto nitrocellulose blotting membranes 
(Sartorius, GOttingen, Germany) as described previously (Towbin et al., 1979). The transfer 




2.4 - Purification of the 20S proteasome from rat liver and rat spleen 
20S proteasomes were purified from rat liver as described previously (Rivett et al., 1994). 
This protocol was also used to purify 20S proteasomes from rat spleen tissue. Small(50-100 
ýd) aliquots of sample were taken at the end of each purification stage. When producing a 
purification table, the protein content of each sample was determined by the Bradford method 
as described in section 2.2. Suitable amounts of each sample were then assayed against 50 ýM 
Suc-LLVY-AMC or 50 ýM AAF-AMC. These assays were conducted according to the basic 
protocol of section 2.5. Greater amounts e. g. 60 ýtg of the crude extract or ammonium 
sulphate fractionation samples were used per assay tube, compared to the later samples e. g. 
MonoQ 10/ 10 column or Superose 6 column samples where 1-4 ýtg of protein was assayed. 
A fluorescence standard curve for 7-amino-4-methylcoumarin (AMC) was produced as 
described in section 2.5.1. The equation for this curve was used to calculate total and specific 
peptidase activities for the six samples from the preparation. The purity of the 20S proteasome 
preparation was assessed by SDS-PAGE as described in section 2.3. 
2.5 - Proteasome assays 
20S proteasomes were assayed against peptide substrates as described in (Rivett et al., 1994). 
kssays N\ ere conducted in 200 ýtl of 50 mM Hepes buffer/KOH, pH 7.5. The chymotrypsin- 
like activity xvas assayed against either Suc-LLVY-AMC, AAF-AMC or Cbz-GGL-ANIC. 
These substrates , vere used at concentrations between 10 and 50 ýM The trypsln-like activity 
was assaved against 40 or 50 pNI Boc-LSTR-AMC. Previous studies suggested that the 
cleavacre of the PGPH substrate Cbz-LLE-NAP was catalysed by two components. The Zn 
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higher-affmity site obeyed Nfichaefis-Menten kinetics between 0-0.1 mM Cbz-LLE-NAP. The 
velocity increased sigrnoidally with substrate concentration above 0.1 mM. These two 
activities were termed LLE I and LLE2 (Djaballah & Rivett, 1992). The LLE I activity was 
assayed using 0.1 mM Cbz-LLE-NAP. 20S proteasome (I or 2 ýig) were used to start the 
assays that were run for 15-30 nunutes at 37'C. Assays for substrates with the AMC leaving 
group were stopped by the addition of 0.1 ml stop mix (75 mM sodium acetate trihydrate & 
175 mM glacial acetic acid) and 2 ml of Super Q water. The fluorescence (excitation: 370 nm, 
emission- 430 nm) of the samples was measured with a Perkin-Elmer LS-3B fluorescence 
spectrometer. Assays with the Cbz-LLE-NAP substrate were stopped with 0.3 m-1 of ethanol 
and 2 ml of Super Q water. The fluorescence of these samples was measured with an 
excitation wavelength of 333 nm and an emission wavelength of 450 nm (Dahlmann et al., 
1985). The fluorescence of both types of cleaved leaving group was measured against a 
suitable substrate blank. 
2.5.1 - Production of a fluorescence standard curve for 7-amino-4-methylcoumarin 
(AMC) 
Assay tubes were set up in duplicate with 200 ýd of 50 mM Hepes buffer/KOH, pH 7.5 
containing selected quantities of AMC. Stop mix (0.1 ml) and 2 ml of Super Q water was 
added to each assay tube. The fluorescence of the samples was read as described in section 
The 0 nmol samples were used as the reagent blank. Microsoft Excel was used to plot 
the relative fluorescence against AMC content and determine the equation for the straight line. 
Figure 22.2' shows a typical standard curve 
determined using 0-0.3 nmols AMC. The 
correlation coefficient of the standard curves was always greater than 0.99. 
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Figure 2.2 - Standard curve for the fluorescence of 7-amino-4-methylcoumarin (AMC) 
Fluorescence standard curves for 7-amino-4-methylcoumann were determined as described in 
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7-amino-4-methylcoumarin (AMC) content (nmols) 
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2.5.2 - Determination of the Km for Sue-LLVY-AMC hydrolysis by liver 20S or 26S 
proteasomes and spleen 20S proteasomes 
Liver 26S proteasome, liver 20S proteasome or spleen 20S proteasome (I ýtg) was incubated 
with selected concentrations of Suc-LLVY-AMC, in 200 ýd of 50 mM Hepes buffer/KOK pH 
7.5. The assays were run for 15 minutes at 37'C before stopping the reaction and measuring 
the fluorescence as described in section 2.5. The results were fitted to the Michaelis-Menten 
equation to determine the Km value. Curve fitting was performed using the following file 
created in the Scientist 2.0 package (NficroMath, Utah, U. S. A)- 
// MicroMath Scientist Model File 
IndVars- S 
DepVars- V 
Params. Vmax, Km 
V=Vmax*S/(Km+S) 
2.5.3 - Time course for inhibition of the 20S proteasome LLVY activity by Bz-Phe- 
boroLeu 
Liver or spleen 20S proteasome (I ýig) was incubated in the absence or presence of Bz-Phe- 
boroLeu (compound 1), in 200 ýtl of 50 mM Hepes bufferiKOH, pH 7.5. Suc-LLVY-AMC 
(40 ýM) was present in the assay tubes from the beginning of the assay. The assays were run 
for selected time periods between 0 and 20 minutes at 37'C. The assays were stopped and 
fluorescence measurements were taken as described in section 2.5. 
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2.5.4 - Effect of peptidyl boronic acids on 20S proteasome peptidase activities 
Liver or spleen 20S proteasome (I ýtg) was incubated vAth selected concentrations of peptidyl 
boronic acid in 180 ýd of 50 mM Hepes buffer/KOH, pH 7.5. This incubation was conducted 
for 15 minutes at 25'C. Substrate e. g. 20 ýd of 400 W Suc-LLVY-AMC, AAF-AMC, Cbz- 
GGL-AMC or Boc-LSTR-AMC in 50 mM Hepes buffer/KOH, pH 7.5 was added and the 
assays were run for 15 nunutes at 37'C. For assays using 100 ýM Cbz-LLE-AMC as 
substrate, the 20S proteasome was incubated with selected concentrations of peptidyl boronic 
acid in 150 ýtl of 50 rnM Hepes buffer/KOH, pH 7.5.50 ýtl of 400 ýM Cbz-LLE-AMC was 
added and the assays were run for 15 minutes at 37'C. The assays were stopped and 
fluorescence measurements were taken as described in section 2.5. 
2.6 - Kinetic analysis 
Ki values for inhibition of the liver or spleen 20S proteasome LLVY activity were initially 
deten-nined using the Henderson equation for tight-binding competitive inhibitors (Henderson, 
1972). 
1, /(l + K, ((St+K .. )/K,,, )vo/vi 
where 1, = total inhibitor concentration, v, = inhibited velocity, vo = urunhibited velocity, E, = 
total enzyme concentration, KI = dissociation constant for the binding of inhibitor to enzyme, 
S, = total substrate concentration and K,,, = the dissociation constant for the binding of 
yme. The data analysis was conducted using the Scientist 2.0 package. The substrate to enz III 
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following Scientist file was written by Prof Rob John of the University of Cardiff to deternune 
the Ki from sets of v, /vo (v) against 1, data- 












The values of E and S were altered for experiments using 2 ýtg (0.014 ýtk[) 20S proteasome 
or substrate concentrations of 10 or 20 ýM Suc-LLVY-AMC - 
Similar adjustments were made 
when fitting various data sets to other models. 
Two fUrther models were closely exammed to see if they produced a better fit to the observed 
data. The first of these assumed that the inhibition was occurring by a non-competitive 
mechanism, with the putative El complex allowing a low rate of substrate velocity. Prof Rob 
John wrote the following Scientist model file for this type of inhibition-. 
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H MicroMath Scientist Model File 
IndVars- I 
DepVars- v 





x==(-b-sqrt(b/12-4 *a* c))/(2 *a) 
m= VE 
n= I -x/E 
v= r*m+n 
r= ratio of the ka, values for the EIS and ES complexes. Value will be less than I because 
EIS undergoes hydrolysis to El +P much less readily than ES hydrolyses to E+P. 
The third model file written by Prof Rob John assumed that the inhibition was occurring via 
a partially competitive mechanism. In this mechanism, product can be produced by ES and 
EIS complexes. The substrate is assumed to combine more readily with E than El, hence the 
use of Km and Kmi values. Because the Ki values for the peptidyl boroffic acids are very much 
lower than the Km for Suc-LLVY-AMC, only a single Ki value was employed in the model. 




H MicroMath Scientist Model file 
IndVars: I 
DepVarsý v 








x=(-b+sqrt(b"\2-4 *a* c))/(2 *a) 
y=l/(Kmi/Km*Ki/x +I +Kmi/S) 
v=Vm*x/E+r*Vm*y/E 
Kmi = the dissociation constant for the binding of substrate to the El complex, r= the 
difference in catalytic activity of the EIS and ES complexes. 
A fourth subpopulation model was also considered. This model assumed that a subpopulation 
of 20S proteasomes exhibited an LLVY activity that could not be inhibited by the peptidyl 
boronic acids. The vi/vo data for each experiment was processed with following equation-. 
Corrected vi/vo = [(vi/vo) - b]/c 
Where b= the fraction of activity remaining at highest inhibitor concentration e. g. 500 rM and 
c= factor required to express the vi/vo values as a fraction of the LLVY activity that can be 
inhibited. For example if v, /vO at the highest inhibitor concentration is 0.14, then b=0.14 and 
0.86. 
The corrected (v) and I %'alues were then fitted to the competitive Henderson equation 
usiniz Scientist 2.0. 
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2.7 - Investigating the reversibility of peptidyl boronic acid binding to liver 20S 
proteasomes 
Liver 20S proteasome (38 ýtg at 0.02 ýtg/ýd or 21.5 ýtg at 0.05 ýtg/ýtl) was incubated in the 
absence or presence of peptidyl boronic acid in 50 mM Hepes buffer/KOH, pH 7.5. The 
amount of DMSO added with the peptidyl boronic acid did not exceed 0.1%. Theiricubation 
was conducted for 15 or 20 minutes at 25'C. AJlquots of 20S proteasome (2 ýtg) were 
assayed against either 40 ýM Suc-LLVY-AMC, AAF-AMC, Boc-LSTR-AMC or 100 ýM 
Cbz-LLE-NAP. Assays were conducted as described in section 2.5. The remaining portions 
(I. I or 0.3 5 ml) of 20S proteasome were dialysed separately against 400-600 or 200 ml 
volumes of 50 mM Hepes buffer/KOH, pH 7.5. Dialysis was conducted using collodion bags 
(75 IcDa cut-off, Schleicher & Schiffl) at 4'C overnight. The dialysed samples were assayed 
against the four substrates as before. 
2.8 - Cell culture 
L-132 human embryonic lung cells were grown in Dulbecco's modified essential medium 
(DMEM) supplemented with 10% (v/v) new-born bovine serum and penicillin/ streptomycin 
(50 IU/mI and 50 ýtg/ml, respectively) in a humidified atmosphere of 
5%(V/V) C02/air (Mason 
et al., 1996). IMR-32 human neuroblastoma cells were cultured to 80% confluency in 
Dulbecco's modified Eagle's medium/F12 containing 10% (v/v) foetal calf serum, 2 m. M 
olutamine and 50 ýtg/ml penicillin/streptomycin (Christie et al., 1999). INIR-32 APP-751 
murine tetraplold neuronal cells were cultured to 80% confluency in a complex medium 
containing 60"o DNIEN 1,30% (v/v) Ham F- 12,5% (\, Iv) (x-NIIEM, I% (v/v) foetal calf 
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serum and 4% (v/v) new-born calf serum. The medium also contained 6 g/L glucose, 200 mM 
L-glutamine, 15 mM Hepes buffer, I mM dibutyryl cAW and 2.5 ýM 5-bromo-deoxyundine. 
The pH of the medium was adjusted to 7.4 with IM NaOH (Neill et al., 1994). 
2.9 - Inhibition of 20S and 26S proteasomes in cultured cells 
Growth medium was removed from subconfluent. L- 13 2 cells and replaced with fresh medium 
containing DMSO (1%), selected concentrations of peptidyl boronic acid or Cbz-LLL-vinyl 
sulphone in DMSO. For experiments with IMR-32 and IMR-32 APP-751 cells the growth 
medium was removed and replaced with serum-free growth medium containing DMSO (I%) 
or selected concentrations of 2-pyrazinylcarbonyl-Phe-boroLeu. Flasks were incubated at 
37'C for 2 or 24 hours before washing the cells with 3xlO ml of PBS. The cells were lysed 
using two different protocols designed to favour the recovery of 20S or 26S proteasomes. In 
the first protocol the cells were lysed with I mi of RIPA buffer (50 mM TfisiHCI, pH 8.0,150 
rnM NaCl, 0.5% sodium deoxycholate, 1% (v/v) Nonidet P-40,0.1% SDS) as described 
previously (Mason et al., 1996). RIPA buffer causes the dissociation of 26S proteasomes into 
20S proteasomes and 19S regulatory complexes. Alternatively, L-132 cells were released from 
the flask through incubation with I ml of a trypsin-versene solution (I - 10; GIBCO BRL) for 
10 minutes at 3 7'C. PB S (5 ml) was added to each flask before resuspending the cells. The 
IMR-332 and IMR-32 APP-751 cells were scraped from the surface of the flask into the 5 ml 
of PBS. The cell suspensions were transferred to separate tubes and the cells were pelleted 
by centrifugation at I 000xg for 5 minutes. The cells were then lysed in 0.5 ml of 20 mM Tns 
buffer/1-10. pH 7.5 containing 5 mM ATP, 10% glycerol and 0.2% Nonidet P-40 (Mason et 
al., 199S). ATP and glycerol were added to the lysis buffer to maintain the structure of the 
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26S proteasome during cell lysis. The lysed cells were diluted 1: 10, %Nith lysis buffer containing 
no Nonidet P-40. The protein content of the cell lysates was deterrmned using the Lowry 
method (Lowry et al., 195 1). The protein in 0.2 ml of the 20S proteasome samples and 0.5 
ml of the 26S proteasome samples was precipitated by the addition of 0.02% sodium 
deoxycholate and 8% trichloroacetic acid at O'C. The protein was pelleted by centrifugation 
at 20,000xg for 15 minutes at 4'C. After discarding the supernatant, the pellets were washed 
with I ml of ice-cold 90% acetone. These samples were centrifuged as above for 10 minutes 
and the supernatants were discarded. The protein pellets were air-dried and then dissolved in 
0.5 ml of 0.5 M NaOH. Two, 0.2 ml aliquots of each sample were used in the determination. 
The absorbance (750 nm) was measured using 3 ml plastic cuvettes and a Pharmacia Ultraspec 
III spectrophotometer. 
Immunoprecipitations were carried out for the two sets of samples using the same amount of 
protein. MCP20 or Ab 186 antibody (20 ýtl) and a 50% suspension of protein A-agarose in 
PBS (150 ýil) were added to the samples. The tubes were tumbled end-over-end at 4'C for 
16 hours. The 20S proteasome immunoprecipitates were washed with 3xI ný of Net buffer 
(50 mM Tris/HCI, pH 7.0,150 mM NaCl, 5 niM EDTA, 0.5% sodium deoxycholate, 0.1% 
bovine serum albumin, 0.1% SDS and 0.5% (v/v) Nonidet P-40). The 26S proteasome 
immunoprecipitates were washed with 3xI rt-ý of 26S lysis buffer containing 0.02% NOnIdet- 
P40 instead of 0.2%. The 20S and 26S proteasome immunoprecipitates were then washed 
with 33 xI ml of 50 mM Hepes buffer/KOH, pH 7.5 or 50 mM Hepes buffer/KOH, pH 7.5 
contairi-ing 2 mM ATP respectively. The level of buffer above the pellets was adjusted to give Z 
50', o suspension (-150 [d total volume) . 
Two, 60 [tI aliquots of the resuspended pellets 
Nvere assayed against 50 pM Suc-LLNY-AMC. The substrate was added as 40 ýil of 125 pM 
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Suc-LLVY-AMC in either 50 mM Hepes buffer/KOH, pH 7.5 or 50 mM Hepes buffer/KOH, 
pH 7.5 containing 2 mM ATP for 20S and 26S proteasomes samples respectively. These 
assays were run for 2 hours at 37'C. After 2 hours, 20 ýd of the supernatant above the peflets 
was removed into a separate tube and diluted with 2.28 ml of Super Q water. The 
fluorescence of these samples was measured as described in section 2.5. Substrate blanks ývere 
produced by running two tubes with 60 ýtl aliquots of 50% protein A-agarose in 50 mM Hepes 
bufferiKOH, pH 7.5 or 50 mM Hepes buffer/KOH, pH 7.5 containing 2 mM ATP. 
2.10 - Investigating the inhibition of proteasomes in cells 
Single flasks of subconfluent human embryonic lung L-1 32 cefls were cultured in fresh medium 
(5 ml) amended with either 5 ýtl of ethanol or 5 ýtl of ethanol containing 100 ýtM or I mM ['H] 
Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor). The resultant [3 H] Phenacetyl-Leu- 
Leu-boroLeu concentration in the culture medium was 100 nN4 or I ýM respectively. The 
flasks were incubated for 2 hours at 37'C. Cells were released from the flask through 
incubation with I ml of a trypsin-versene solution (I A 0; GEBCO BRL) for 10 minutes at 
370C. PBS (5 ml) was added to each flask before resuspending the cells. The suspension was 
transferred to a separate tube and the cells were pelleted by centrifugation at 1000xg for 5 
minutes. The cells were then lysed in 200 ýtl of 20 mM Tris buffer/HCI, pH 7.5 containing 5 
mM ATP, 10% glycerol and 0.2% Nonidet P-40. Lysis was conducted by passing the 
suspension through a 25 gauge needle. The lysate was transferred to a separate tube and 
centrifuged at 20,000xg for 8 minutes. The supernatant was immediately fractionated by gel I 
filtration using a Pharmacia Superose 6 10/30 column. The column was equilibrated with 50 
nil of 20 mNI Tris buffer/HCI, pH 7.5 containing 5 mM ATP, 10% glycerol and 150 mM KCI. 
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The lysate was resolved at a flow rate of 0.2 ml. /rnin and I ml fractions were collected from 
time zero of the run. Aliquots of each fraction (350 W) were mixed with 12 nil of Opt, phase 
HiSafe 2 liquid scintillation cocktail before conducting tritium counting as described in section 
2.11. Two, 150 ýtl aliquots of the fractions were assayed against 40 ýM Suc-LLVY-ANIC. 
The assays were conducted either in the absence or presence of 0.02% SDS for 30 minutes at 
37'C. Low (0.02%) concentrations of SDS activates the LLVY activity of 20S proteasomes 
whilest inhibiting the same activity of 26S proteasomes. Assays were stopped and the 
fluorescence read as described in section 2.5. 
2.11 - Radioactivity measurements 
Samples for tritium counting (0.2-0.35 ml) were diluted with 8 or 12 ml of Optiphase HiSafe 
2 liquid scintillation cocktail in 20 ml polyethylene scintillation vials (Packard, Meriden, 
U. S. A. ). The samples were inverted approx. 20 times and then left in the dark for at least one 
hour before counting. Tritium counting was performed using a Tri-Carb 1600 TR liquid 
scintillation analyzer (Packard, Pangbourne, U. K. ). The average count per minute (cpm) 
reading was determined over 5 or 10 minutes for each sample. The background cpm reading 
was determined with suitable control samples and then used to correct the observed cpm 
readings. 
2.12 - HPLC separation of liver 20S proteasome subunits 
Liver 20S proteasome (280 ýig, 1.1 ýig/ýtl) was dialysed against 50 mM Hepes buffer[KOH, 
pH 7.5 using a 75 k-Da collodion bag. Dialysis was conducted at 4'C for 3 hours. Dialysed 
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20S proteasome (270 ýtg) was then nuxed with 1% DMSO and 0.5% trifluoroacetic acid 
(TFA) and incubated at room temperature for 30 minutes. TFA (0.5%) reduced the pH of the 
solution to approx. 2 causing the dissociation of the complex. Acetonitrile (20%) was added 
to the sample and the resultant solution was centrifuged for 10 minutes at 10,000xg. A Vvdac 
C4 reverse-phase HPLC column was connected to a Hewlett-Packard I 100 FEPLC system. The 
column was equilibrated with 10 ml of 10% acetonitrile containing 0.1% TFA. A flow rate 
of 0.3 mUmin was used and the column temperature was regulated to 22'C. An aliquot (200 
ýtg) of the centrifuged sample was loaded onto the column in 10% acetonitrile contai rung 0- I% 
TFA. The column was washed with 6 ml of this buffer. The following acetonitrile gradient 














The absorbance (220 nm) was measured throughout the run. The results were integrated and 
presented using the Hewlett Packard Chernstation A. 04.02 software. Fractions (2 minute, 0.6 
ml) were collected from 6 minutes into the run. 
2.12.1 - HPLC separation of Cbz-Leu-Leu-boroLeu (pinacol ester) (compound 8) 
modified liver 20S proteasome subunits 
Liver 20S proteasome (2SO ýig- 1.1 ýtg/ýtl) was dialysed against 50 mM Hepes I 
buffer/KOH, 
Percent acetonitrile (%) 
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pH 7.5 using a 75 kDa collodion bag. Dialysis was conducted at 4'C for 3 hours. DIalysed 
20S proteasome (270 ýtg; 1.6 ýM) was incubated, %Nith 10 ýM Cbz-Leu-Leu-boroLeu (pinacol 
ester) (DMSO). The remaining 10 ýtg of 20S proteasome was Incubated with 1% DMSO as 
a control. Both samples were incubated at 25'C for 30 minutes. Aliquots (2 ýtg) of the 
proteasome samples were assayed with 40 ýM Suc-LLVY-AMC as described in section 2.5. 
TFA (0.5%) was added to the remaining Cbz-Leu-Leu-boroLeu (pinacol ester) modified 
proteasome sample. This solution was incubated at room temperature for 30 minutes. The 
dissociated proteasome subunits were then resolved on the Vydac C4 HPLC column as 
described in section 2.12. 
2.12.2 - HPLC separation of [3HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) 
labeled liver 20S proteasome subunits 
Liver 20S proteasome (150 ýtg; 0.8 pM) was dialysed against 50 mM Hepes buffer/KOH, pH 
7.5 using a 75 kDa collodion bag. Dialysis was conducted at 4'C for 3 hours. Dialysed 
proteasome (130 ýtg) was then incubated with 5 ýtM 
[3 H] Phenacetyl-Leu-Leu-boroLeu 
(radiolabelled inhibitor) for 30 minutes at 25'C. A control sample of dialysed proteasome (13 
4g, 0.8 ýM) was incubated with 0.125% ethanol for 30 minutes at 25'C. Aliquots (I ýtg) of 
radiolabelled inhibitor treated, ethanol treated or untreated 20S proteasome were assayed with 
40 pM Suc-LLVY-AMC. The assays were conducted in duplicate as described in section 2.5. 
A PD- 10 gel filtration column (Pharmacia) was equilibrated with 25 ml of 50 m-M Hepes 
buffer/KOH, pH 7.5. The radiolabelled 20S proteasome sample (250 ýtl) was run onto the 
colunin together Nvith 2.25 ml of 50 mM Hepes buffer/KOH, pH 7.5. Five, 0.5 ml fractions 
were collected by applying 0.5 n-d aliquots of 50 mNI Hepes buffer/KOK pH 7.5 to the top of 
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the column. The protein content of the fractions was determined by the Bradford method as 
described in section 2.2. The 20S proteasomes predominantly eluted in fractions 2 and 3 that 
were pooled. This I ml sample was prepared for injection into the C4 HPLC column in 4 
aliquots of 250 ýd. The proteasome subunits were dissociated by the addition of 0.5% TFA 
and incubation at room temperature for 30 M-Inutes. The C4 column was equilibrated with 
10% acetonitrile containing 0.1 % TFA as described in section 2.12. The four samples were 
injected into the column sequentially, washing the sample loop with 1.2 ml of 10% acetonitrile 
containing 0.1% TFA between injections. The acetonitrile gradient was run as described in 
section 2.12. Fractions (0.6 ml) were collected from 14 minutes into the gradient. Half (0. 
ml) of each fraction was mixed with 8 ml of Optiphase HiSafe 2 liquid scintillation cocktail 
before conducting tritium counting as described in section 2.11. 
A control experiment was also performed in which 0.2 ýil of I mM radiolabelled inhibitor, was 
added to 260 ýd of 50 mM Hepes buffer/KOH, pH 7.5 containing 0.5% TFA. Acetonitrile 
(20%) was added to the sample. The sample was injected onto the Vydac C4 column and 
resolved using the acetonitrile gradient as described in section 2.12. Fractions (0.6 ml) were 
collected from 14 nunutes into the gradient. Half (0.3 ml) of each fraction was mixed with 8 
ml of Optiphase HiSafe 2 liquid scintillation cocktail before conducting tritium counting as 
described in section 2.11. 
2.13 - Rapid gel filtration of [3 HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) 
labelled liver 20S proteasomes 
Livei- 20S proteasome (80 ýtg at 0.05 pg/pi in 50 mM Hepes buffer/KOH, pH 7.5) was 
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incubated with I ýM radiolabelled inhibitor for 15 nunutes at 250C. A control 20S proteasome 
solution (I I ýtg at 0.05 ýtg/ýd in 50 mM Hepes buffer/KOH, pH 7.5) was also incubated for 
15 minutes at 25'C. AJIquots (I ýtg) of the radiolabelled or control proteasome solutions Nvere 
assayed against either 40 ýM Suc-LLVY-AMC, AAF-AMC, Boc-LSTR-AMC or 100 ýM 
Cbz-LLE-NAP. The assays were conducted as described in section 2.5 using a 30 minute 
incubation at 3 7'C. Two PD- 10 gel filtration columns (Pharmacia) were equilibrated with 25 
ml of 50 mM Hepes buffer/KOH, pH 7.5. The remaining radiolabel-led proteasome sample was 
diluted to 2.5 ml with 50 mM Hepes buffer/KOH, pH 7.5. This sample was run onto the first 
column. Five, 0.5 ml fractions were collected by sequentially adding 0.5 H aliquots of 50 mM 
Hepes buffer/KOH, pH 7.5 to the column. Fractions 2 and 3 were pooled and diluted to 2.5 
ml with 50 m-M Hepes buffer/KOH, pH 7.5. This sample was applied to the second column. 
Five, 0.5 ml fractions were collected as above. The Bradford method was used to determine 
the protein concentration of the five fractions (section 2.2). Aliquots (I ýtg) of 20S 
proteasome were then assayed against the four peptidase substrates as above. 
2.14 - Investigation of the ability to block the labelling of 20S proteasomes by 13 HI 
Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) 
To investigate whether an irreversible inhibitor of the chyrnotrypsin-like activity can block 
incorporation of counts from the radiolabelled peptidyl boronic acid, two Eppendorf tubes 
were set up containing liver 20S proteasome (27.5 ýtg at 0.05 ýtg/ýd in 50 mM Hepes 
buffer/KOH, pH 7.5). Cbz-LLL-vinyl sulphone (10 ýtM) was added to tube 2 and both tubes 
were incubated at 37'C for 60 minutes. Radiolabelled inhibitor (I ýN) was added to both 
tubes that were then incubated at 215'C for 15 rrunutes. Four PD-10 columns were equilibrated 
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with 25 n-d of 50 mM Hepes buffer/KOK pH 7.5. The contents of tube 1 (550 ýtl) were run 
into the first PD- 10 column followed by 1950 ýtl of 50 mM Hepes buffer/KOH, pH 7.5. Five. 
0.5 ml fractions were collected by applying 0.5 ml aliquots of 50 mM Hepes buffer/KOH, pH 
7.5 to the top of the column. The first four fractions were pooled. This sample was run onto 
the second PD-10 column followed by 0.5 ml of 50 mM Hepes buffer/KOH, pH 7.5. Five, 0.5 
ml fractions were collected as before. The contents of tube 2 were also fractionated using the 
same method and PD- 10 columns 3 and 4. The Bradford method was used to determine the 
protein content of the fractions from PD- 10 columns 2 and 4. Aliquots (100 ýtl) of fractions 
1-4 and 2-4 were used respectively. Two, 3 ýtg aliquots of 20S proteasome from either PD- 10 
column 2 or 4 were individually mixed with 8 ml of Optiphase HiSafe 2 liquid scintillation 
cocktail and subjected to radioactivity counting as described in section 2.11. 
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Chapter 3- Characterisation of proteasome inhibition by peptidyl boronic acids 
3.1 - Introduction 
Peptidyl boronic acids are potent inhibitors of serine proteases including pancreatic elastase, 
cc-lytic protease and dipeptidyl pepticlase IV (Zembower et al, 1996; Kettner et al., 1988, 
Coutts et al., 1996). In normal substrate hydrolysis the oxygen from the hydroxyl group of the 
catalytic serine, attacks the electrophilic carbonyl carbon of the peptide bond. A tetrahedral 
transition state results with the proton from the hydroxyl group being donated to the histidine 
of the catalytic triad. Peptidyl boromc acids also form a tetrahedral transition state complex 
with the catalytic serine residue. An empty p-orbital on the boron atom readily accepts the 
lone pair of electrons fTom the catalytic oxygen atom. This complex is relatively stable with 
the Ki values for peptidyl boronic acid inhibition often being in the low nanomolar range. For 
example the Ki for inhibiting the Ac-APA-pNA cleaving activity of a-lytic protease by Boc- 
Ala-Pro-(L)boroVal was 0.35 nM at pH 7.5 (Kettner et al., 1988). The dipeptidyl peptidase 
IV catalysed hydrolysis of H2N-Ala-Pro-4-methoxy-2-napthylamide was inhibited by a number 
of peptidyl boronic acids. These peptidyl boronic acids had the general structure H2N-Xaa- 
boroPro. The best IC50 values of II and 15 nN4 were obtained using i--2-armnobutyric acid 
or L-Ala as X,,,, (Coutts et al., 1996). The tight association of peptidyl boronIc acids to serine 
proteases has been used to purify mixtures of senne proteases (Zembower et al., 1996). 
Affinity matrices were made by removing the Cbz groups from e. g. Cbz-Ala-Ala-boroVal. The 
N-ternlinal residues were then immobiliZed by reaction with Sepharose 6B. This affinity matrix 
v,, as used to separate nuxtures of porcine pancreatic elastase with bovine (x-chymotrypsin and 
human neLitrophil elastase with human cathepsM G (Zembower et al., 1996). Peptidyl boronic 
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acids often exhibit slow binding to the catalytic sites of serine proteases. Inhibition of cc-lytlc 
protease catalysed Ac-APA-pNA hydrolysis by 25 nM MeOSuc-Ala-Ala-Pro-boroVal 
increased to the full extent after approximately 10 minutes (Kettner et al., 1988). 
Recent publications have described the potent inhibition of the 20S proteasome chymotrypsin- 
like activity by peptidyl boronic acids (IqbaI et al., 1996; Adams et at., 1998). The peptidyl 
boronic acids would presumably be reacting with particular catalytic arnino-terminal threonines 
(Seerniffler et al., 1995; Groll et al., 1997; Bogyo et al., 1998). In these recent studies only one 
and three peptidyl boronic acids were tested respectively. Therefore no conclusions could be 
drawn on the best combination of amino acids for inhibiting the chymotrypsin-like activity. 
One dipeptidyl boromc acid containing the NI-nitroArg-Leu combination of amino acids, did 
not inhibit the trypsin-like activity at I [tM concentration (Iqbal et al., 1996). The effect of 
peptidyl boronic acids on other 20S proteasome activities were not investigated. Chemists at 
SmithKline Beecham synthesized a large number of peptidyl boronic acids for use in their 
experimental work. In this chapter I will describe initial experiments that characterised the 
effects of a number of di- and tripeptidyl boronic acids on the peptidase activities of the 20S 
proteasome. 
3.2 - Purification of the 20S proteasome from rat liver and determination of the Km for 
Suc-LLVY-AMC hydrolysis 
20S proteasomes were purified from rat liver as described previously (Rivett et al., 1994). 
Table 3,1 shows, the punfication table from a typical liver preparation using 230 g of rat liver. 
Subsequent preparations Yielded up to II mg of 20S proteasome vAth similar specific activities 
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Chapter 3- 3 
The Km for Suc-LLVY-AMC hydrolysis by liver 20S proteasomes was determined using 
selected concentrations of Suc-LLVY-AMC and I ýtg portions of liver 20S proteasome as 
described in Chapter 2. Figure 3.1 shows a typical set of data fitted to the Nfichaefis-Menten 
equation using Scientist 2.0. The rate of hydrolysis ceased to follow Michaelis behaviour 
above 150 ýM. This was probably due to product accumulation rather than substrate 
depletion, as approx. 5% of the substrate was cleaved using 200 ýxM Suc-LLVY-AMC. The 
average Km value from 4 determinations was 130 ± 23 pM. The Km for the 26S proteasome 
LLVY activity was also deternýned. A typical set of data for the 26S proteasome is also 
shown in Figure 3.1. The Krn was determined to be 95 ýM (range ± 2) from two 
determinations. Under normal assay conditions the LLVY activity of the 26S proteasome is 
5-6 times higher than the 20S proteasome. This difference can be explained partially by the 
lower Km value but primardy by the 4.5 times higher Vmax value. Hence the 19S regulatory 
groups substantially increase the rate of catalysis of this substrate, without significantly 
affecting its ability to bind to the appropriate catalytic sites. 
3.3 - Time course for inhibition of the liver 20S proteasome LLVY activity by peptidyl 
boronic acids is consistent with slow binding 
Figure 3.2 shows the time course for inhibition of the liver 20S proteasome LLVY activity by 
10 rA4 Bz-Phe-boroLeu (compound 1). Below are the chemical structures of Bz-Phe-boroLeu 
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Preliminary studies had shown that a number of peptidyl boronic acids caused potent inhibition 
of the liver 20S proteasome LLVY activity. In these assays the peptidyl boronic acid was 
preincubated with 20S proteasome for 15 minutes. This allowed the peptidyl boro ic acid to ni I 
bind to the 20S proteasome before addition of substrate. Compound I was shown to be the 
most potent inhibitor of the 20S proteasome LLVY activity. In the time course assays 20S 
proteasome (I ýtg) was added to assay tubes containing either substrate or substrate and 
compound 1. Assays were performed at 37'C for selected times. The LLVY activity in the 
absence of inhibitor was linear for at least 20 minutes. In the presence of 10 nN4 compound 
I the fully inhibited rate of reaction was only observed after approximately 10-12 minutes. 
This is in contrast to classical reversible inhibitors, that produce the fully inhibited reaction rate 
from time zero. The enzyme concentration used in the experiment was 7 nM. Therefore 
compound I can be described as a tight-binding inhibitor that inhibits the LLVY activity at 
concentrations comparable to the enzyme concentration (Morrison, 1982). The slow-binding 
behaviour could be explained by steric hinderance, slowing the passage of inhibitor to the 
catalytic sites. This may be a significant factor for the 20S proteasome, which has catalytic 
sites embedded in the centre of the complex. Also a slow conformational change may occur 
following inhibitor binding to the catalytic threonine(s). This confonnation change would 'eld I YI 
the fully inhibited structure. 
Previous studies have shown that peptidyl boronic acids often exhibit slow-binding inhibition 
of serine proteases. Slow-binding inhibition is particularly common with peptidyl boronic 
acids that are substrate analogues (Kettner et al., 1988; Bachovchin et al., 1988). MeOSuc- 
Ala-Ala-Pro-boro\'al was shown to be a slow-binding inhibitor of a-lytic protease (Kettner 
et al., 1988). The cleavage of 4 m'. \I Ac-APA-pNA by 5 nM cc-IýIic protease was only fully 
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inhibited by 25 nM MeOSuc-Ala-Ala-Pro-boroVal, after 10 nunutes incubation at 25T. This 
slow-binding behaviour was observed even with a relatively high (4 x Ki) concentration of 
inhibitor. Bachovchin and coworkers (1988) used "N and 'H NMR spectroscopy to 
investigate the binding of peptidyl boronic acids to the serine protease (x-lytic protease. They 
suggested that a large activation energy may need to be overcome before covalent bond 
formation occurs. Hence the residues of the catalytic site may need to move following 
inhibitor binding to ease covalent bond formation. Slow binding of peptidyl aldehydes to the 
Cbz-GGF-pAB cleaving site of pituitary 20S proteasomes was previously observed. 
Micromolar concentrations of Cbz-LLF-al or Ac-LL-Nle-al needed 20-30 minutes 
preincubation with 20S proteasome before exerting the full inhibitory effect (Vinitsky et al., 
1992). Analysis of the progress curves suggested that the peptidyl aldehydes were either 
binding slowly in a single step or rapidly binding to the catalytic site before undergoing a slow 
conformational change that exerted full inhibition of catalysis. 
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Figure 3.1 - Hydrolysis of Sue-LLNY-AMC by liver 20S and 26S proteasomes (page 71) 
The 20S (circles) or 26S (triangles) proteasomes were assayed with a range of Suc-LLVY- 
AMC concentrations in 50 mM Hepes buffer/KOH, pH 7.5. Assays were conducted for 15 
minutes at 37'C, using I ýtg of either proteasome form. Results from a typical experiment 
performed in duplicate are shown. Mean Km values were determined by fitting the data from 
separate experiments to the Michaelis-Menten equation. Values of 130 ýtm (S. D. ± 23, n=4) 
for 20S proteasomes and 95 ýtM (range ± 2, n=2) for 26S proteasomes were calculated. 
Figure 3.2 - Time course for inhibition of the liver 20S proteasome LLVY activity by 10 
nM Bz-Phe-boroLeu (compound 1) (page 72) 
Liver 20S proteasomes (I ýtg) were incubated at 37'C in the presence (filled circles) or 
absence (open diamonds) of 10 nM compound 1. Substrate (40 ýM Suc-LLVY-AMC) was 
present from time zero and substrate hydrolysis was determined after incubation for selected 
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3.4 - Effect of Bz-Phe-boroLeu (compound 1) on selected activities of liver 20S 
proteasomes 
Table 3.2A shows the effect of compound I on the LLVY, LSTF, GGL, AAF and LLE I 
activities of liver 20S proteasomes. Compound I caused inhibition of the LLVY activity at 
both 20 and 80 rM concentrations. Compound I was much less effective against the other 
peptidase activities. The LLEI activity was substantially inhibited at 80 nM compound 1, 
suggesting an IC50 value of approximately 100 nM. 80 nM compound I did not signIficantly 
inhibit the cleavage of the chymotrypsin-like substrates Cbz-GGL-AMC or AAF-AMC. 
Previous studies have employed peptidyl chloromethanes as inhibitors of the 20S proteasome. 
14-4-F -C H20, LLE-CH2Cl and Cbz-LLE-CH2CIwere all more potent inhibitors of the LLVY 
activity than the AAF activity. Taken together these results suggest that the chyrnotrypsin-like 
substrates AAF-AMC and Cbz-GGL-AMC are partially hydrolysed at a site distinct from the 
Suc-LLVY-AMC cleaving site (Reidfinger et al., 1997; Savory et al., 1993). In another study 
the antitumor drug Aclacinomycin A inhibited the LLVY activity of pituitary 20S proteasomes, 
to a greater extent than the cleavage of the chymotrypsin-like substrates Cbz-EAL-pNA or 
Cbz-GGL-pNA (Figueiredo-Pereira et al., 1996). The hydrolysis of Cbz-EEAL-pNA and Suc- 
LLVY-AMC was inhibited to a sinfflar extent using 50 and 100 ýM Aclacinomycin A. 
Compound 1 (20 and 80 rtM) caused a slight stimulation of the LSTR activity. This effect has 
been observed with other types of proteasome inhibitor e. g. 3,4-dichloroisocoumarin and 
certain peptidyl chloromethanes (Djaballah et al., 1992; Savory et al., 1993). Stimulation of 
the LSTR activity may result from inhibitor binding to non-trypsin-like sites, causing 
conformational changes that stimulate the trypsin-like activity. 
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3.4.1 - Cbz-Leu-boroLeu (80 nM) only causes significant inhibition of the liver 20S 
proteasome LLVY activity 
Cbz-Leu-boroLeu was found to be an effective inhibitor of the liver 20S proteasome LLVY 
activity. Table 3.2B illustrates the effect of 20 and 80 rM Cbz-Leu-boroLeu on the LLN"Y', 
LSTR, GGL, AAF and LLEI activities of liver 20S proteasomes. Only the LLVY activity was 
inhibited by 20 and 80 n. M Cbz-Leu-boroLeu. Of note is the fact that compared to Bz-Phe- 
boroLeu (compound 1), 80 nT\4 Cbz-Leu-boroLeu caused much less inhibition of the LLE I 
activity and no stimulation of the LSTR activity. This suggests that modification of the LLE I 
catalysing site(s) by compound I may cause the observed stimulation of the LSTR activity. 
Alternatively, the modification of the LLVY cleaving sites by the smaller Cbz-Leu-boroLeu 
compound, may not cause the conformational changes that stimulate the LSTR activity. 
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Table 3.2 - Inhibition of the liver 20S proteasome chymotrypsin-like activity by Bz-Phe- 
boroLeu (compound 1) (Panel A) and Cbz-Leu-boroLeu (Panel B) 
Panel A 
Substrate Activity (% of control) 
20 nM Bz-Phe-boroLeu 
Activity (% of control) 
80 nN4 Bz-Phe-boroLeu 
Suc-LLVY-AMC 53 31 
AAF-AMC 89 82 
Cbz-GGL-AMC 93 82 
Boc-LSTR-AMC 113 124 
Cbz-LLE-NAP 96 61 
Panel B 
Substrate 
Activity (% of control) 
20 nM Cbz-Leu-boroLeu 
Activity (% of control) 
80 nM Cbz-Leu-boroLeu 
Suc-LLVY-AMC 65 34 
AAF-AMC 96 86 
Cbz-GGL-AMC 100 90 
Boc-LSTR-AMC 96 98 
Cbz-LLE-NAP 97 84 
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Assays were performed as described in Chapter 2 using I ýtg of liver 20S proteasome. The 
substrate concentration was 40 ýM for Suc-LLVY-AMC, AAF-AMC, Cbz-GGL-AMC and 
Boc-LSTR-AMC. Cbz-LLE-NAP was used at 100 ýM Values are from two experiments 
(Panel A) or one experiment (Panel B) performed in duplicate. These values are expressed as 
percent of control activity in samples containing no inhibitor. 
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3.5 - Modification of liver 20S proteasome catalytic sites by peptidyl boronic acids is 
reversible 
Dialysis was employed to confirm that the effects of peptidyl boronic acids on 20S proteasome 
activities were reversible. In one experiment liver 20S proteasome (3 8 ýtg at 0.02 4g/ýd) was 
incubated with either 0,70 nM or I ýM compound I in 50 mM Hepes buffer/KOH, pH 7.5. 
After a preincubation of 15 minutes at 25'C, 2 ýtg portions of the liver 20S proteasome were 
assayed against either 40 ýtM Suc-LLVY-AMC, AAF-AMC, Boc-LSTR-AMC or 100 ýM 
Cbz-LLE-NAP. The remaining 20S proteasome solutions (I. I ml) were dialysed separately 
against 50 mM Hepes buffer/KOH, pH 7.5 using 75 kDa collodion bags. The peptidase assays 
were then repeated with the dialysed 20S proteasome. The results of this experiment are 
shown in Table 3.3. Overnight dialysis only partially reversed the inhibition of the LLVY 
activity. Compound I therefore exhibited a slow off-rate from the chymotrypsin-like catalytic 
sites. This was the case even though the concentration of compound I around the 20S 
proteasomes had been reduced to 0.1 and 1.6 nM respectively. The inhibition of the AAF and 
LLE I activities was also not readily reversed. Table 3.4 shows the results of a similar dialysis 
experiment using IW of either compound 1, Cbz-Leu-boroNle (pinacol ester) or Cbz-Leu- 
Leu-boroLeu (pinacol ester). The results in Tables 3.3 and 3.4 confinn that inhibition of the 
LLVY, AAF and LLE I activities by compound I can be slowly reversed. Sufficient time as 
well as changes in dialysis buffer would be required to recover fuH activity. Compound I was 
found to either stimulate or have no effect on the LSTR activity. This stimulation tended to 
increase rather than be reversed by dialysis. Stimulation of the LSTR activity may result from 
inhibitor binding to non-trypsin-like catalytic sites, causing conformational changes that 
stimulate activity at trypsin-like catalytic sites. The reason why the observed stimulation 
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should increase during dialysis was unclear. 
Compared to compound 1, Cbz-Leu-boroNle (pinacol ester) was a less effective inhibitor of 
the liver 20S proteasome LLVY, AAF and LLE I activities. In contrast to compound I the 
effects of Cbz-Leu-boroNle (pinacol ester) on these activities were all readily reversible. This 
illustrates the fact that the amino acid composition of a peptidyl boronic acid will affect both 
the potency of inhibition and rate of detachment from a particular catalytic site. The effects 
of I ýM Cbz-Leu-Leu-boroLeu (pinacol ester) on the LLVY, AAF and LLE I activities were 
similar to I ýM Cbz-Leu-boroNle (pinacol ester). Cbz-Leu-Leu-boroLeu (pinacol ester) 
(I ýM) also caused significant inhibition of the LSTR activity. Only the small inhibition of 
the LLE I activity by this inhibitor appeared to be readily reversible. Modification of both the 
chymotrypsin-like and trypsin-like catalytic sites was slowly reversible. Compared to Cbz-Leu- 
boroNle (pinacol ester), the longer Cbz-Leu-Leu-boroLeu (pinacol ester) maybe restrained 
more in the vicinity of the catalytic site. This could lead to the inhibitor repeatedly rebinding 
to the catalytic site. 
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3.5.1 - Photoaffinity labelling (PAL) peptidyl boronic acids are highly effective 
inhibitors of the 20S proteasome LLVY activity that slowly detach from the complex 
Chemists from SmithKline Beecham supplied four photoaffinity labelling (PAL) peptidyl 
boronic acids. These peptidyl boronic acids contain a photoactivatable group e. g. 
benzophenone or phenyl azide that is activated by UN. fight. Activation of this group creates 
a reactive species that can covalently bind to nearby protein residues. All four PAL peptidyl 
boronic acids caused inhibition of the liver 20S proteasome LLVY activity (Table 3.5). SBFC 
and SBFE exhibited a similar potency to compound I at I ýM concentration. The PAL 
peptidyl boronic acids were found to slowly detach from the LLV-Y hydrolysing sites of the 
20S proteasomes, during overnight dialysis. 
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Table 3.3 - Binding of Bz-Phe-boroLeu (compound 1) to liver 20S proteasomes is not 
readily reversible 
Peptidase 70 nM Bz-Phe-boroLeu I ýM Bz-Phe-boroLeu 
activity 
Activity Activity Activity Activity 
(% of control) (% of control) (% of control) (% of control) 
after 15 min after subsequent after 15 min after subsequent 
preincubation dialysis preincubation dialysis 
LLVY 36 79 8 36 
AAF 88 88 53 63 
LSTR 136 125 99 131 
LLEI N. D. N. D. 34 33 
Liver 20S proteasome (38 ýtg at 0.02 ýtg/ýtl) was incubated with either 0,70 nM or I ýN 
compound I in 50 mM Hepes buffer/KOH, pH 7.5. The incubation was conducted for 15 
minutes at 25'C. 20S proteasome aliquots (2 ýtg) were assayed against either 40 ýM Suc- 
LLVY-AMC, AAF-AMC, Boc-LSTR-AMC or 100 ýM Cbz-LLE-NAP. Assays were 
conducted as described in Chapter 2. The remaining portions (I. I ml) of 20S proteasome were 
dialysed separately against approx. 600 ml volumes of 50 mM Hepes buffer/KOH, pH 7.5. 
Dialysis was conducted using 75 kDa collodion bags at 4'C overnight. The dialysed samples 
were assayed against the four substrates as before. Values are given as the average of a single 
experiment performed in duplicate. These values are expressed as percent of control activity 
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Table 3.5 - Photoaffinity labelling (PAL) peptidyl boronic acids do not readil. v detach 
from liver 20S proteasome chymotrypsin-like catalytic sites 
PAL peptidyl boronic acid LLVY activity (% of control) 
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diazeno)ethyl))Pz-(4-iodo)benzyl-boroLeu 
(pinane diol ester)) 
Liver 20S proteasome (21.5 ýtg at 0.05 ýtg/ýtl) was incubated without peptidyl boronic acid or 
with I VtM SBFC, SBFD, SBFE or SBFF in 50 mM Hepes buffer/KOH, pH 7.5. The 
incubation was conducted for 20 minutes at 25'C. 20S proteasome aliquots (2 ýtg) were 
assayed against 40 ýM Suc-LLVY-AMC as described in Chapter 2. The remaining portions 
(0.35 ml) of 20S proteasome were dialysed separately against approx. 200 ml volumes of 50 
mM Hepes buffer/KOH, pH 7.5. Dialysis was conducted using 75 kDa collodion bags at 40C 
overnight. The dialysed samples were assayed against the LLVY substrate as before. Values 
are in\cii as the average of two experiments performed in duplicate. These values are CN C, 




3.6 - High concentrations of compound I cause near complete inhibition of the liver 20S 
proteasome LLVY activity 
Figure 3.3 shows the effect of 0-500 nN4 compound I on the liver 20S proteasome LLVY 
activity. The inhibition data were initially fitted to the Henderson equation for tight-binding 
competitive inhibitors (Henderson, 1972). The curve generated using the competitive 
Henderson equation fitted the data points up to approximately 3 xKi. The observed inhibition 
above 3xKi was less than predicted by the Henderson equation on each of the three occasions 
the experiment was performed. This was also shown to be the case for other peptidyl boronic 
acids. For example Figure 3.4 shows the effect of selected concentrations of Cbz-Leu-Leu- 
boroLeu on the 20S proteasome LLVY activity. The deviation from ideal behaviour above 
2xKi was observed in all four expts with this inhibitor. To confirm that the maximum effect 
of compound I was exerted at higher inhibitor concentrations, the experiment was repeated 
using preincubation times of 15 and 60 n-finutes. The results of this expenment are shown in 
Figure 3.5. Increasing the preincubation time did not increase the effectiveness of compound 
I at either low or high inhibitor concentrations. Because of the poor fit of the competitive 
Henderson equation to the experimental data above 2-3 Ki, other equations were used to 
attempt to produce a better curve fit to the whole of the data. The first model assumed that 
the inhibition was non-competitive i. e. inhibitor was binding to residues distinct from the 
principal LLVY hydrolysing sites. These residues could be associated with other catalytic 
sites. The model also assumed that the proteasome-inhibitor complex allowed a low level of 
Suc-LLN')'-AMC hydrolysis. This may explain why the level of activity fails to closely 
approach zero at high inhibitor concentrations. The equation was written by Prof Rob John 
of University of Wales at Cardiff and is shown in Chapter 2. 
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Figure 3.3 - Inhibition of the liver 20S proteasome LLNN' activity by Bz-Phe-boroLeu 
(compound 1) (page 86) 
Liver 20S proteasome (I ýtg) was incubated with selected concentrations of compound I in 
50 m. M Hepes buffer/KOH, pH 7.5, for 15 minutes at 25'C. Substrate (40 ýLM Suc-LLN"Y- 
AMC) was added and the assays were run for 15 minutes at 37'C, as described *in Chapter 2. 
Values are from a typical experiment performed in duplicate. Activities are expressed as the 
fraction of control activity in samples containing no inhibitor. The competitive Henderson 
equation for tight-binding inhibitors was used to generate a curve fit to the data. 
Figure 3.4 - Inhibition of the liver 20S proteasome LLVY activity by Cbz-Leu-Leu- 
boroLeu (page 87) 
An experiment was performed as described in the legend to Figure 3.3 using selected 
concentrations of Cbz-Leu-Leu-boroLeu. 
Figure 3.5 - Increasing the length of preincubation does not increase the extent of 
inhibition of the 20S proteasome LLVY activity by Bz-Phe-boroLeu (compound 1) (page 
88) 
Liver 20S proteasome (I ýtg) was incubated with selected concentrations of compound I in 
50 mM Flepes buffer/KOH, pH 7.5. The incubation was conducted for 15 (solid circles) or 
60 (open triangles) minutes at 25'C. Substrate (40 pM Suc-LLVY-AMC) was added and the 
assays w-ere incubated at 37'C for 15 minutes, as described in Chapter 2. Values are from one 
experiment performed in duplicate. Activities are expressed as percent of control activity in 
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Chapter -3 3 
The equation produced a good fit to the whole of the data sets for compound I and Bz-Phe- 
boroLeu (pinane diol ester). One of the curve fits for compound I is shown in Figure 3.6 
(page 91). However, a curve fit could not be generated by Scientist 2.0 using certain sets of 
data obtained with 2 ýtg liver 20S proteasome instead of I ýtg. This was the case for 
compound I but not for Bz-Phe-boroLeu (pinane diol ester). Also the effect of compound I 
on the LLVY activity of liver 20S proteasomes was determined using 10 or 20 ýM substrate 
rather than 40 ýM Figures 3.7A and 3.7B (pages 92,93) illustrate the competitive curve fits 
to a set of data obtained using 10 or 20 pM Suc-LLVY-AMC. Figures 3.8A and 3.8B (pages 
94,95) illustrate the corresponding non-competitive curve fits. The Ki values generated by 
the competitive equation over a 0-40 rA4 compound I range, were 8 and II rA4 for 10 and 
20 ýM substrate respectively (Table 3.6, page 96). These values compared well with a Ki 
value of 19 nM deten-nined for two experiments using 40 ýM substrate. Ki values generated 
by the non-competitive equation for experiments using 10 and 20 ýM substrate were 
significantly lower at 2 and 4 nM respectively (Table 3.6). Analysis of the inhibition data 
clearly indicated that Ki values of 2 or 4 rM were not reasonable. At these compound I 
concentrations the LLVY activity was inhibited by less than 20%. Ki values of 8 or II nM 
were feasible because the LLVY activity was inhibited by approx. 40%. Therefore the 
noncompetitive model was discarded at this stage. 
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Figure 3.6 - An equation that describes non-competitive tight-binding inhibition 
produces a good fit to LLVY inhibition data over a large compound I concentration 
range (page 91) 
The experimental protocol is described in the legend to Figure 3.3. The non-competitive 
equation for tight-binding inhibitors was used to generate a curve fit to the data. 
Figure 3.7 - Competitive equation curve fits to data describing the inhibition of the liver 
20S proteasome LLVY activity by Bz-Phe-boroLeu (compound 1) measured with 10 or 
20 pM Suc-LLVY-AMC 
Experiments were performed and the data analysed as described in the legend to Figure 3.3 
using 10 ýM (Panel A) or 20 ýM (Panel B) Suc-LLVY-AMC as substrate. 
Panel A on page 92. Panel B on page 93. 
Figure 3.8 - Non-competitive equation curve fits to data describing the inhibition of the 
liver 20S proteasome LLVY activity by Bz-Phe-boroLeu (compound 1) measured with 
10 or 20 ýiM Suc-LLVY-AMC 
Experiments were performed and the data analysed as described in the legend to Figure 3.6 
using 10 ýM (Panel A) or 20 ýtkl (Panel B) Suc-LLVY-AMC as substrate. 
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Table 3.6 - Summary of Ki values determined for compound I 






10 8 (range 1) 
20 11 (range 1) 
40 19 (range 2) 
Non-competitive tight-binding 
equation 
10 2 (range ± 0) 
20 4 (range ± 1) 
40 31 (range 0) 
Partially competitive tight-binding 
equation 
10 4 (range 0) 
20 8 (range 1) 
40 25 (range 0) 
Assays were performed as described in Chapter 2 using I ýig of liVer 20S proteasome. Ki 
values were determined by fitting data from separate experiments performed in duplicate, to 
the three equations describing either competitive, non-competitive or partially competitive 
tight-binding inhibition. Curve fits were generated using a limited 0-40 rM compound I 
concentration range. Ki values are given as the mean ± range from two separate experiments. 
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3.6.1 - Inhibition data were fitted to a partially competitive model 
Discussions with Prof Rob John lead to a proposal that the observed inhibition could be 
partially competitive inhibition. In this scenario, substrate can bind to and be hydrolysed by 
20S proteasome and 20S proteasome-Inhibitor complexes. An equation that represents this 
type of inhibition was written by Prof Rob John and is shown in Chapter 2. The substrate was 
proposed to bind less efficiently to the 20S proteasome-inhibitor complex than the 20S 
proteasome. Hence Km and Kmi values were used in the equation. Ki values for peptidyl 
boronic acid binding to the 20S proteasome were very much lower than the Km for the LLVY 
activity. Therefore only one Ki value was used in the equation. This type of inhibition was 
thus termed tight-binding partially competitive inhibition. This model was attractive because 
imately 90%, even at 30 x Ki it could explain why the inhibition failed to extend past approxi 1. 
Initial fits to sets of data for compound I using I ýtg liver 20S proteasome and 40 ýM 
substrate were good, over a large range of inhibitor concentrations. One of these fits is shown 
in Figure 3.9A (page 100). Figures 3.9B and 3.9C (pages 10 1,102) illustrate curve fits using 
the partially competitive equation and sets of data obtained using I ýtg liver 20S proteasome 
and either 10 or 20 4M substrate. The Ki values using 10,20 and 40 ptM substrate over a 
limited (0-40 nM) inhibitor range were 4,8 and 25 n. M respectively (Table 3.6). The value of 
4 rM was unacceptably low with only 20-25% inhibition being recorded at this concentration. 
Moreover, the calculated value of Knu varied from 7 ýtM for experiments with 10 ýtM 
substrate up to several hundred or even thousands of ýtmol/l from experiments with 40 ýM 
substrate. This constant also changed significantly with the value inserted into the parameter 
file, Rough estimates of Ki, Knu and r were inserted into the parameter file to assist the curve 
fitting process. Estimates of these constants were then generated by the program. In addition, 
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the terrn r that is the difference (expressed as a ftaction) in catalytic activity between the EIS 
and ES complexes was often estimated to be negative rather than positive. Therefore this 
partially competitive model was judged to be unsatisfactory. 
3.6.2 - Inhibition data were fitted to a subpopulation model 
One further model was considered. This assumed that a subpopulation of 20S proteasomes 
was present whose LLVY activity could not be inhibited by the peptidyl boronic acids. This 
could occur for example if a subpopulation of 20S proteasomes had an unusual arrangement 
of catalytic subunits. Inhibition data for compound I and Bz-Phe-boroLeu (pinane diol ester) 
were processed with the equation given in Chapter 2. This involved subtracting the fraction 
of activity (Vi/Vo) remaining using the highest inhibitor concentration from each initial VINO 
result. These results were then expressed as a fraction of the LLVY activity that could be 
inhibited. The competitive Henderson equation was then used to generate a curve fit. Initial 
fits for experiments using I ýtg liver 20S proteasome and 40 [tM substrate were good over a 
large range of inhibitor concentrations. However, the curve fits obtained for experiments using 
lower [Suc-LLVY-AMC] or 2 ýtg 20 proteasome were unconvincing. One of these curve fits 
from an experiment using 2 ýtg liver 20S proteasome and 0-500 nM compound I is shown in 
Figure 3.10 (page 103). 
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Figure 3.9 -A partially competitive tight-binding equation can generate curve fits to 
data describing the inhibition of the liver 20S proteasome LLVY activity by Bz-Phe- 
boroLeu (compound 1) 
The experimental protocol is described in the legend to Figure 3.3. The VI/Vo values were 
expressed as percent rather than fraction of control before data analysis. The partially 
competitive equation was used to generate a curve fit to data from experiments using 40 ýIM 
(Panel A), 10 ýtk[ (Panel B) or 20 ýM (Panel Q Suc-LLVY-AMC as substrate. 
Panel A on page 100. Panel B on page 10 1. Panel C on page 102. 
Figure 3.10 - Subpopulation model curve fit to data describing the inhibition of the liver 
20S proteasome LLVY activity by Bz-Phe-boroLeu (compound 1) (page 103) 
Liver 20S proteasome (2 ýtg) was incubated in the presence of a range of compound I 
concentrations in 50 mM Hepes buffer/KOH, pH 7.5, for 15 minutes at 25'C. Substrate (40 
ýM Suc-LLVY-AMC) was added and the assays were incubated at 37'C for 15 minutes. 
Values are from a typical experiment performed in duplicate. The initial ViNo values were first 
processed using the equation for the subpopulation model given in Chapter 2. The competitive 
Henderson equation for tight-binding inhibitors was then used to generate a curve fit through 
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3.6.3 - Further experimental work strengthens the case for a competitive model of 
inhibition and rules out non-competitive and partially competitive models 
At this stage the competitive Henderson equation was producing the best fits to data ftom all 
four assay conditions, using a limited inhibitor concentration range. Figure 3.11 shows a 
competitive Henderson equation fit to the data used in Figure 3.3, over a limited 0-40 rLM 
compound I concentration range. Panel A of Table 3.7 shows the results of an experiment 
designed to determine the exact mechanism of inhibition. At 130 and 300 ýM Suc-LLVY- 
AMC concentrations the level of inhibition was decreased across the range of compound I 
concentrations. This rules out a non-competitive mechanism that would be unaffected by 
increases in substrate concentration. Ki values were calculated at the three different substrate 
concentrations using the competitive Henderson equation. These Ki values are shown in panel 
B of Table 3.7. Over the full compound I concentration range the Ki values were between 
16 and 18 nM. However, the curve fits were below the data points at high compound I 
concentrations. The Ki values estimated over a limited 0-2xKi concentration range were also 
in good agreement at 13-16 n-M. 
The effect of I -10 ýM compound I on the LLVY activity of I ýtg fiver 20 S proteasome was 
subsequently deten-nined. A substrate concentration of 40 W was used in the assays. In both 
determinations the LLVY actiVity was inhibited 95% and 97% using I and 2 ýM compound 
I respectively. 10 ýM compound I caused 98% inhibition of the LLVY activity. In the 
partially competitive model, 20S proteasomes with bound inhibitor could still hydrolyse 
substrate to a limited extent. Therefore these results rule out the partially competitive 
mechanism. In addition the subpopulatIon model listed above can be rejected. The LLVY 
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activity of the 20S proteasome subpopulation should continue to be resistant to inhibition, as 
the compound I concentration increases to 10 ýM This was not shown to be the case. 
Figure 3.11 - The competitive Henderson equation produces a good fit to LLVY 
inhibition data over a limited Bz-Phe-boroLeu (compound 1) concentration range 
(page 106) 
The experimental protocol is described in the legend to Figure 3.3. The competitive 








Table 3.7 - Inhibition of liver 20S proteasomes by compound I at different 
concentrations of the substrate, Suc-LLVY-AMC 
Panel A 
[Suc-LLVY- LLVY activity (% of control) at [compound I] (nM) 
AMC] (ýM) 
0 8 14 20 40 80 150 300 
40 100 80 65 50 35 29 20 14 
130 100 81 73 62 49 32 29 22 
300 100 71 75 76 57 42 33 25 
Assays were performed as described in Chapter 2 using I ýtg of liver 20S proteasome. The 
values for 150 nM compound I were obtained from a single experiment performed in 
duplicate. The other values are given as the average of two experiments performed in 
duplicate. These values are expressed as percent of control activity in samples containing no 
inhibitor. The six sets of data were individually fitted to the Henderson equation for 
competitive tight-binding inhibitors. The Ki values for the full 0-300 nN4 and shortened 0-40 
nM range of concentrations are shown in panel B. These values are given as the mean ± the 
range for the two separate experiments. 
Panel B 
[Suc-LLVY-AMC] (ýM) Ki (nM) 
0-300 nM compound 1 0-40 nM compound 1 
40 17 ±4 15 ±4 
130 18 ±2 16 ±5 
300 16 ±1 13 ±2 
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The best model to describe the observed inhibition of the LLVY activity was therefore chosen 
to be the competitive tight-bindmg model. NMR spectroscopy was previously used to show 
that substrate analogue peptidyl boronic acids covalently mod4 the catalytic serine of (x-lytic 
protease (Bachovchin et al., 1988). The use of the model was limited to peptidyl boronic acid 
concentrations of 0 to 2xKi. The deviation fTom ideal behaviour above 2xKi was presumably 
due to the multicatalytic nature of the 20S proteasome. Each 20S proteasome contains at least 
two sites that are proposed to cleave the Suc-LLVY-AMC substrate. It is not known whether 
both of these catalytic sites are fully operational at any one time. It maybe the case that 
binding of inhibitor to one of these sites obstructs the binding of inhibitor to the other site. 
This phenomenum was observed with AAF-chloromethyl ketone where only 50% of the LLVY 
activity could be inhibited (Reidlinger et al., 1997). Hydrolysis of Suc-LLVY-AMC will occur 
to some extent at all the 20S proteasome catalytic sites. Modification of the main LLVY 
hydrolysing sites by peptidyl boronic acid, may cause conformational changes that increase the 
extent of LLVY hydrolysis at other sites. This would mean the apparent inhibition was less 
than the extent of peptidyl boronic acid modification. Peptidyl boronic acids vvill also modify 
the main trypsin-like and PGPH catalytic sites. Modification of these sites will tend to be 
greater at inhibitor concentrations above the Ki for the LLVY activity (see Tables 3.2A and 
3.2B). Resultant conformational changes may inhibit or activate hydrolysis at the main LLVY 
hydrolysing sites, further complicating the inhibition data. 
3.7 - Compound I causes potent inhibition of activated 20S proteasomes 
Early studies on 20S proteasomes showed that 0.01-0.02% SDS stimulated the chymotrypsin- 
like and PGPH activities. The trypsin-like activity was either stimulated or inhibited depending 
on the substrate and assay conditions used (Rivett et al., 1989, Arribas & Castaflo, 1990). 
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Higher concentrations of SDS e. g. 0.1% caused complete inhibition of the peptidase activities. 
SDS was proposed to stimulate or inhibit peptidase activities by causing conformational 
changes. The effects of SDS could be reversed by simple dilution suggesting that the 20S 
proteasome was not dissociating at higher SDS concentrations (Arribas & Castaho, 1990). 
Some research groups have chosen to investigate the effect of enzyme inhibitors on the 20S 
proteasome in assay buffers containing low concentrations of SDS. For example Ki values for 
the effect of peptidyl aldehydes on the 20S proteasome LLVY and LLE activities were 
determined in an assay buffer containing 0.035% SDS (Rock et al., 1994). Also K.,, b, /[I] values 
for the effect of peptidyl vinyl sulphones on 20S proteasome activities, were determined in a 
Hepes assay buffer containing 0.01% SDS (Bogyo et al., 1998). Figure 3.12 shows the effect 
of compound I on the LLVY activity of I [tg liver 20S proteasome in the absence or presence 
of 0.02% SDS. Initial exarnination of the data suggested that the Ki value in the presence of 
SDS was 25-30 nM. Therefore the Ki value was not significantly altered by the presence of 
0.02% SDS. What was interesting was the rapid decrease in percent activity values between 
20 and 100 nM compound 1. The inhibition was essentially complete using 100 nN4 compound 
1. This showed that 0.02% SDS was assisting the binding of compound I to one or both of 
the proposed chymotrypsin-like catalytic sites. Binding of one molecule compound I to one 
of the catalytic sites may inhibit the binding of another molecule of compound I to the second 
site. Greater conformational flexibility induced by the presence of 0.02% SDS may assist the 
modification of the second site. 
The level of. AMC produced by the 20S proteasome in the presence of 0.02" SDS was eight 
times higher than normal. It was proposed that product inhibition may be assisting the 
inhibition of the LLVY acti,. -ity by compound 1. Therefore the assay conditions were changed 
Ii -er 20S proteasome and an assay period of 6 minutes. These by using 0.5 ýtg aliquots of 1*% 
109 
Chapter 3 
changes were designed to reduce the AMC production to 1.6 times the normal level in assay 
buffer containing 0.02% SDS. The results of this experiment are shown in Figure 3.13. The 
AMC production was reduced to the predicted level in the presence of 0.02% SDS. 
Compound I was shown to cause potent inhibition of the LLVY activity both in the absence 
and presence of 0.02% SDS. In the absence of SDS the Ki was slightly higher than anticipated 
at 53 W (Figure 3.14). In the presence of SDS the Ki was estimated to be 10 nM with 
inhibition being virtually complete at 50 n. N4 compound 1. 
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Figure 3.12 - SDS (0.02%) increases the extent of inhibition of the 20S proteasome 
LLVY activity above Ki concentrations of compound 1 (page 112) 
Liver 20S proteasome (I ýtg) was incubated with selected concentrations of compound I in 
50 mM Hepes buffer/KOH, pH 7.5 containing no (Red circles) or 0.02% (open squares) SDS- 
This preincubation was conducted for 15 minutes at 25'C. Substrate (40 ýM Suc-LLVY- 
AMC) was added and the assays were incubated at 37'C for 15 minutes, as described in 
Chapter 2. The values are from a single experiment conducted in duplicate. These values are 
expressed as percent of control activity in samples containing no inhibitor. 
Figure 3.13 - SDS (0.02%) increases the extent of inhibition of the 20S proteasome 
LLVY activity above Ki concentrations of compound I using half the amount of 20S 
proteasome and a shorter assay time (page 113) 
Liver 20S proteasome (0.5 ýtg) was incubated with selected concentrations of compound I in 
50 m. M Hepes buffer/KOH, pH 7.5 containing no (filled circles) or 0.02% (open squares) SDS. 
This preincubation was conducted for 15 minutes at 25'C. Substrate (40 ýtM Suc-LLVY- 
AMC) was added and the assays were incubated at 37'C for 6 minutes. Values are from a 
single experiment conducted in duplicate. These values are expressed as percent of control 
activity in samples containing no inhibitor. 
Figure 3.14 - Bz-Phe-boroLeu is a tight-binding inhibitor of the 20S proteasome LLVY 
activity at low (3.5 nM) proteasome concentrations (page 114) 
The experimental protocol is described in the legend to Figure 33.13. The data obtained in the 
absence of SDS were fitted to the competitive Henderson equation over a limited 0- 100 rM 
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3.8 - Compound I is a potent inhibitor of the 26S proteasome LLVY activity 
Dr Steve Assinder characterised the effects of a number of peptidyl boronic acids on the 26S 
proteasome. He showed that peptidyl boronic acids were slow binding reversible inhibitors 
of the 26S proteasome LLVY activity. Experiments were performed to determine the effect 
of 0-200 rM compound I on the liver 26S proteasome LLVY activity. 26S proteasome (0.1 
ýtg)- 0.25 nM) and 40 ýM Suc-LLVY-AMC were used in these assays. The Henderson 
equation for competitive tight-binding inhibition is applicable to situations where the total 
enzyme concentration divided by the Ki is between 0.0 1 and 100 (Henderson, 1972). When 
the ratio is below 0.0 1, virtually all the inhibitor molecules are free and the Nlichaelis-Menten 
equation for competitive inhibitors is then applicable (Henderson, 1972). The competitive 
Henderson equation gave a good fit to the data over the full 0-200 nM concentration range. 
The Ki was determined to be II±6 nM from three separate determinations. The Et,,,,,, /Ki ratio 
was 0.02, which means that this equation can be correctly used with the Bz-Phe-boroLeu data. 
The Ki value for inhibition of the liver 20S proteasome LLVY activity by compound I was 
determined to be 17 ±4 nM for three separate determinations (Table 4.1). Ki values for 
inhibition of the 20S and 26S proteasome LLVY activities, were predicted to be similar 
because the same catalytic sites are present in both complexes. More surprising was the good 
tit of the competitive equation to experimental data that rapidly approached zero. The 26S 
proteasorne contains two 19S regulatory complexes at the ends of the 20S proteasome. These 
regulatory complexes are known to assist the process of protein degradation. They may also 
constrain the structure of the 20S proteasome, This may mean that the catalytic sites operate 
in a more independent manner, being less effected by conformational changes at other sites. 
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3.9 - Summary 
Some peptidyl boronic acids are tight-binding inhibitors of the liver 20S proteasome LLVY 
activity. Bz-Phe-boroLeu (compound 1), the most effective of these compounds exerts 
inhibition through an apparent slow binding mechanism. Bz-Phe-boroLeu (80 nM) caused 
significant inhibition of the LLE I activity and stimulation of the LSTR activity. The inhibition 
of 20S proteasome activities was reversible during dialysis, although long time periods were 
often required to recover significant amounts of activity e. g. LLVY activity. Kinetic analysis 
showed that peptidyl boronic acid inhibition of the 20S proteasome LLVY activity, did not 
follow ideal behaviour. Even at high nanomolar concentrations of the tight-binding peptidyl 
boronic acids, it was not possible to achieve complete inhibition of the liver 20S proteasome 
LLVY activity. The Henderson model for competitive tight-binding inhibitors gave a good fit 
to the experimental data, over a limited inhibitor concentration range. Sirrular Ki values were 
detemuned for Bz-Phe-boroLeu inhibition of the LLVY activity of liver 20S proteasomes, liver 
20S proteasomes activated with 0.02% SDS and liver 26S proteasomes. 
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Chapter 4- Determining the stru cture- activity relationships that govern the interaction 
of peptidyl boronic acids with the chymotrypsin-like catalytic sites of liver and spleen 
20S proteasomes 
4.1 - Introduction 
In this chapter I will describe the determination of Ki values for inhibition of the liver 20S 
proteasome LLVY activity by a number of peptidyl boronic acids. All of the peptidyl boronic 
acids supplied by the chemists at SmithKline Beecham contained a hydrophobic PI residue. 
These compounds were predicted to be most effective against the chymotrypsin-like activity. 
However the nature of the residues other than PI have been shown to play important roles in 
directing peptide substrates and peptidyl inhibitors to particular catalytic sites (Orlowski et al., 
1993-, Cardozo et al., 1994; Reidlinger et al., 1997; Bogyo et al., 1998). Competition 
experiments using two or more peptide substrates, do not readily give information on which 
amino acids combinations bind effectively to catalytic sites. The peptide substrates usually 
exhibit a weak affinity for the catalytic sites with Km values very much greater than the enzyme 
concentration. Comparison of Ki values for these potent inhibitors reveals amino acid 
arrangements that bind particularly effectively to the chymotrypsin-like catalytic sites. Other 
amino acid combinations are less effective due to unfavourable non-covalent interactions with 
nearby protein residues. Hence these studies allow a greater understanding of the catalytic site 
structure particularly in conjunction with crystallographic data (Lowe et al., 1995; Groll et al., 
1997). It was also of interest to determine whether pinacol ester or pinane diol ester blocked 
peptidyl boronic acids, were equally effective compared to the corresponding free acid. At the 
time these experiments were perfon-ned, cell culture studies had shown no significant difference 
in potency between the blocked and unblocked forms in experiments where cells were 
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incubated %ith peptidyl boronic acid for 24 hours (Christie et al., 1999). In related studies the 
effect of several peptidyl bororuc acids on the liver 20S proteasome trypsin-like acw,, ity was 
determined. None of the peptidyl boron-ic acids were shown to be tight-binding inhibitors of 
this activity. The most effective of these inhibitors exhibited an IC50 value of approximately 
I ýtm. 
In the second part of the chapter I wdl compare and contrast the effect of the peptidyl boronic 
acids on liver and spleen 20S proteasomes. Liver 20S proteasomes are constructed of 
approximately equal amounts of the constitutively expressed and EFN-y inducible 0 catalytic 
subunits. Spleen 20S proteasomes in contrast are predominantly assembled with IFN-y 
inducible P catalytic subunits. Hence these comparisons will illustrate how readily the two 
types of catalytic subunits are modified by the peptidyl boronic acids. 
4.2 Determination of Ki values for the inhibition of the liver 20S proteasome LLVY 
activity by peptidyl boronic acids 
Ki values were determined using the competitive Henderson equation over a limited 
concentration range of 0 to 2xKi. Ideal competitive tight-binding behaviour was observed 
from 0 to 2xKi for all the tested peptidyl boronic acids. Deviation from ideal behaviour 
typically occurred at inhibitor concentrations above 2-3xKi. Tables 4.1 and 4.2 list the 
structures and inhibitor constants for the peptidyl boronic acids. All the peptIdyl boronic acids 
were synthesized with an N-terminal blocking group e. g. benzoyl or benzoyloxycarbonyl. If 
the N-terminus is unprotected the anude group can react with the boronic acid group to form 
ail inactive cyclic structure (Coutts et al., 1996). As stated chapter 3, the most effective 
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inhibitor of the liver 20S proteasome LLVY activity was Bz-Phe-boroLeu (compound 1). The 
pinane diol ester form of this inhibitor (compound 2) was less effective with a K, of 53 nM. 
Hydrolysis of the hydrophobic pinane diol blocking group may be slow and incomplete in 
aqeuous solution, causing the observed reduction in Ki value (Coutts et al., 1996). 
Dipeptidyl Leu-boroLeu based inhibitors were shown to be particularly potent. The Ki values 
for the free acid and pinacol ester forms of Cbz-Leu-boroLeu (compounds 3 and 4) were both 
in the region of 25-35 nM. This showed that the pinacol ester was readily hydrolysed from the 
Cbz-Leu-boroLeu structure during the assay procedure. Use of a benzoyl rather than a 
benzoyloxycarbonyl N-terminal group did not significantly change the potency of the Leu- 
boroLeu (pinacol ester) inhibitor (compare compounds 4 and 5). In contrast, Phenylsulfonyl- 
Leu-boroLeu (pinacol ester) (compound 15) was a relatively poor inhibitor causing 46% 
inhibition at I ýM. This clearly indicates that the polar sulfonyl group is not easily 
accommodated in the inhibitor binding site. Phenylhexanyl-Leu-boroLeu (pinane diol ester) 
(compound 6) was a more effective inhibitor with a Ki of 116 nM. The elongated N-terminal 
group was not as well accommodated as Bz or Cbz groups. 
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Table 4.1 - Ki values for inhibition of the liver 20S proteasome LLVY activity by 
peptidyl boronic acids 
Compound Compound structure 
Concentration Ki value 
number range (nM) (nM) 
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Assays were performed as described in Chapter 2 using I ýtg of liver 20S proteasome. The 
substrate concentration was 40 ýtkl. Ki values were deterrruned by fitting data from separate 
experiments perforrned in duplicate, to the competitive Henderson equation for tight-binding 
inhibitors. The curve fits were generated using the MicroMath Scientist 2.0 program. Ki 
values are given as the mean ± S. D. from three or four separate experiments. 
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Table 4.2 - Some peptidyl boronic acids are relatively weak inhibitors of the liver 20S 
proteasome LLVY activity 
Compound Compound structure Concentration LLVY activity 
number range (ýiM) (% of control) 
with I ýtM 
compound 
15 
0 H 0 
a 0-1 54 
,NC \S\ "'ýN R, S B"O H 
0 0- --r 




















H R, S \ 
0- 
Cbz-Pro-boroLeu (pinacol ester) 
Assays were performed as described in Chapter 2 using I ýtg of liver 20S proteasome. The 
substrate concentration was 40 ýM Values are given as the average of two separate 
experiments performed in duplicate 
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4.2.1 - Tri-leucine peptidyl boronic acids are less effective than di-leucine peptidyl 
boronic acids 
Extending the amino acid structure by an additional P3 Leu residue did not increase the 
potency of the peptidyl boronic acids. Cbz-Leu-Leu-boroLeu and the corresponding pinacol 
ester (compounds 7 and 8) exhibited Ki values of 46 and 99 n. M. The P3 Leu residue and/or 
the Cbz group may be positioned in an unfavourable location causing the observed reduction 
in potency. A much lower Ki value of 0.03 rA4 was previously reported for the effect of Cbz- 
Leu-Leu-boroLeu on the 20S proteasome chymotrypsin-like activity (Adams et al., 1998). 
The reasons for the large difference in Ki value are unclear. The assay buffer used by Adams 
et al. contained 0.5 mM EDTA and 0.035% SDS. This concentration of SDS is known to 
activate the LLVY activity of 20S proteasomes. Results in Figures 3.12 and 3.13 show that 
activating the LLVY activity of liver 20S proteasomes with 0.02% SDS, did not significantly 
change the Ki value of compound 1. The equation used to fit the experimental data was not 
clearly stated by Adams and coworkers. The equations describing parabolic inhibition in (Stein 
et al., 1996) were probably used. This model was successfully used with a non tight-binding 
inhibitor, but is unlikely to be directly applicable for a tight-binding inhibitor without some 
modification. 
4.2.2 - Effect of changing either PI or P2 residues of dipeptidyl boronic acids on the 
recorded Ki 
The effect of altering PI can be seen by comparing compounds 4,9,10 and 16. The isobutyl 
sidechain of leucine vvas best accommodated. The rank order of the other three PI residues 
Nvas Plie, Me and t-butyl-Leu. It is interesting to note that the slightly more elongated n-butyl 
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structure of Nle, made a significant difference to the binding affinity of the boronic acid, 
compared to the iso-butyl structure of Leu. The bulky hydrophobic tert-butylmethyl side chain 
of t-butyl-Leu was least well accommodated. The effect of varying the P2 residue can be 
determined by comparing compounds 4,11,12,13 and 17. Both compounds 4 and II had Ki 
values of 25-35 nM. Hence benzyl and isobutyl side chain are equally acceptable to the 
inhibitor binding site. A NI-nitroArg residue in P2 is also well accommodated (compound 12). 
The non-physiological N-nitroArg residue is more elongated and polar than Phe or Leu. The 
structure of the inhibitor binding pocket may fold around this residue in a different manner to 
the more hydrophobic Phe and Leu residues. A related peptidyl boronic acid inhibitor of the 
20S proteasome LLVY activity has been reported (Iqbal et al., 1996). This inhibitor had the 
same N-nitroArg-boroLeu structure with a different N-terminal blocking group. The 
determined IC50 for this inhibitor was of a similar magnitude at 8 nM. Lys-(Boc) at P2 
produces a relatively weak inhibitor of the LLVY activity (compound 13). The elongated 
sidechain ends in a tert-butyl group. This hydrophobic group is also found in compound 16 
that was a very poor inhibitor of the LLVY activity. The least favourable P2 residue was Pro. 
Cbz-Pro-boroLeu (pinacol ester) was barely active at I ýM concentration producing 9% 
inhibition. Proline is known to cause bending of polypeptide chains. Hence the Pro residue 
probably causes the inhibitor structure to kink creating unfavourable interactions with nearby 
protein residues. Proline has been used successfully in the construction of peptidyl boronic 
acid inhibitors of other enzymes. Dipeptidyl peptidase IV is a serine protease that cleaves a 
dipeptide from the amino terminus of polypeptides, where the penultimate residue is proline. 
A series of highly effective inhibitors of the general structure H-, N-X,,, -boroPro were 
synthesized (Coutts et al., 1996). Bz-N'al(Ph)-boroLeu (pinane diol ester) was structurak, 
related to compounds 4,11,12,13, and 17. This was one of the least effective inhibitors w-ith 
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a Ki of 201 rA4. 
4.2.3 - The trypsin-like activity of liver 20S proteasomes can be inhibited using high 
concentrations of peptidyl boronic acids 
In a series of experiments, the effect of selected peptidyl boronic acids on the liver 20S 
proteasome LSTR activity was investigated. The assays were conducted using 2 ýtg portions 
of liver 20S proteasome, 40 ýM Boc-LSTR-AMC and 0-1 ýM peptidyl boronic acid. A 
number of the peptidyl boronic acids did not inhibit the LSTR activity at I ýM concentration. 
These included Bz-Val(Ph)-boroLeu (pinane diol ester), PhS02-Leu-boroLeu (pinacol ester), 
Cbz-Leu-t-butylboroLeu (pinacol ester) and Cbz-Pro-boroLeu (pinacol ester). All four of 
these peptidyl boronic acids were relatively poor inhibitors of the liver 20S proteasome LLVY 
activity (Tables 4.1 and 4.2). 
Table 4.3 illustrates the extent of inhibition produced by the more effective inhibitors of the 
LSTR activity. Both the free acid and pinacol ester forms of Cbz-Leu-Leu-boroLeu were 
relatively potent inhibitors of the LSTR activity. This was intriguing because both Leu-Leu- 
Leu-Leu-vinyl sulphone and Bz-Phe-Leu-Leu-Leu-vinyl sulphone were relatively potent 
inhibitors of the muscle 20S proteasome trypsin-like activity (Bogyo et al., 1998). The 
importance of a large P4 residue was demonstrated by the poor inhibitory effect of Leu-Leu- 
Leu-vinyl sulphone and Gly-Leu-Leu-Leu-vinyl sulphone. The moderate activity of Tyr- 
Leu-Leu-Leu-%-ii1vl sulphone confirmed that the structure of the bulky P4 residue was also 
ition of the LSTR activity. Thi important. I ýiM Bz-Phe-boroLeu (compound 1) caused Inhibi III is 
effect was found to be dependent on the 20S proteasome concentration. When the 20S 
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proteasome concentration was lowered from 0.01 to 0.005 mg/ml the same level of inhibition 
was observed. Increasing the 20S proteasome concentration from 0.01 to 0.02 mg/ml caused 
I ýtkl compound I to moderately stimulate the LSTR activity (see Table 3.4). The reasons for 
these observations were unclear. Modification of trypsin-like catalytic sites may only take 
place at permissable [20S proteasome] -1compound 1] ratios. I ýM Cbz-Leu-Leu-boroLeu 
(pinacol ester) was shown to be equally effective at 20S proteasome concentrations of 0.01 
and 0.02 mg/ml (Tables 4.3 and 3.4). 
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Table 4.3 - Tri-leucine peptidyl boronic acids are the most potent inhibitors of the liver 
20S proteasome trypsin-like activity 
Peptidyl boronic acid 100 n-M I ýIm 
(compound no. ) (% of control) (% of control) 
Bz-Phe-boroLeu 122 64 
(compound 1) 
Cbz-Leu-Leu-boroLeu 100 48 
(compound 7) 
Cbz-Leu-Leu-boroLeu (pinacol ester) 97 56 
(compound 8) 
Cbz-Leu-boroPhe (pinacol ester) 101 80 
(compound 9) 
Cbz- nitro Arg-b oroLeu (pinacol ester) 102,103 81,85 
(compound 12) 
Cbz-Lys(boc)-boroLeu (pinacol ester) 101,102 70,70 
(compound 13) 
Assays were performed as described in Chapter 2 using 2 ýtg of liver 20S proteasome. The 
Boc-LSTR-AMC concentration was 40 ýiM. Values are from one or two experiments 
performed in duplicate. These values are expressed as percent of control activity in samples 
containing no inhibitor. 
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4.3 - SDS-PAGE analysis of liver and spleen 20S proteasomes 
Figure 4.1 shows a SDS-PAGE separation of 20S proteasomes purified from rat spleen and 
liver. The gel was scanned using a Bio-Rad GS-90 densitometer and Molecular Analyst 
software supplied by Bio-Rad. Note the characteristic pattern of subunits with molecular 
weights of 20-34 kDa. A small amount of high molecular weight (- 90 kDa) impurity protein 
was observed in the rat spleen lane. Densitometric analysis of this lane was conducted using 
the Molecular Analyst software. The amount of impurity protein was judged to be less than 
2% of the total protein. This 90 kDa protein is sometimes observed in rat liver 20S 
proteasome preparations and may be HSP90, 
4.3.1 - Determination of the Km for hydrolysis of Suc-LLVY-AMC by spleen 20S 
proteasomes 
The Km for Suc-LLVY-AMC hydrolysis by I ýtg spleen 20S proteasome was determined as 
described in Chapter 2. Figure 4.2 shows a typical set of data fitted to the Michaelis-Menten 
equation. The average Km was 63 ±8 ýM from three determinations. This value was 
approximately half the value of 130 [tM, determined for the LLVY activity of liver 20S 
proteasomes. The value of Vmax was also reduced by approximately half Therefore the 
kcat/Krn ratio or catalytic efficiency of liver and spleen 20S proteasomes are approximately 
equal. Spleen 20S proteasomes bind more efficiently to the Suc-LLVY-AMC substrate but 
are less effective at catalysing the hydrolysis of the substrate. 
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Figure 4.1 - SDS-PAGE analysis of rat spleen and rat liver 20S proteasome (page 132) 
Spleen and liver 20S proteasomes (4 ýtg/sample) were prepared and run on a 15% SDS-PAGE 
gel as described in Chapter 2. The gel was stained with Coomassie brillant blue stain solution 
and then destained as described in Chapter 2. The destained gel was scanned using a Bio-Rad 
GS-90 densitometer and Molecular Analyst software supplied by Bio-Rad. The three lanes are 
labelled M (marker protein lane), S (spleen 20S proteasome) and L (liver 20S proteasome). 
Figure 4.2 - Hydrolysis of Sue-LLVY-AMC by spleen 20S proteasomes (page 133) 
Spleen 20S proteasome (I [ig) was assayed against a range of Suc-LLVY-AMC 
concentrations in 50 mM Hepes buffer/KOH, pH 7.5. Assays were conducted for 15 minutes 
at 37'C, as described in Chapter 2. Results from a typical experiment performed in duplicate 
are shown. Krn values were determined by fitting the data from separate experiments to the 
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4.4 - Liver and spleen 20S proteasomes display different specific activities to trypsin-like 
and PGPH substrates 
Table 4.4 compares the specific activities of liver and spleen 20S proteasomes to four 
peptidase substrates. The specific activity of liver 20S proteasomes to the Suc-LLVY-AMC 
and AAF-AMC substrates were shown to be similar and in line with previous liver 20S 
proteasome preparations (Rivett et al., 1994). Cbz-GGL-AMC was less effectively cleaved 
by the liver 20S proteasome. One study investigated how the nature of the amino acids 
affected the hydrolysis of larger tetra- and pentapeptide substrates. The nature of the PI and 
P3 anuno acids, was proposed to influence the cleavage of a substrate by a particular catalytic 
site (Cardozo et al., 1994). The specific activities for hydrolysis of the three chymotrypsin- like 
substrates by spleen 20S proteasomes were comparable to liver 20S proteasomes. In contrast 
the specific activity of spleen 20S proteasomes to Boc-LSTR-AMC was three times lower than 
liver 20S proteasomes. The P-subunits Z and MECLI have been proposed to catalyse the 
trypsin-like activity (Bogyo et al., 1998). This result suggests that the catalytic efficiency of 
MECL I is much less than Z. Eleuteri and coworkers (1997) found only a small difference in 
the specific activity of spleen and pituitary 20S proteasomes, measured using Cbz-(D)ALR- 
NAP. Pituitary 20S proteasomes contain very low levels of IFN-y-inducible P-subunits. 
However, these experiments were performed with I 0-fold more substrate than the results 
described in Table 4.4. This higher substrate concentration produced a 16-fold increase in 
activity. Therefore at the higher substrate concentration both catalytic sites may be equally 
efficient. 
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Table 4.4 - Comparison of the specific peptidase activities of liver and spleen 20S 
proteasomes 
Substrate Liver 20S proteasome 
specific activity 
(nmoUmin/mg protein) 
Spleen 20S proteasome 
specific activity 
(rirnoUmin/mg protein) 
Suc-LLVY-AMC 10 1 12 
AAF-AMC 91 9 
Cbz-GGL-AMC 50 5 
Boc-LSTR-AMC 51 2 
Assays were performed as described in Chapter 2 using I ýtg of liver or spleen 20S 
proteasome. The substrate concentration was 40 W for Suc-LLVY-AMC, AAF-AMC, Cbz- 
GGL-AMC and Boc-LSTR-AMC. A fluorescence standard curve for 7-amino-4- 
methylcournarin (AMC) quantities of 0-0.12 nmol was produced as described in Chapter 2. 
The equation for the standard curve was then used to calculate the specific activities. Values 
for the liver 20S proteasome were from two separate experiments performed in duplicate. The 
range of the readings are listed. Values for the spleen 20S proteasome were from one 
experiment performed in duplicate. 
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A fluorescence standard curve for 0-naphthylamide was not produced. Fluorescence readings 
obtained from assays using I ýtg liver 20S proteasome and either 40 ýM Suc-LLN, 'Y-AMC or 
100 ýM Cbz-LLE-NAP were compared. This comparison suggested that the LLE I activity 
was - 10 times less than the LLVY activity. Of note was the fact that the LLE I activity of I 
ýtg liver 20S proteasome was three times greater than I ýtg spleen 20S proteasome. Eleuteri 
et al. (1997) showed that the PGPH activity of spleen 20S proteasomes was eight times lower 
than pituitary 20S proteasomes. In another study 20S proteasomes were purified from U937 
cells either cultured in the absence or presence of human IIFN-y. EFN-y treatment caused a 
small (13%) decrease in the PGPH activity (Gaczynska et al., 1993). Proteasome complexes 
are proposed to play an important role in generating antigenic peptides for MEC class I 
molecules. These peptides end almost exclusively with C-terminal hydrophobic or basic 
residues. Therefore a reduction in the PGPH activity will cause more of the required peptides 
to be produced, assisting the immune response (Gaczynska et al., 1993; Benham & Neefjes, 
1997). 
4.5 - Time course for inhibition of the spleen 20S proteasome LLVY activity by peptidyl 
boronic acids is consistent with slow binding 
Figure -4.3A (page 139) shows the time course for inhibition of the spleen 20S proteasome 
LLVY activity by 10 nM compound 1. In the presence of 10 rM compound I the fully 
inhibited rate of reaction was only observed after approximately 10- 12 minutes. Studies using 
radiolabelled vinyl sulphone inhibitors suggested that subunits X/MB I and LW7 were 
predominantly responsible for the chymotrypsin-like activity of 20S proteasomes (Table 1.3) 
(Bo(y, yo et al., 1998). The results of Reidlinger and coworkers (1997) using [. H]-acetyl-. Ada- 
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Ala-Phe-CH2CI supported this assignment In contrast, studies using 
[14C] labelled 3,4- 
dichloroisocournarin and peptidyl aldehydes suggested that subunit X/NlB I of pituitary 20S 
proteasomes and LNIP2 of spleen 20S proteasomes catalysed the chyrnotrypsin-like activity 
(Orlowski et al., 1997). Whatever the final assigment of catalytic subunits to the 
chyrnotrypsin-like activity, these catalytic subunits are inhibited by peptidyl boronic acids 
through an apparent slow-binding mechanism. 
4.5.1 - Apparent slow binding is also observed at high Bz-Phe-boroLeu (compound 1) 
concentrations 
Figure 4.3B (page 140) shows the time course for inhibition of the spleen 20S proteasome 
LLVY activity by 100 nM compound 1. The Ki for compound I against the LLVY activity 
of I ýtg spleen 20S proteasome was determined to be 13 nM (Table 4.6). Therefore the 
compound I concentration used in this experiment was eight times higher than Ki. At this 
concentration the full inhibitory effect was observed after a shorter time period of 5-7 minutes. 
This result suggests that steric hindrance probably plays a significant role in apparently slowing 
the onset of full inhibition, by 10 nM compound 1. Use of a large amount of compound I will 
tend to overcome any hindrance of inhibitor movement towards the catalytic sites and increase 
the concentration of inhibitor in close proximity to the catalytic sites. Both of these factors 
probably decrease the time required for covalent modification to occur. 
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Figure 4.3 - Time course for inhibition of the spleen 20S proteasome LLVY activity by, 
10 or 100 nM Bz-Phe-boroLeu (compound 1) 
Spleen 20S proteasome (I ýtg) was incubated at 37'C in the presence (filled circles) or absence 
(open diamonds) of 10 nM (Panel A) or 100 nM (Panel B) Bz-Phe-boroLeu. Substrate (40 
ýM Suc-LLVY-AMC) was present from time zero and substrate hydrolysis was determined 
after incubation for selected times as described in Chapter 2. 































4.6 - Compound 1 (80 nM) inhibits the LLVY activity but not the LLE1 activity of 
spleen 20S proteasomes 
Table 4.5 illustrates the effect of 20 and 80 rM compound I on the LLVY, AAF, GGL, LSTR 
and LLE I activities of spleen 20S proteasomes. At the selected concentrations of compound 
I only the LLVY activity was significantly inhibited. The results for the PGPH activity are in 
contrast to liver 20S proteasomes. The fiver 20S proteasome LSTR activity was inhibited 39% 
by 80 nM compound 1. Studies using radiolabelled peptidyl vinyl sulphones linked inhibition 
of the PGPH activity with modification of subunits LMP2 and Y/6 (Table 1.3) (Bogyo et al., 
1998). A separate study using [ 14 C]-3,4-dichloroisocoumarin also linked the PGPH activity 
to subunit Y/5 (Orlowski et al., 1997). If LNW2 and Y/8 are predominantly responsible for 
the PGPH activity, modification of Y/5 but not LNW2 at 80 nM compound I would explain 
these results. As discussed previously, stimulation of the trypsin-fike and PGPH activities may 




Table 4.5 - Bz-Phe-boroLeu (compound 1) (80 nM) inhibits the LLVY activity and 
stimulates the trypsin-like and PGPH activities of spleen 20S proteasomes 
Substrate Activity (% of control) 
20 nM compound 1 
Activity (% of control) 
80 rM compound I 
Suc-LLVY-AMC 52 33 4 
AAF-AMC 95 86 
Cbz-GGL-AMC 96 87 
Boc-LSTR-AMC 107 108 
Cbz-LLE-NAP 108 121 
Assays were performed as described in Chapter 2 using I ýtg of spleen 20S proteasome. The 
substrate concentration was 40 ýM for Suc-LLVY-AMC, AAF-AMC, Cbz-GGL-AMC and 
Boc-LSTR-AMC. Cbz-LLE-NAP was used at 100 ýtkl. Values are from one experiment 
performed in duplicate. These values are expressed as percent of control activity in samples 
containing no inhibitor. 
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4.7 - Compound I inhibits the LLVY activity of liver and spleen 20S proteasomes in a 
very similar manner 
Figure 4.4 shows the effect of selected concentrations of compound I on the spleen 20S 
proteasome LLVY activity. The competitive Henderson equation was used to generate the 
curve fit to the data. The effect of compound I on the LLVY activity of I ýtg spleen 20S 
proteasome was very similar to the corresponding experiment for liver 20S proteasomes shown 
in Figure 3.3. The curve fit in both figures followed the velocity data over a limited 
[compound 1] range. Deviation from ideal behaviour was found to occur at approximately 70 
n-M for both types of 20S proteasome. Figure 4.5 shows the effect of selected concentrations 
of Cbz-Leu-Leu-boroLeu (compound 7) on the spleen 20S proteasome LLVY activity. Of 
interest is the comparison between Figures 4.5 and 3.4. Inhibition of the spleen 20S 
proteasome LLVY activity by compound 7 follows ideal behaviour up to 200 nM. This was 
equivalent to 5xKi. In Figure 3.4 inhibition of the liver 20S proteasome LLVY activity by 
compound 7, deviated from ideal behaviour above 100 nM (2xKi). Furthermore the deviation 
from ideal behaviour was greater for the liver 20S proteasome compared to the spleen 20S 
proteasome, particularly at 0.5 and I ýM The tri-Leu arrangement of compound 7 may cause 
greater conformational. changes than the Phe-Leu. arrangement of compound 1. This could 
cause an increase in Suc-LLVY-AMC hydrolysis at the trypsin-like and PGPH catalytic sites 
in liver 20S proteasomes. When compared to fiver 20S proteasomes, spleen 20S proteasomes 
exhibit three-fold lower specific activities to trypsin-like and PGPH substrates. Hence the 
basal le%-el of LLVY activity at these sites may be lower. Modification of LLVY hydrolysing 
sites mav stimulate little or no increase in LLVY hydrolysis at other sites, thus explaining the 
greater adherence to ideal behaviour. In support of this theory was the observation that 
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inhibition of I ýtg liver 20S proteasome by the large Cbz-nitroArg-boroLeu (pinacol ester) 
inhibitor, significantly deviated from ideal behaviour at high inhibitor concentrations (data not 
shown). Unfortunately this inhibitor was not tested with the spleen 20S proteasome. 
Figure 4.4 - Inhibition of the spleen 20S proteasome LLVY activity by Bz-Phe-boroLeu 
(compound 1) (page 145) 
Spleen 20S proteasome (I ýtg) was incubated with selected concentrations of compound I in 
50 m. M Hepes buffer/KOH, pH 7.5, for 15 minutes at 25'C. Substrate (40 ýM Suc-LLVY- 
AMC) was added and the assays were incubated at 37'C for 15 minutes, as described in 
Chapter 2. Values are from a typical experiment performed in duplicate. Activities are 
expressed as the fraction of control activity in samples containing no inhibitor. The 
competitive Henderson equation for tight-binding inhibitors was used to generate a curve fit 
to the data. 
Figure 4.5 - Inhibition of the spleen 20S proteasome LLVY activity by Cbz-Leu-Leu- 
boroLeu (compound 7) (page 146) 
Experiments were performed as described in the legend to Figure 4.4 using selected 
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4.8 - Ki values for inhibiting the LLVY activity of liver and spleen 20S proteasomes are 
very similar 
Table 4.6 compares the Ki values for 4ihibition of the liver and spleen 20S proteasome LLVY 
activity by peptidyl boronic acids. Five peptidyl boronic acids were chosen to investigate 
whether the Ki values for the spleen 20S proteasome would differ significantly from the liver 
20S proteasome. These included the most effective inhibitor of the liver 20S proteasome 
LLVY activity, compound I and the closely related compound Cbz-Phe-boroLeu (pinacol 
ester). Two of the less effective dipeptidyl boronic acids, Cbz-Leu-boroPhe (pinacol ester) and 
Bz-Val(Ph)-boroLeu (pinane diol ester) were chosen along with the most effective tripeptidyl 
boronic acid Cbz-Leu-Leu-boroLeu. Large differences in the Ki values were not observed. 
Compared to liver 20S proteasomes the Ki for Cbz-Phe-boroLeu (pinacol ester) and Bz- 
Val(Ph)-boroLeu (pinane diol ester) using spleen 20S proteasomes increased 1.9 and 1.5 times 
respectively. In contrast the Ki values for Bz-Phe-boroLeu and Cbz-Leu-Leu-boroLeu using 
spleen 20S proteasomes decreased 1.4 and 1.3 fold respectively. The P-subunits X/N4B I and 
LM[P7 are proposed to catalyse the chymotrypsin-like activity of mammalian proteasomes 
(Table 1.3). Approximately equal amounts of X/N1BI and LNIP7 are found in liver 20S 
proteasomes, whereas spleen 20S proteasomes contain less than 10% X/MB I compared to 
LMP7 (Eleuteri et al., 1997; P. Brooks, personal communication). Therefore the observed 
differences may reflect the different affinities of the peptidyl bororuc acids for the two different 
catalytic sites. X/MB I and LNIP7 exhibit a high degree of identity. However, single residue 




Table 4.6 - Peptidyl boronic acids inhibit the LLVY activity of liver and spleen 20S 
proteasomes 
Peptidyl boronic LLVY activity 
acid 
(compound no. ) 
Liver 20S proteasome Spleen 20S proteasome 
Concentration Ki value Concentration Ki value 
range (rA4) (nM) range (W) and (nm) 
and number of number of 
determinations determinations 
Bz-Phe-boroLeu 0-40(3) 17 4 0-30(2) 13 
(compound 1) (range ± 2) 
Cbz-Phe-boroLeu 0-60(3) 25 11 0-100(2) 45 
(pinacol ester) (range ± 7) 
(compound 11) 
Cbz-Leu-Leu- 0-100(4) 46 8 0-80(2) 35 
boroLeu (range ± 5) 
(compound 7) 
Cbz-Leu-boroPhe 0-200(3) 84 12 0-210(2) 92 
(pinacol ester) (range ± 0) 
(compound 9) 
Bz-Val(Ph)-boroLeu 0-500(4) 201 87 0-650(2) 307 
(pinane diol ester) (range 
(compound 14) 
Assays were conducted as described in Chapter 2 using I pg of either liver or spleen 20S 
proteasonle. Values are from 2-4 separate experiments performed in duplicate. Ki values were 
determined by fitting data from separate experiments to the competitive Henderson equation. 
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4.9 - Summary 
Bz-Phe-boroLeu was the most effective of the seventeen peptidyl boronic acids, tested against 
the liver 20S proteasome LLVY activity. Other dipeptidyl boronic acids e. g Cbz-Leu- 
boroLeu and Bz-Leu-boroLeu (pinacol ester) were also particularly effective inlýbitors of this 
activity. Tri-leucine compounds e. g. Cbz-Leu-Leu-boroLeu were less effective, although these 
compounds were the best inhibitors of the trypsin-like activity. Compounds containing Pro 
at P2 or large bulky hydrophobic groups at Pl/P2 e. g. Lys(boc), Val(Ph) or t-butylLeu were 
relatively ineffective. In contrast Cbz-nitroArg-boroLeu (pinacol ester) containing the large 
polar nitroArg residue, was one of the most effective inhibitors. Pinacol ester blocked peptidyl 
boronic acids were generally as effective as the corresponding unblocked compounds. Results 
obtained with Bz-Phe-boroLeu and Bz-Phe-boroLeu (pinane diol ester) suggested that the 
pinane diol group is only partially hydrolysed during the assay procedure. The specific activity 
of liver or spleen 20S proteasomes to chymotrypsin-like substrates was approximately equal. 
In contrast the specific activity of spleen 20S proteasomes to trypsin-like or PGPH substrates 
was three-fold lower than liver 20S proteasomes. These results are In line with the proposal 
that proteasomes containing the IFN-y inducible catalytic subunits, play a major role in 
producing antigenic peptides that exhibit hydrophobic or basic C-terminal residues. Bz-Phe- 
borol-eu was a tight-binding inhibitor of the spleen 20S proteasome LLVY activity, with 
inhibition apparently occurring through a slow binding mechanism. Ki values for Inhibition of 
the liver or spleen 20S proteasome LLVY activity by selected peptidyl boronic acids, were 
shown to be very similar. 
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Chapter 5- Inhibition of proteasome complexes in cultured cells and radiolabelling of 
proteasomes in vivo and in vitro 
5.1 - Introduction 
As described in Chapter 1, four separate proteasome complexes are observed inside eukaryotic 
cells. These are named the 26S proteasome, the 20S proteasome, the PA28-20S proteasome 
complex and the hybrid proteasome. The 26S proteasome catalyses ubiquitin-dependent and 
ubiquitin-independent pathways of protein degradation. Ubiquitinated substrates of the 26S 
proteasome include the transcriptional activators Gcn4, STAT I and c-Jun. Other ubiquitmated 
substrates include a number of cell cycle regulatory proteins e. g. c-Mos and various cyclins. 
Modulators of immune and inflammatory responses are also ubiquitinated and degraded e. g. 
IKBot or partially degraded e. g. during the production of the mature NF-KB p50 subunit (Rivett 
et al., 1995, Kuehn & Dahlmann, 1996; I-lilt & Wolf, 1996, Kim & Maniatis, 1996; Ishida et 
al., 1993; Alkalay et al., 1995; Palombella et al., 1994, Lin et al. 1998b). Proteasome 
complexes are also implicated in the generation of antigenic peptides, for presentation on class 
I N4HC molecules (Grant et al., 1995; Hughes et al., 1996; Vinitsky et al., 1997). Potent cell 
permeable inhibitors of proteasome complexes, are valuble tools for investigating the 
degradation of proteins and the biochemistry of various diseases. 
In this chapter I will describe a series of immunoprecipitation experiments which sho,, v that 
peptidyl boronic acids are potent inhibitors of 20S and 26S proteasomes in cultured cells. 
Furthermore flasks of cells vvere cultured in the presence of a radiolabelled peptidyl boronic 
acid, [3 H] Phenacetyl-Leu-Leu-boroLeu. Proteasome complexes were shown to be the only 




have linked potent inhibition of the LLVY activity of proteasomes to potent inhibition of 
protein degradation. Certain peptidyl aldehydes e. g. Cbz-Leu-Leu-norVal-al or Cbz-Leu-Leu- 
Leu-al were shown to potently inhibit the LLVY activity of 20S and 26S proteasomes. These 
peptidyl aldehydes also potently inhibited the degradation of casein, ubiquitinated lysozyme and 
the production of the NF-KB p50 protein by the 26S proteasome (Rock et al., 19941 
Palombella et al., 1994). Other peptidyl aldehydes e. g. Ac-Leu-Leu-Nle-al and Ac-Leu-Leu- 
Met-al were less effective inhibitors of the 20S and 26S proteasome LLVY activity. They 
were also less effective at inhibiting the degradation of casein, ubiquitinated lysozyme and the 
production of the p50 protein. Results in Table 5.4 show that the Ki values for peptidyl 
boronic acid inhibition of the liver 20S proteasome LLVY activity, correlate well with IC50 
values for the inhibition of P-amyloid production and NF-KB activation in cultured cells. 
In the later sections of the chapter I will describe a series of experiments whose objective was 
to determine the peptidyl boronic acid modified subunits in 20S proteasomes. Cbz-Leu-Leu- 
boroLeu (pinacol ester) and ['H] Phenacetyl-Leu-Leu-boroLeu were used to modify 20S 
proteasome subunits, that were separated by either HPLC or SDS-PAGE. Peptidyl boronic 
acid modification did not survive either HIPLC or SDS-PAGE separation of the proteasome 
subunits. However, Cbz-Leu-Leu-Leu-vinyl sulphone (Z-LLL-VS) was used to block the 
incorporation of the radiolabelled inhibitor into the chyrnotrypsin-like catalytic sites of 20S 
proteasomes. 
5.2 - Peptidyl boronic acids inhibit proteasome complexes in cultured cells 
L- 1 '332 human embryonic lung cells were employed to determine whether peptidyl boronic 
acids could cros,,, the plasma membrane to inhibit proteasome complexes. Subconfluent flasks 
151 
Chapter 5 
of cells were cultured in fresh medium containing DMSO (1%) or selected concentrations of 
peptidyl boronic acid in DMSO. Flasks were incubated for 2 hours at 37C before washing 
the cells with 3x 10 ml of PB S. The cells were lysed by two different protocols. In the first 
the cells were lysed using RIPA buffer (50 mM Tris/fiCl, pH 8.0 containing 0.5% sodium 
deoxycholate, 0.1% SDS, 1% Nonidet P-40 and 150 mM NaCI). Previous studies showed that 
RIPA buffer causes the dissociation of 26S proteasomes into 20S proteasomes and 19S 
regulatory complexes (Mason et al., 1996). Alternatively cells were harvested using a 
trypsin/versene solution. Cells were then pelleted before lysing in 0.5 ml of 20 mM Tris 
buffer/HCI, pH 7.5 containing 5 mM ATP, 10% glycerol and 0.2% Nonidet P-40 (Mason et 
al., 1998). The contents of this buffer were chosen to maintain the structure of both the 20S 
and 26S proteasomes during cell lysis. Protocols for immunoprecipitation under both sets of 
conditions, using the MCP20 monoclonal antibody and subsequent assays are described in 
Chapter 2. The MCP20 antibody binds to one site on each of the 20S proteasome (x-subunit 
rings (Kopp et al., 1993). These binding sites are exposed in the 26S proteasome, facilitating 
efficient immunoprecipitation of 20S and 26S proteasomes from cell lysate. In addition 
attachment of MCP20 to proteasomes does not affect the proteolytic activity of the complexes 
(Kopp et al., 1993). 
Figure 5.1 shows the results of immunoprecipitation experiments using selected concentrations 
of Bz-Phe-boroLeu (compound 1). In vitro assay results show that the 26S proteasome 
LLVY activity is approximately 5-6 times greater than the 20S proteasome LLVY activity. 
Previous studies in this laboratory showed that a large proportion of the proteasomes 
immunoprecipitated from L- 132 ceUs using the MCP20 antibody, were 26S proteasomes using 
the more gentle lysis conditions (Mason et al., 1998). Hence the LLVY activity of MCP20 Z' - 
ininitinoprecipitates obtained 
LIS I TI '-the (-Yentle IN'sis conditions, approximates to the 26S 
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proteasome LLVY activity. Inhibition of the 20S and 26S proteasome LLVY activities was 
observed with 10 and 100 rM compound 1. This confirms that compound I readily crosses 
the plasma membrane of L-132 cells and is in agreement with other cell-based experiments 
with this inhibitor (Christie et al., 1999). The tight association of compound I to the Suc- 
LLVY-AMC cleaving catalytic sites was previously observed in dialysis experiments (Tables 
3.3 and 3.4). The fact that the association survives overnight incubation and six washing 
stages, shows that the off-rate is very slow. The inhibition of the 26S proteasome activity was 
consistently greater than the 20S proteasome activity. The reasons for this observation were 
unclear. 
Figure 5.1 - Activity of 20S proteasomes in immunoprecipitates after treatment of L- 
132 cells with Bz-Phe-boroLeu (compound 1) (page 154) 
Subconfluent human embryonic lung L-132 cells were cultured in fresh medium containing 
DMSO (I%) or appropriate amounts of compound I in DMSO for 2 hours at 3 7'C. Flasks 
were washed with 3x 10 n-d of PBS before conducting the immunoprecipitation of proteasome 
complexes under 20S or 26S conditions laid out in Chapter 2. The Immuno precipitated 
proteasorne complexes were assayed against 50 ýN Suc-LLVY-AMC. Values are from three 
experiments conducted in duplicate. These values are expressed as percent of control activity 
in samples containing no inhibitor. The results for 20S and 26S proteasomes are represented 
by grey and N\-Iilte bars respectively. 
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Another peptidyl boronic acid Cbz-Leu-Leu-boroLeu (pinacol ester) (compound 8) was found 
to readily enter L-132 cells and inhibit proteasome complexes. Table 5.1 shows the LLVY 
activity of 20S proteasomes in immunoprecipitates after treatment of L-132 cells wth selected 
concentrations of compound 8. The LLVY activity of the 20S proteasomes was inhibited by 
25% using 10 rM compound 8, with the inhibition approaching completion using I ýtkl 
compound 8. This proved that pinacol ester as well as free acid forms of the peptidyl boronic 
acids can effectively traverse the plasma membrane. 
5.2.1 - Compound 1, Cbz-Leu-boroNle (pinacol ester) (compound 10) and Cbz-Leu- 
Leu-Leu-vinyl sulphone (Z-LLL-VS) can all enter L-132 cells to inhibit the 
chymotrypsin-like activity of proteasome complexes 
Subconfluent L- 13 2 cells were cultured in fresh medium containing DMSO (I %) or 10 ýM 
compound 1,10 ýM Cbz-Leu-boroNle (pinacol ester) or 20 ýM Cbz-Leu-Leu-Leu-vinyl 
sulphone in DMSO for 2 hours at 37'C. Proteasome complexes were then 
immuno precipitated under 20S or 20S+26S conditions as described in Chapter 2. The basic 
method for 20S conditions was modified by using 5 mi of RIPA buffer instead of I mi. The 
20S and 20S+26S immunoprecipitated proteasomes were assayed against 50 ýM Suc-LLVY- 
AMC. The 20S inimunoprecipitates were washed three times with 50 mM Hepes buffer/KOK 
pH 7.5 and then assayed with 50 ýiM AAF-AMC. These immunoprecipitates were washed 
again before assaying with 50 pM Boc-LSTR-AMC. The results of this experiment are shown 
in Table 5.2. 
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Table 5.1 - Activity of 20S proteasomes in immunoprecipitates after treatment of L- 
132 cells with Cbz-Leu-Leu-boroLeu (pinacol ester) (compound 8) 
[Cbz-Leu-Leu-boroLeu (pinacol ester)] 
(nM) 
20S proteasome LLVY activity 
(% of control) 
10 75 
100 2 33 
1000 4 
Subconfluent human embryonic lung L-132 cells were cultured in fresh medium containing 
DMSO (1%) or appropriate amounts of compound 8 in DMSO for 2 hours at 37'C. Flasks 
were washed with 3x 10 ml of PBS, before conducting the immunoprecipitation of 
proteasome complexes under 20S proteasome conditions laid out in Chapter 2. The 
immunoprecipitated proteasome complexes were assayed with 50 ýtM Suc-LLVY-AMC. 
Values are from a single experiment conducted in duplicate. These values are expressed as 
percent of control activity in samples containing no inhibitor. 
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Table 5.2 - Activities of 20S and 26S proteasomes immunoprecipitated from L-132 cell 
extract following treatment of ceUs with either Bz-Phe-boroLeu (compound 1), Cbz-Leu- 
boroNle (pinacol ester) (compound 10) or Cbz-Leu-Leu-Leu-Ninyl sulphone (Z-LLL-VS) 
[Inhibitor] (ýM) 20S proteasome activity 26S proteasome 
(% of control) LLVY activity 
(% of control) LLVY AAF LSTR 
10 ýtM Bz-Phe-boroLeu 8 21 171 10 
10 ýtM Cbz-Leu-boroNle 57 28 121 81 
(pinacol ester) 
20 ýtkl Cbz-Leu-Leu-Leu- 6 12 79 13 
vinyl sulphone 
Subconfluent human embryonic lung L- 13 2 cells were cultured in fresh medium containing 
DMSO (1%) or appropriate amounts of proteasome inhibitor in DMSO for 2 hours at 37'C. 
Flasks were washed with 3x 10 ral of PBS before conducting the immunoprecipitation of 
proteasome complexes under 20S or 26S conditions laid out in Chapter 2. The basic protocol 
for immunoprecipitation under 20S conditions was modified by using 5 ml of RIPA buffer 
rather than I ml. The immunoprecipitated proteasome complexes were first assayed with 50 
ýM Suc-LLVY-AMC. The immunoprecipitates containing only 20S proteasomes were then 
washed three times with 50 mM Hepes buffer/KOH, pH 7.5. These immunoprecipitates were 
then assayed with 50 ýM AAF-AMC. The 20S immunoprecipitates were washed as above 
before assayed with 50 ýM Boc-LSTR-ANIC. Values are fTom a single experiment conducted 
in duplicate. These values are expressed as percent of control activity in samples containing 
no inhi itor. 
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Inhibition of the LLVY activity of 20S and 26S proteasomes by 10 ýM compound I was in 
agreement with the results in Figure 5.1. Cbz-Leu-boroNle (pinacol ester) was much less 
effective at inhibiting these two activities. As described in Table 3.4, the inhibition of the 20S 
proteasome LLVY activity by Cbz-Leu-boroNle (pinacol ester) was readily reversible during 
overnight dialysis. However, in this experiment the 20S proteasome LLVY activity was still 
inhibited by 43% after the washing stages. If the off-rate of the inhibitor was very slow in the 
presence of detergents during the overnight immunoprecipitation and slow in Hepes buffer 
solutions, then the inhibition would only be partially reversed as observed. Cbz-Leu-Leu-Leu- 
vinyl sulphone was previously shown to irreversibly inhibit the chymotrypsin-like, trypsin-like 
and PGPH activities of 20S and 26S proteasomes (Bogyo et al., 1997). Cbz-Leu-Leu-Leu- 
vinyl sulphone (20 ýM) caused near complete inhibition of the 20S and 26S proteasome 
LLVY activities. 
Adl three compounds were shown to inhibit the AAF activity of the immunoprecipitated 20S 
proteasomes (Table 5.2). The results for compound I are similar to those of a dialysis 
experiment shown in Table 3.4. Previous studies using peptidyl diazomethanes and peptidyl 
chloromethanes showed that the LLVY activity of liver 20S proteasomes was more readily 
inhibited than the AAF activity (Savory et al., 1993; Reidfinger et al., 1997). However these 
compounds were relatively weak proteasome inhibitors that were used at millimolar 
concentrations. The relatively high concentrations of peptidyl boronic acid or Cbz-Leu-Leu- 
Leti-vinvI sulphone used in this experiment, apparently caused heavy modification of the one 
or two types of catalytic site that catalyse the AAF activity. This modification was only slowly 
reversed during the procedure. Both compound I and Cbz-Leu-boroMe (pinacol ester) caused 
stimulation of the 20S proteasome LSTR activitv. These results are in good agreement 'with 
the corresponding results in Table 3.4. Stimulation of the LSTR activity may result from 
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inhibitor binding to non-trypsin-like catalytic sites, causing conformational changes that 
stimulate the trypsin-like activity. Cbz-Leu-Leu-Leu-vinyl sulphone caused moderate 
inhibition of the LSTR activity. This inhibitor was previously shown to inhibit the trypsin-like 
activity of 20S proteasomes measured with the Boc-LRR-AMC substrate (Bogyo et al., 1997). 
5.3 - Peptidyl boronic acids readily enter IMR-32 and IMR-32 APP-751 cells to inhibit 
proteasome complexes 
As part of my CASE studentship with SmithKline Beecham, I was given the opportunity to 
work at the main SmithKline Beecham site in Harlow, Essex. During my visit to Harlow I 
performed the immunoprecipitation experiments with two neural cell lines and 2- 
pyrazinylcarbonyl-Phe-boroLeu. The first cell line was the human neuroblastoma cell line 
INIR-32. A murine tetraploid neuronal cell line named IMR-32 APP-751 was also used. 
Table 5.3 shows a single set of results for the IMR-32 cells. 2-pyrazinylcarbonyl-Phe-boroLeu 
was added to the culture medium for 24 rather than 2 hours in these experiments. 
Immuno precipitated 20S or 26S proteasomes exhibited an IC50 value of approx. 5 n-M for 
inhibition of the LLVY activity. The IC50 value for L-132 cells using compound I and a2 
hour incubation period was approx. 40 nM. The same experimental protocol was initially tried 
with the IMR-32 APP-751 cells. However, the MCP20 antibody which was raised in mice, 
does not immunoprecipitate mouse proteasome complexes. A polyclonal anti-proteasome 
antibody, Ab 186 that was raised in rabbit was therefore used for immunoprecipitation. Figure 
5.2 illustrates the results of two experiments in which IMR-32 APP-751 cells were incubated 
with 2-pý, razinylcarboný, I-Phe-boroLeu for 24 hours, before immunoprecipitating proteasome 
complexes with AbI86. Immunoprecipitated 20S or 26S proteasomes exhibited an IC50 
,,,, alue of approx. 20 nNI for inhibition of the LLVY activitv. This is in good agreement with 
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the results for the IMR-32 cells. Therefore proteasome complexes can be potently and 




Table 5.3 - Activities of proteasomes immunoprecipitated from [MR-32 cell extract 





(% of control) 
26S proteasome 
LLVY activity 
(% of control) 
115 69 
10 38 19 
100 24 14 
1000 15 N. D. 
Subconfluent human neuroblastoma IMR-32 cells were cultured in fresh medium containing 
DMSO (1%) or appropriate amounts of 2-pyrazinylcarbonyl-Phe-boroLeu in DMSO for 24 
hours at 37'C. Flasks were washed with 3x 10 ml of PBS before conducting the 
immunoprecipitation of proteasome complexes under 20S or 26S conditions, laid out in 
Chapter 2. The immunoprecipitated proteasome complexes were assayed with 50 ýtkl Suc- 
LLVY-AMC. Values are from a single experiment conducted in duplicate. These values are 




Figure 5.2 - Activity of 20S proteasomes in immunoprecipitates after treatment of 
IMR-32 APP-751 cells with 2-pyrazinylcarbonyl-Phe-boroLeu (page 163) 
Subconfluent murine tetraploid neuronal IMR-32 APP-751 cells were cultured in fresh medium 
containing DMSO (1%) or appropriate amounts of 2-pyrazinylcarbonN, I-Phe-boroLeu in 
DMSO for 24 hours at 37C. Flasks were washed with 3x 10 ml of PBS before conducting 
the immunoprecipitation of proteasome complexes under 20S or 26S conditions, laid out in 
Chapter 2. The immunoprecipitated proteasome complexes were assayed against 50 ýIM Suc- 
LLVY-AMC. Values are from two experiments conducted in duplicate. These values are 
expressed as percent of control activity in samples containing no inhibitor. The results for 20S 
and 26S proteasomes are represented by grey and white bars respectively. The error bars 
represent the range of readings over the two experiments. 
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5.4 - Effect of 13 HI Phenacetyl-Leu-leu-boroLeu (radiolabefled inhibitor) on the LLVY 
activity of liver 20S proteasomes 
Sn-tithKIine Beecham supplied 18.5 M[Bq of a radiolabelled peptidyl boronic acid [-H] 
Phenacetyl-Leu-Leu-boroLeu. The peptidyl boronic acid was stored as aI mM solution in 
ethanol at -80'C. The effect of I ýM radiolabelled inhibitor on the LLVY activity of I ýtg liver 
20S proteasome was determined. These assays were conducted as described in Chapter 2. The 
percent activity relative to the control for three experiments was 37 ± 5%. The corresponding 
values for Cbz-Leu-Leu-boroLeu and Cbz-Leu-Leu-boroLeu (pinacol ester) were 25 ± 2% and 
22 ± 8% respectively. The small decrease in potency of the radiolabelled inhibitor was 
probably due to the different N-terminal group. 
5.5 - Investigating the cellular targets of a radiolabelled peptidyl boronic acid 
The radiolabelled inhibitor was used to confirm that proteasome complexes are a cellular target 
of peptidyl boronic acids. A single flask of subconfluent L- 132 cells was cultured with fresh 
culture medium containing I ýM radiolabefled inhibitor. Following a2 hour incubation period 
at 37'C, the cells were harvested using a trypsin/versene solution. The pelleted cells were 
lysed in 200 ýtl of 20 mM Tris buffer/ECI, pH 7.5 contairung 5 mM ATP, 10% glycerol and 
0.2% Nonidet P-40. The resultant cell extract was fractionated by gel filtration using a 
Pharmacia Superose 6 10/30 column. The column was equilibrated in 20 mM Tris buffer/HCI, 
pH 7.5 containing 5 mM ATP, 10% glycerol and 150 niM KCI. ATP and glycerol were used 
in the Ivsis and fractionation buffers to help maintain the structure of the 26S proteasome 
(Figure 5-33 on page 168). In previous experiments the structure of the PA28-20S proteasome 
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complex was shown not to survive gel filtration using the listed lysis and fractionation buffers 
(Paul Brooks, personal communication). The 26S proteasome was shown using Western 
blotting to elute after approximately 10- 12 nil (fiactions 10- 12) from the start of fractionation, 
using the Superose 6 column (Brooks et al., in press). The smaller 20S proteasome elutes after 
approXimately 12-14 ml (fractions 12-14). There are peaks of LLVY activity associated with 
these fractions, and the LLVY substrate is also hydrolysed by an enzyme eluting in fractions 
16-18. The majority of the radiolabelled inhibitor was associated with the 20S proteasome in 
fractions 12-14, but fraction 17 also contained radiolabelled material. 
The minor peak of radioactivity observed in fraction 17, coincided with a peak of LLVY 
activity that was observed only in the absence of 0.02% SDS. The radioactivity in fraction 17 
was approx. 5% of the total recorded activity. Figure 5.4 (page 169) shows the results of a 
similar fractionation experiment using 100 nM radiolabelled inhibitor. At the lower inhibitor 
concentration the minor peak of radioactivity is eliminated and all the bound inhibitor was 
associated with 20S proteasomes. Figure 5.5 (page 170) shows the results of a control 
fractionation experiment, where the flask of cells was cultured with fresh medium containing 
no radiolabelled inhibitor for 2 hours. When comparing Figures 5.4 and 5.5 it is clear that the 
26S proteasomes in fractions 10 and II are not inhibited by the radiolabelled inhibitor. This 
correlates with the very low level of radioactivity in fi7actions 10 and II of Figure 5.4. Greater 
levels of radioactivity were measured in fractions 13 and 14 of Figure 5.4 compared to 
fractions 10- 12. When comparing Figures 5.4 and 5.5 this modification did give rise to a 
significant decrease in the LLVY activity of 2-OS proteasomes in fraction 13 and 14. For 
fraction 13 the percent decrease in activity was calculated in m, o stages ý 0.8 8/1,46 x 100% = 
60% and then 100%-60% = 40%. For fraction 14 - 0.72/ 1.033 ( 100% = 70% and then 100%- 
70% = '100,6. It should also be noted that a significant amount of radiolabelled inhibitor in 
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Figure 5.4, has run through in the column volume. This is presumably radiolabelled inhibitor 
that has dissociated from 20S and particularly 26S proteasomes during the column run. 
small amount of radiolabelled inhibitor has run through in the column volume of the expenment 
illustrated in Figure 5.3. In vitro assay results show that I ýM radiolabefled inhibitor does not 
inhibit the trypsin-like and PGPH activities of liver 20S proteasomes (Table 5.7). The 
chymotrypsin-like activity measured with the Suc-LLVY-AMC or AAF-AMC substrates was 
substantially inhibited. Moreover, this inhibition was not readily reversed during rapid Igel 
filtration. If the rate of radiolabelled inhibitor detachment from 26S proteasomes was faster 
than 20S proteasomes, the 20S proteasomes would apparently be modified to a greater extent. 
It should be noted that this type of experiment may not detect other cellular targets, if the 
binding of radiolabelled inhibitor is readily reversed. 
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Figure 5.3 - Fractionation of cell extract following treatment of L-132 cells with I PNI 
13 HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) (page 168) 
One flask of subconfluent human embryonic lung L- 13 2 cells was cultured in fresh medium 
containing I ýM radiolabelled inhibitor for 2 hours at 37'C. The cells were harvested using 
a trypsin/versene solution and then pelleted. The pelleted cells were lysed in 200 ý11 of 20 m. M 
Tris buffer/HCI, pH 7.5 containing 5 mM ATP, 10% glycerol and 0.2% Nonidet P-40. The 
cell extract was fractionated by gel filtration using a Pharmacia Superose 6 10/30 column. The 
column was equilibrated with 50 ml of 20 rnM Tns buffer/HCI, pH 7.5 containing 5 mM. ATP, 
10% glycerol and 150 mM KCL Buffer was pumped through the column at a rate of 0.2 
ml/min and I ml fractions were collected. Aliquots (350 ýtl) of each fraction was mixed with 
12 ml of scintillation cocktail before conducting radioactive counting (filled bars) as described 
in Chapter 2. Two, 150 ýtl aliquots of each fraction were assayed with 40 uM Suc-LLVY- 
AMC, either in the absence (open circles) or presence (filled circles) of 0.02% SDS. The 
assays were incubated at 37'C for 30 minutes before stopping and reading as described in 
Chapter 2. 
Figure 5.4 - Fractionation of cell extract following treatment of L-132 cells with 100 nM 
13 HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) (page 169) 
An experiment was performed as described in the Legend to Figure 5.3 with the L-132 cells 
being cultured in fresh medium containing 100 rM radiolabeRed inhibitor for 2 hours at -')7'C. 
Figure 5.5 - Fractionation of L-132 cell extract on a 
Superose 6 gel filtration column 
(page 170) 
An experiment was performed as described in the Legend to Figure 5.3 with the L- 13 2 cells 
being cultured in fresh medium containing 5 ýtl ethanol for 2 hours at 37'C. The fractions 
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5.6 - Kinetic constants for inhibition of purified 20S proteasomes by peptidyl boronic 
acids are comparable to IC50 values for inhibition of proteolytic reactions in cultured 
cells 
Table 5.4 compares Ki values for inhibition of the liver 20S proteasome LLVY activity with 
IC50 values for inhibition of P-amyloid production or NF-KB activation in cultured cells. The 
Ki values were similar in magnitude to the IC50 values for all the listed peptidyl boronic acids 
except Cbz-Leu-boroPhe (pinacol ester) (NF-KB assay only) and Cbz- nitro Arg-boroLeu 
(pinacol ester). The presence of the non-physiological nitro-Arg residue presumably blocked 
the entry of Cbz-nitroArg-boroLeu (pinacol ester) into cultured cells. The three relatively poor 
inhibitors of the LLVY activity listed in panel B were relatively poor inhibitors of the other 
proteolytic reactions. The amyloid precursor protein (APP) is usually cleaved in neural cells 
by an (x-secretase, to yield a large soluble N-tern-iinal fragment named sAPP(x and a membrane- 
bound polypeptide. Alternatively 0- and y-secretases cleave APP to yield P-amylold and a 
soluble APP polypeptide (Haass & Selkoe, 1998). Several forms of P-amyloid are produced 
with AP40 and AP42 being the predominant species (Christie et al., 1999). AP42 and AP43 
ffle plaques in cases of Alzheimer's disease and Down's syndrome are major components of ser II 
(Hamazaki et al., 1998). Peptidyl boronic acids are proposed to inhibit the y-secretase activity 
through inhibiting proteasome complexes, because they inhibit the production of AD and the 
p3 peptide that is produced by the action of ot- and y-secretases (Christie et al., 1999). They 




Table 5.4 - Kinetic constants for inhibition of purified 20S proteasomes by peptidyl 
boronic acids are comparable to IC50 values for inhibition of proteolytic reactions in 
whole cells 
Panel A 
Peptidyl boronic acid Ki for inhibition IC50 for inhibition IC50 for inhibition 
(compound no. ) of the liver 20S of NF-KB of P-amyloid 
proteasome LLVY activation (nM) production (nM) 
activity (W) 
Bz-Phe-boroLeu 17 ±4 74,96 6,14 
(compound 1) 
Bz-Phe-boroLeu 53 ±5 92 19 
(pinane diol ester) 
(compound 2) 
Cbz-nitroArg-boroLeu 39 ±4 >101000 >3,000 
(pinacol ester) 
(compound 12) 
Bz-Val(Ph)-boroLeu 201 ± 87 670 48 
(pinane diol ester) 
(compound 14) 
Cbz-Leu-boroPhe 84 12 2,300 295 
(pinacol ester) 
(compound 9) 








Peptidyl boronic acid LLVY activity IC50 for inhibition IC50 for Inhibition 
(compound no. ) (% of control) at of NF-rB of P-amylold 
I ýtkl compound activation (nM) production (nM) 
PhS02-Leu-boroLeu 54 6,400 > 1,000 
(pinacol ester) 
(compound 15) 
Cbz-Leu-t-butylboroLeu 73 >10,000 N. D. 
(pinacol ester) 
(compound 16) 
Cbz-Pro-boroLeu 91 > 10,000 > 10,000 
(pinacol ester) 
(compound 17) 
The Ki and LLVY activity values were deternuned as described in the legends to Tables 4.1 
and 4.2. The Ki values are given as the mean ± S. D. from three or four separate experiments. 
The LLVY activity data is given as the average of two separate experiments. IC50 values for 
inhibiting the activation of NF-KB or the production of P-amyloid were determined by 
Scientists at SmithKline Beecham as descnbed on page 174 or in (Christie et al., 1999). These 
results are from one or Mo experiments and are either published in (Christie et al., 1999), 




Assay of NF-icB activation 
A luciferase reporter plasmid containing the EL-8 "core" promoter was engineered and stably 
transfected in U937 cells as previously described (Breton & Chab ot-Fl etcher, 1997). 
Transcription of the reporter construct from the EL-8 "core" promoter is stimulated by active 
p50-p65 NF-KB complexes. These complexes are produced through the proteasome 
dependent degradation of inhibitory IKB proteins and proteasome dependent production of 
mature NF-KB p50 proteins (See sections 1.1 and 1.9). Transfected U93 7 cells were twice 
centrifuged at 3 00 xg for 5 minutes and resuspended in RPNII 1640 medium with 10% foetal 
bovine serum to a density of IX 106 cells/ml. Aliquots (200 ýd) were added to the wells of an 
opaque 96-well filter bottom plate. Inhibitor or dimethyl sulphoxide carrier (I ý11) was added 
to the appropriate wells in triplicate and the plate was incubated at 37'C, 5%CO2 for 30 
minutes. The stimulus was added (5 ng/ml tumor necrosis factor-ot) and the samples were 
incubated for 5 hours at 37'C, 5%CO2. At the end of the incubation, the medium was 
removed by filtration and the cells were washed twice with PBS without Ca 2+' Mg2+ . 
The 
resulting cell pellets were lysed in 20 ýtl of Ix lysis buffer (Promega Corporation, 
Southampton, U. K. ) and incubated for 15 minutes at room temperature. Luciferase activity 
was measured in a MicroLumat LB 96P luminometer (EG&G Berthold, Bad Wilbad, 
Germany) which dispensed 100 ýd of luciferase assay reagent (Promega Corporation, 
Southampton, U. K. ) into each well and recorded the integrated light output for 20 seconds. 
Light output was measured in relative light units. 
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5.7 - HPLC separation of Cbz-Leu-Leu-boroLeu (pinacol ester) (compound 8) labelled 
liver 20S proteasomes 
Peptidyl vinyl sulphones are irreversible inhibitors of the chymotryptic, tryptic and PGPH 
activities of proteasome complexes (Bogyo et al., 1997; Bogyo et al., 1998). McCormack and 
coworkers (1997) showed that Cbz-Leu-Leu-Leu-vinyl sulphone (Z-LLL-VS) inhibited the 
chymotrypsin-like activity of recombinant Rhodococcus 20S proteasomes. These 
proteasomes were composed of the Rhodococcus ()C2andP2 subunits in the standard OC70707OC7 
arrangement. Rhodococcus 20S proteasomes were incubated in the absence or presence of 
50 ýiM Z-LLL-VS, before separating the proteasome subunits on a D4 reverse phase HPLC 
column. Z-LLL-VS modification caused a 1.9 minute shift in the elution position of the 0 
subunit, without effecting the elution position of the (x subunit (McConnack et al., 1997). The 
proteasome inhibitor lactacystin did not cause a similar shift. Preincubation of Rhodococcus 
20S proteasomes with lactacystin followed by Z-LLL-VS, prevented the shift in elution 
position of the P-subunit. 
It was of interest to determine whether binding of a tripeptidyl boronic acid to one or more 
catalytic 0 subunits would also shift the elution position(s) on a HPLC trace. Cbz-Leu-Leu- 
boroLeu (pinacol ester) (compound 8) had the same tri-Leu peptide arrangement as Z-LLL- 
VS and was used in these experiments. In the first experiment 280 pg of liver 20S proteasome 
xvas dialysed against 50 mM Hepes buffer, 'KOH, pH 7.5. Dialysed 20S proteasome (270 
was then incubated with 10 pM compound 8. Compound 8 (10 ýM) was used to inhibit the 
high (1.6 pM) concentration of 20S proteasome in the incubation mixture. After incubation 
at 25'C for 30 minutes, 2 pg portions of compound 8 treated and untreated 20S proteasome 
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were assayed against 40 pM Suc-LLVY-AMC as described in Chapter 2. The recorded 
percent inhibition was 73%. This result confirmed that compound 8 caused inhibition of the 
LLVY activity even at the high 20S proteasome concentrati Compound 8 treated IOS 
proteasome (200 ýtg) was separated on a Vydac C4 reverse-phase HPLC column as described 
in Chapter 2. The Absorbance (220 nm) versus elution time plot for this column run is showti 
in Figure 5.6 (page 178). In the first control run, 280 ýtg of liver 20S proteasome was dialysed 
against 50 mM Hepes buffer/KOH, pH 7.5. Dialysed 20S proteasome (200 pg) was prepared 
and then separated on the Vydac C4 column. The corresponding plot for this column run is 
shown in Figure 5.7 (page 179). Comparison of Figures 5.6 and 5.7 revealed the fact that the 
peak at 47.5 minutes in the control run, had disappeared in the compound 8 run and a new 
early peak at 53 minutes was visible in this profile. Previous separations of liver 20S 
proteasomes on a Vydac C4 column were analysed by immunoblotting. The first protein peak 
was identified as LN/fP7 (Reidlinger et at., 1997). Experiments utilising unlabelled and 
radiolabelled peptidyl vinyl sulphones, clearly suggested that the catalytic P-subunits LN4P7 
and X/MB I catalyse the chymotrypsin-like activity of mammalian 20S proteasomes (Table 1. "1) 
(Bogyo et al., 1998). 
However, the two column runs were repeated and the Absorbance (220 nm) versus elution 
time plots for these HPLC separations are shown in Figures 5.8 and 5.9 (pages 180 and 18 1). 
The position of the putative LNV7 peak in the compound 8 and control runs was 50 and 51 
minutes respectively. Therefore it was concluded that this peak exhibited a degree of vanation 
between 47 and -53) minutes. 
These results did not disprove the theory that compound 8 
remained bound to the cataklic 0 subunits, during HPLC separation. Hence the radiolabelled 
inhibitor was used in the next set of experiments. 
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Figure 5.6 - Separation of Cbz-Leu-Leu-boroLeu (pinacol ester) (compound 8) modified 
20S proteasome subunits by reverse-phase HPLC (page 178) 
Liver 20S proteasome (280 ýtg; 1.6 pM) was dialysed against 50 MM Hepes buffer/KOH, pH 
7.5 using a 75 IcDa collodion bag. Dialysis was conducted at 4'C for 3 hours. Dialý'sed 
proteasome (270 ýtg) was then incubated with 10 ýM compound 8 for 30 minutes at 25'C. 
Aliquots (2 ýtg) of untreated and compound 8 treated 20S proteasome ýý ere then assayed 
against 40 ýtM Suc-LLVY-AMC. The assays were conducted in duplicate as described in 
Chapter 2. Compound 8 modification caused 73% inhibition of the LLVY activity. The 
compound 8 treated 20S proteasome sample was then prepared for injection onto a Vydac C4 
reverse-phase HPLC column. Details of the preparation and subsequent separation of 200 Pty 
20S proteasome are given in Chapter 2. The figure illustrates the Absorbance (220 nm) 
against elution time (minutes) plot. Absorbance peaks are marked with corresponding 
retention times in minutes. 
Figure 5.7 - Separation of 20S proteasome subunits by reverse-phase HPLC (page 179) 
Liver 20S proteasome (280 ýtg; 1.6 ýM) was dialysed against 50 m-M Hepes buffer/KOH, pH 
7.5 using a 75 kDa collodion bag. Dialysis was conducted at 4'C for 33 hours. The dialysed 
20S proteasome sample was then prepared for injection onto a Vydac C4 reverse-phase HPLC 
column. Details of the preparation and subsequent separation of 200 ýIg 20S proteasome are 
given in Chapter 2. The figure illustrates the Absorbance (220 nm) against elution time 
(minutes) plot. Absorbance peaks are marked with corresponding retention times in minutes. 
Figure 5.8 - Separation of Cbz-Leu-Leu-boroLeu (pinacol ester) (compound 8) modified 
20S proteasome subunits by reverse-phase HPLC (page 180) 
An experiment was performed as described in the legend to Figure 5.6. Compound 8 
modification caused 82% inhibition of the LLVY activity. 
Figure 5.9 - Separation of 20S proteasome subunits 
by reverse-phase HPLC (page 181) 


















































































































5.7.1 - HPLC separation of 
3 HI Phenacetyl-Leu-Uu-boroLeu (radiolabelled inhibitor) 
modified liver 20S proteasomes 
Liver 20S proteasome (130 ýtg; 0.8 ýM) was first dialysed against 50 mM Hepes buffer/KOK 
pH 7.5 and then incubated with 5 ýtM ['H] Phenacetyl-Leu-Leu-boroLeu (radiolabelled 
inhibitor). This sample was incubated at 25'C for 30 minutes along with a second sample (I ", 
ýig- 0.8 ýM) of dialysed liver 20S proteasome, incubated with 0.125% ethanol. This second 
sample was a control to measure the effect of the ethanol on the LLVY activity. Aliquots (I 
ýtg) of the dialysed and the two preincubated 20S proteasome samples, were assayed against 
40 ýM Suc-LLVY-AMC as described in Chapter 2. Compared to the dialysed 20S 
proteasome, the LLVY activity of the ethanol and radiolabelled inhibitor treated samples were 
98% and 59% respectively. 
The radiolabelled 20S proteasomes were separated from the unbound radiolabelled inhibitor 
using a Pharmacia PD- 10 column. This column run was performed as described in the legend 
to Figure 5.10. The 20S proteasomes were shown to elute in fractions 2 and 3 that were 
pooled. This I ml sample was prepared and subjected to HPLC separation as described in the 
legend to Figure 5.10. Figure 5.10 Panel A (page 185) shows the Absorbance (220 nm) 
against elution time (minutes) plot. The pattern of peaks were similar to previous traces 
obtained from the elution of 100 ýtg 20S proteasome. Figure 5.10 Panel B (page 186) 
illustrates the elution of the radioactivity during this experiment and a subsequent control run. 
In the control run, 0.2 pl of I m-M radiolabelled inhibitor was prepared and separated on the 
C4 column, according to the standard protocol. It was anticipated that the radioactivity 
associated with the proteasome subunits would elute In 
distinct peaks. These peaks of 
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radioactivity were expected to coincide with protein peaks on the absorbance (220 nm) plot. 
However, the radioactivity eluted in a single broad peak. Most of the counts eluted between 
49 and 99 minutes of the acetonitrile gradient with peak counts being recorded betýveen 55 and 
63 nunutes. This peak did coincide with certain protein peaks on the absorbance plot. But the 
results suggested that the radiolabelled inhibitor had dissociated from the 20S proteasomes, 
during preparation and separation of the subunits. The results of the control run helped to 
confirm this hypothesis. An aliquot of radiolabelled inhibitor (0.2 pmol) eluted from the C4 
column in a single peak. The majonty of the counts eluted between 50 and 70 minutes xvhich 
correlates closely with the 20S proteasome separation. 
To further confirm this hypothesis, HPLC fractions containing the subunit eluting at 56 
minutes were pooled. This sample was run onto a Pharmacia PD- 10 column as described in 
the legend to Figure 5.10. If radiolabelled inhibitor was still bound to the putative LMP7 
subunit, the radioactivity should elute in the first 5,0.5 ml fractions. Very low levels of 
radioactivity were recorded for the first eight 0.5 ml fractions. These results clearly showed 
that the radiolabelled inhibitor was not bound to the putative LNIP7 subunit. 
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Figure 5.10 - Separation of 13 HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) 
modified 20S proteasome subunits by reverse-phase HPLC 
Liver 20S proteasome (150 ýtg; 0.8 W) was dialysed against 50 mM Hepes buffer/KOH, pH 
7.5 using a 75 kDa collodion bag. Dialysis was conducted at 4'C for 3 hours. DiaIN'sed 
proteasome (130 ýtg) was then incubated with 5 ýM [3H] Phenacetyl-Leu-Leu-boroLeu 
(radiolabeHed inhibitor) for 30 minutes at 25'C. A control sample of dialysed proteasome (13) 
ýtg; 0.8 ýM) was incubated with 0.125% ethanol for 30 minutes at 25'C. Aliquots (I pg) of 
radiolabelled inhibitor treated, ethanol treated or untreated 20S proteasome were assayed 
against 40 ýM Suc-LLVY-AMC. The assays were conducted in duplicate as described in 
Chapter 2. Radiolabelled inhibitor and ethanol caused 41% and 2% inhibition of the LLVY 
activity respectively. A PD-10 gel filtration column (Pharmacia) was equilibrated with 25 ml 
of 50 mM Hepes buffer/KOH, pH 7.5. The radiolabelled 20S proteasome sample (250 ý11) was 
run onto the column together with 2.25 ml of 50 mM Hepes bufferiKOH, pH 7.5. Five, 0.5 
ml fractions were collected by applying 0.5 rrýl aliquots of 50 mM Hepes buffer/KOH, pH 7.5 
to the top of the column. The protein content of the fractions was determined by the Bradford 
method as described in Chapter 2. The 20S proteasomes predominantly eluted in fractions 2 
and 3 that were pooled. This I ml sample was prepared for injection into the C4 HPLC 
column in 4,250 ýd aliquots as described in Chapter 2. The four samples were injected into 
the column sequentially, washing the sample loop with 1.2 ml of 10% acetonitrile in 0.1% 
trifluoroacetic acid between injections. The acetonitrile gradient was run as before. Panel A 
(page 185) illustrates the Absorbance (220 nm) against elution time (minutes) plot. 
Absorbance peaks are marked with corresponding retention times in minutes. Fractions were 
collected every 2 minutes from 14 nunutes into the gradient. Aliquots (0.3 ml) of each fraction 
was mixed with 8 ml of scintillation cocktail before conducting tritium counting as described 
in Chapter 22. 
Panel B (page 186) shows the radioactivity results for this experiment (solid circle) and a 
control experiment (open square). In the control experiment 0.2 pi of I m-M radiolabelled 
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5.8 - SDS-PAGE separation of I'HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled 
inhibitor) labelled liver 20S proteasomes 
3.4-dichloroisocoumarm' (DCI) causes Irreversible inhibition of the liver. pituitary and spleen 
20S proteasome chymotrypsin-fike, trypsin-like, PGPH and SNAAP activities (Djaballah et al., 
1992; Orlowski et al., 1993- Eleuten et al., 1997). The pituitary 20S proteasome BrA-AP 
activity was strongly activated by 10 ýM DCI whereas the spleen 20S proteasome BrAAP 
activity was not significantly effected by 20 ýM DCL Results obtained using rat liver 20S 
proteasomes suggested that DCI caused stimulation of trypsin-like and PGPH activities under 
certain conditions (Djaballah et al., 1992). SDS-PAGE was used to separate 20S proteasome 
subumts labelled with 
[ 14C ] DCI (Orlowski et al., 1997). The protein bands were transferred 
onto Immobilon P membranes which were washed and dried before conducting 
autoradiography. Six protein bands were labelled Nvith ["C] DCI. In control experiments 
unlabelled 20S proteasome subunits were separated by SDS-PAGE and blotted onto the 
Immobilon P membranes. The protein bands were sequenced to determine the migration 
patterns of the different P-subunits. The four intensely labelled bands 1,2,3 and 5 contained 
P-subunits X, Y and C5, RN-3), and Z respectively. The P-subunits in the labelled bands 4 and 
6 were not identified. The slower migrating cc-subunits were not labelled. 
In order to investigate whether the radiolabelled inhibitor remains bound to proteasome 
subunits during SDS-PAGE separation, liver 20S proteasome (150 ýtg) was incubated xvith 
either 2.5,5 or 10 ýLkl radiolabelled inhibitor for 30 n-unutes at 2 5C. These samples were then 
run on a1 -5% 
SDS-PAGE gel and blotted onto nitrocellulose according to the protocol given 
in Chapter -' 
Fluorography of the blot was performed but no clearly definable bands ký ere 
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observed even after an exposure time of six months. 
5.9 - Effect of Cbz-Leu-Leu-Leu-vinyl sulphone (Z-LLL-VS) on the peptidase activities 
of liver 20S proteasomes 
Z-LLL-VS is a irreversible inhibitor of 20S and 26S proteasomes (Bogyo et al., 1997). It was 
proposed that preincubation of 20S proteasome with Z-LLL-VS, may block modification of 
the 20S proteasome catalytic sites by the radiolabelled inhibitor. In addition Z-LLL-VS could 
be used at a concentration that effectively inhibited only the 20S proteasome chymotrypsin- 
like activity. Reduction in label incorporation could then be specifically linked to reduction in 
modification of the chymotrypsin-like catalytic sites. Peptidyl vinyl sulphones are thought to 
inhibit the chyrnotrypsin-like activity by modifying the X/MB I and LNIP7 P-catalytic subunits 
(Table 1.3) (Bogyo et al., 1998). Table 5.5 describes the effect of 0-10 ýM Z-LLL-VS on 
the LLVY activity of liver 20S proteasomes. Preincubation of I ýtg 20S proteasome with Z- 
LLL-VS was conducted for either 15 or 60 minutes at 37'C. The extent of inhibition was 
found to depend on both the concentration of inhibitor and the length of preincubation. The 
results in Table 5.5 are in close agreement with the results presented by Bogyo et al. ( 1997) 
using a purified mixture of 20S and 26S proteasomes. In a subsequent experiment, liver 20S 
proteasomes (I ýtg) were preincubated with 10 ýM Z-LLL-VS at 37'C for I hour, before 
assaying against four peptide substrates. The results of this experiment are shown in Table 
5.6. The chymotrypsin-like activity measured with 40 ýM Suc-LLVY-AMC or AAF-AMC 
was substantially inhibited, NvIth the LLVY activity being inhibited to a greater extent than the 
This outcome was also observed with other types of proteasome inhibitor e. gy 
compound 1, diisopropyl fluorophosphate, Tyr-Gly-Arg-CH20 and Z-Phe-Gly-Tyr-CHN2 
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(Djaballah et al., 1992; Reidlinger et al., 1997). This difference may anse ftom the fact that 
the AAF-AMC substrate is partially hydrolysed at a second site. Z-LLL-NIS (10 jiN 1) ýý a-s 
found to weakly inhibit the LSTR and LLE I activities. This is in agreement with the results 
of (Bogyo et al., 1997). Hence at this concentration the vinyl sulphone inhibitor is primarily 
effective against the chymotrypsin-like activity. 
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Table 5.5 - Concentration and length of preincubation govern the inhibition of the liver 
20S proteasome LLVY activity by Cbz-Leu-Leu-Leu-vinyl sulphone (Z-LLL-N'S) 
[Z-LLL-VS] (ýM) 20S proteasome LLVY activity (% of control) 
Preincubation for 
15 min at 37'C 
Preincubation for 
60 min at 3 7'C 
0.5 84 70 
1 84 67 
5 65 34 
10 55 18 
Assays were performed as described in Chapter 2 using I ýtg of liver 20S proteasome. The 
Suc-LLVY-AMC concentration was 40 [tM. Values are given as the average of one 
experiment performed in duplicate. These values are expressed as percent of control actlvltý, 
in samples containing no inhibitor. 
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Table 5.6 - Cbz-Leu-Leu-Leu--*, inyl sulphone (Z-LLL-VS) (10 ýIM) primarily inhibits the 
chymotrypsin-like activity of liver 20S proteasomes 







Assays were performed as described in Chapter 2 using I ýtg of liver 20S proteasome and a 
preincubation of I hour at 37'C. The substrate concentration was 40 ýM for Suc-LLVN- 
AMC, AAF-AMC and Boc-LSTR-AMC. Cbz-LLE-NAP was used at 100 ýM Values are 
given as the average of one experiment performed in duplicate. These values are expressed 
as percent of control activity in samples containing no inhibitor. 
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5.9.1 - Inhibition of the 20S proteasome chymotrypsin-like activity by [3 HI Phenacetyl- 
Leu-Leu-boroLeu (radiolabelled inhibitor) is not easily reversed by gel filtration 
Table 5.7 (page 195) illustrates the effect of the radiolabelled inhibitor on liver 20S 
proteasome activities before and after gel filtration. Liver 20S proteasome (80 ýtg at 0.05 
ýtg/ýtl) was incubated with I ýM radiolabelled compound for 15 minutes at 25'C. A control 
20S proteasome solution (I I ýtg at 0.05 ýtg/ýtl) was also incubated for 15 minutes at 25 -C 
Aliquots (I ýtg) of radiolabelled and control 20S proteasome solutions were then assayed with 
either 40 [tM Suc-LLVY-AMC, AAF-AMC, Boc-LSTR-AMC or 100 PM Cbz-LLE-NAP. 
Both the LLVY and AAF activities were significantly inhibited by the radiolabelled inhibitor. 
In contrast the LSTR and LLE I activities were stimulated by I ýM radiolabelled inhibitor. 
Stimulation may have resulted from modification of chymotrypsin-like catalytic sites, causing 
conformational changes that stimulated activity at other catalytic sites. Also the radiolabelled 
inhibitor may bind to allostenc sites close to the trypsin-like and PGPH catalytic sites. These 
interactions may stimulate the corresponding, activities. The remaining radiolabelled I 
proteasome sample was separated from unbound radiolabelled inhibitor using two PD- 10 
columns. The Bradford method was used to determine the protein concentration of the 
fractions from the second column. Aliquots (I ýtg) of 20S proteasome were then assayed 
against the four peptidase substrates. The inhibition of the chymotrypsin-like activity was 
essentially maintained during gel filtration. Cbz-Leu-Leu-boroLeu (pinacol ester) was shown 
to bind tightly to the 20S proteasome LLVY cleavincy sites, during dialysis and I 
immunoprecipitation experiments. Therefore it was not surprising that the closely related 
radiolabelled inhibitor also exhibited tight binding to the LLVY cleaving sites. The stimulation 




interactions of radiolabelled inhibitor with proteasome P-subunits could cause the obsen, ed 
stimulation that was lost during gel filtration. 
5.9.2 - Z-LLL-VS blocks the labelling of chyrnotrypsin-like catalytic sites by the 
radiolabelled inhibitor 
Table 5.8 (page 196) shows the results of two experiments in which 10 ýiM Z-LLL-VS was 
used to block the incorporation of I ýM radiolabelled inhibitor into liver 20S proteasomes. 
The vinyl sulphone proved to be an effective blocking agent, reducing incorporation of tritiated 
compound by 70% over two experiments. Z-LLL-VS (10 ýM) inhibited the LLVY activity 
of I ýtg liver 20S proteasome by 87±5% (see Tables 5.5 and 5.6). Therefore 10 ýM Z-LLL- 
VS was expected to reduce the incorporation of the radiolabelled inhibitor by approx. 85%. 
In the competition experiments the concentration of 20S proteasome was I 0-fold higher than 
for the assays shown in Tables 5.5 and 5.6. At this higher concentration, the extent of 
modification of the LLVY cleaving catalytic sites was probably lower. This would allow the 
modification of the remaining sites by the more reactive radiolabelled inhibitor. It was 
observed that the radioactivity measured per microgram of 20S proteasome was lower than 
expected for the control experiments (data not shown). Tritium exchange was thought to be 
occuring during the gel filtration steps. Results from other experiments suggested that the 
level of tritium exchange was inversely proportional to the amount of radiolabelled 20S 
proteasorne, loaded onto the PD-10 columns. The radioactivity readings for the vinyl sulphone 
untreated and treated samples were similar in magnitude, for both competition experiments 
Because the samples contained identical amounts of 20S proteasome and were fractionated 
using the sarne protocol, it would be reasonable to expect the same level of tritium exchange 
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to apply to both samples. This hypothesis could be tested by repeating the competition 
experiment using e. g. 15 or 50 Rg portions of 20S proteasome in the initial incubation tubes. 
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Table 5.7 - Inhibition of the liver 20S proteasome chymotrypsin-like activity by 13 Hj 
Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) is not readily reversed during gel 
filtration 
Substrate Activity (% of control) 
after treatment with the 
radiolabelled inhibitor 
-7 
Activity (% of control) 
after removal of excess 
radiolabelled inhibitor 
Suc-LLVY-AMC 30 43 
AAF-AMC 66 61 
Boc-LSTR-AMC 128 96 
Cbz-LLE-NAP 253 120 
Liver 20S proteasome (80 ýtg at 0.05 ýtg/[tl in 50 mM Hepes buffer/KOH, pH 7.5) was 
incubated with I ýM radiolabelled inhibitor for 15 rninutes at 25'C. A control 20S proteasome 
solution (I I ýtg at 0.05 ýtg/ýtl in 50 mM Hepes buffer/KOH, pH 7.5) was also incubated for 
15 nunutes at 25'C. Aliquots (I ýtg) of the radiolabelled or control proteasome solutions were 
assayed against either 40 ýM Suc-LLVY-AMC, AAF-AMC, Boc-LSTR-AMC or 100 ýt\l 
Cbz-LLE-NAP. The assays were conducted as described in Chapter 2 using a 30 minute 
incubation at 37'C. Two PD-10 gel filtration columns (Pharmacia) were equilibrated 1xith 25 
ml of 50 mM Hepes buffer/KOH, pH 7.5. The remaining radiolabelled proteasome sample 
was diluted to 2.5 m-1 with 50 mM Hepes buffer/KOH, pH 7.5. This sample was run onto the 
first column. Five, 0.5 ml fractions were collected by sequentially adding 0.5 ml aliquots of 
50 mM Hepes buffer/KOH, pH 7.5 to the column. Fractions 2 and -3) were pooled and 
diluted 
to 2.5 ml with 50 m. M Hepes buffer/KOH, pH 7.5. This sample was applied to the second 
column. Fi-ve, 0.5 ml fractions were collected as above. The Bradford method was used to 
determine the protein concentration of the five fractions Aliquots (I ýtg) of 220S proteasome 
xýere then assayed against the four pept, dase substrates as above. 
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Table 5.8 - Cbz-Leu-Leu-Leu-vinyl sulphone (Z-LLI-, N'S) (10 ýt. Nf) blocks the 
incorporation of I ýLM 13 HI Phenacetyl-Leu-Leu-boroLeu (radiolabelled inhibitor) into 
the chymotrypsin-like catalytic sites of liver 20S proteasomes 
Experiment Radiolabelled inhibitor Radiolabelled inhibitor Reduction in 
no. incorporated in the incorporated following radiolabelled Inhibitor 
absence of Z-LLL-VS preincubation with incorporation in the 
(Cpm) Z-LLL-VS (cpm) presence of 
Z-LLL-N'S (0,,, o) 
1 991 362 64 
2 1090 278 75 
Two Eppendorf tubes were set up containing liver 20S proteasome (27.5 p(I at 0.05 ýIg/ýIl in 
50 mM Hepes buffer/KOH, pH 7.5). Z-LLL-VS (10 ýtkl) was added to tube 2 and both tubes 
were incubated at 37'C for 60 minutes. Radiolabelled inhibitor (I ýM) was added to both 
tubes that were then incubated at 25'C for 15 minutes. Four PD- 10 columns were equilibrated 
with 50 mM Hepes buffer/KOH, pH 7.5. The contents of tube 1 (5 50 ýtl) were run into the 
first PD- 10 column followed by 1950 ýd of 50 ni-M Hepes buffer/KOH, pH 7.5. Five, 0.5 mi 
fractions were collected by applying 05 ml aliquots of 50 mM Hepes buffer/KOH, pH 7.5 to 
the top of the column. The first four fractions were pooled. This sample was run onto the 
second PD-10 column followed by 0.5 nil of 50 mNI Hepes buffer/KOH, pH 7.5. Five, 0.5ml 
fractions were collected as before. The contents of tube 2 were also fractionated using the 
same method and PD-10 columns 33 and 4. The Bradford method was used to determine the 
protein content of the fractions from PD-10 columns 2 and 4. Two, 33 pg aliquots of 20S 
proteasome from either PD-10 columns 2 or 4 were individually mixed with 8 ml of' 
scintillation cocktail and subjected to radioactivity counting as described in Chapter 2. The 
average results from two separate c\periments performed in dupl, cate are shown n the table 
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5.10 - Summary 
A number of peptidyl boronic acids were shown to traverse the plasma membrane of 
mammalian cells and inhibit proteasome complexes. The peptidyl boronic acids were found 
to bind tightly to the chymotrypsin-like active sites, with inhibition surviving either an 
immunoprecipitation procedure or gel filtration of a cell extract. IC50 values for the LLVY 
activity of 20S or 26S proteasomes immu no precipitated from cells treated with Bz-Phe- 
boroLeu, were similar to Ki values for Bz-Phe-boroLeu inhibition of the same activitN, in 
purified 20S or 26S proteasomes. Ki values for peptidyl boronic acid inhibition of the li,,, er 
20S proteasome LLVY activity were also shown to be similar to IC50 values for inhibition of 
P-amylold production and NF-KB activation in cultured cells. This relationship was observed 
with a variety of peptidyl boronic acids, displaying a large range of Ki values. ['H] Phenacetyl- 
Leu-Leu-boroLeu labelled 20S proteasome subunits could not be separated by UIPLC or SDS- 
PAGE, without the radiolabelled inhibitor dissociating ftom tile subunits. Competition 
experiments showed that Cbz-Leu-Leu-Leu-vinyl sulphone, could block the ['H] Phenacetyl- 
Leu-Leu-boroLeu labelling of 20S proteasome chymotrypsin-like sites. Previous studies ha\, e 
suggested that peptidyl vinyl sulphones inhibit the chymotrypsin-like activity of proteasomes, 
by modifying the amino-terminal threonines of subunits LNIP7 wid X[MB 1. 
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Chapter 6 
Chapter 6- Discussion 
6.1 - Proteasome complexes possess low specific activities compared to many other 
enzymes 
Since the discovery of proteasome complexes, an ever increasing number of research groups 
have been characterising their structure, catalytic properties and the degradation of substi-ate 
proteins. Proteasome complexes are vitally important components of cellular metabolism, 
facilitating the degradation of many protein substrates including short-lived regulators of the 
cell cycle and immune responses. 20S proteasomes are unusual in possessing low specific 
activities compared to many other enzymes. For example the following serine endopeptidases 
all have specific activities that are several orders of magnitude higher than the LLVY activity 
of liver or spleen 20S proteasomes (10 or 12 nmoUmin/mg protein)- 
a) ct-chymotrypsin from bovine pancreas - 65 units/mg, I unit hydrolyses I ýtmol Suc-. -\,, \PF- 
4-NA-P per minute at pH 7.8 and 25'C. 
b) Elastase from human leukocytes - approx. 6 units/mg; I unit hydrolyses I ýtmol 4- 
nitrophenol per minute from Boc-Ala-4-nitrophenyl ester at pH 6.5 and 37C. 
c) Encloproteinase Arg-C from murine submaxiflary glands - 100 units/ing- I unit hydrolysses- 
I [tmol N-tosyl-Arg-methylester per minute at pH 8.0 and 3TT. 
(Specific activities obtained from the Fluka Chemika BioChemika Analytika catalogue I 
1997/1998 produced by Fluka Chemicals, Gillingham, England. The classification of the 
was obtained fforn Proteolytic enzVmes, a practical approach, edited by R. J Beynon 
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& J. S. Bond (1989). fRL PRESS, Oxford). 
Cysteine endopeptidases often have much greater specific activities compared to --oS 
proteasomes. For example: 
a) Papain from Carica papaya - 20 units/mg protein, I unit hydrolyses I ýtmol Bz-Arg-ethýl 
ester per minute at pH 6.2 and 25'C. 
b) Clostripain from Clostridium histolyticum - 100 units/mg, - I unit hydrolyses I ýtrnol Bz- 
Arg-ethyl ester per minute at pH 7.1 and 20C. 
c) Cathepsin B from bovine spleen - 10 units/mg, - I unit hydrolyses I ýtrnol Cbz-Lys-4- 
nitrophenyl ester per minute at pH 5.0 and 25'C. 
One of the main reasons for the low specific activities of 20S proteasomes may be the unusual 
N-terminal catalytic threonine residues. These threonines contain a secondary hydroxyl group 
that is probably not as strong a nucleophile as the primary hydroxyl group of catalytic serine 
residues or the sulfhydryl group of catalytic cysteine residues. The N-terminal location of the 
catalytic threonines may have arisen to increase the nucleophilic nature of the catalytic 
hydroxyl group. This hydroxyl group will be close to the N-terminal (x-amino group that is 
positively charged under physiological conditions. This positive charge will tend to repel the 
hydrogen nucleus of the hydroxyl and attract the electrons from the O-H bond toNk ards the 
oxygen atom. This VAII increase the nucleophilic nature of the oxygen atom. Large complexes 
e. g. 19S regulatory and PA28 complexes combine with the 20S proteasome in cells These 
complexes cause conformational changes that probably ease the entry of substrate molecules, 
The conformational changes may also facilitate the movement of residues surrounding the 
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catalytic threonines to increase the nucleophilic nature of the h%, droxyl groups. 
6.2 - Inhibitors of proteasome complexes 
The peptidase activities of proteasome complexes have been studied using a wide variety of 
protease inhibitors and other compounds. These include peptidyl aldehydes (Rock et al., 1994. 
Vinitsky et al., 1992), the serine protease inhibitors 3,4-dichloroisocoumarin and dilsopropyl 
fluorophosphate (Djaballah et al., 1992, Orlowski et al., 1997), the streptomyces metabolite 
lactacystin (Fenteany et al., 1995) and peptidyl vinyl sulphones (Bogyo et al., 1998). In this 
study, a number of di- and tripeptidyl boronic acids have been shown to be tight-binding 
reversible inhibitors of the 20S proteasome chymotrypsin-like activity. This inhibition is 
apparently exerted via a slow-binding mechanism. Slow binding, inhibition has been 
demonstrated for the peptidyl boronic acid inhibition of certain serine proteases (Kettner et al., 
1988). It has also been shown to occur in some studies investigating the inhibition of the 20S 
proteasome chymotryp si n- like activity by peptidyl alclehydes (Vinitsky et al., 1992). Several 
peptidyl boronic acids exhibited similar Ki values for inhibition of the chymotrypsin-like 
activity of liver and spleen 20S proteasomes. Liver 20S proteasomes contain approximately 
equal amounts of the constitutiVe and IFN-y inducible catalytic subunits, whereas spleen 20S 
proteasomes are predominantly constructed with IFN-y inducible catalytic subunits (Paul 
Brooks. personal communication, Eleuten et al., 1997). Therefore these peptidyl boronic acids 
should cause effective inhibition of the chymotryp si n- like activity of 20S proteasomes, isolated 
from anN, cell or tissue type. 
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6.3 - The peptidyl boronic acids used in this study preferentially inhibited the 
chymotrypsin-like activity of 20S proteasomes 
The peptidyl boronic acids used in this study were designed to inhibit the chymotrypsin-like 
activity of proteasomes and were significantly less effective inhibitors of other 220S proteasome 
activities e. g. trypsin-like and PGPH activities. 3,4-dichloroisocoumarin (DCI) was shown in 
two studies to be more effective against the chymotrypsin-like activity than the trypsin-like or 
PGPH activities. Under certain assay conditions the trypsin-like and PGPH activities were 
stimulated by DCI (Djaballah et al., 1992, Orlowski et al., 1997). Similar effects were 
observed with some of the peptidyl bororUc acids. Lactacystin was shown to be a more potent 
inhibitor of 20S proteasome cleavage after hydrophobic residues compared to basic or acidic 
residues (Fenteany et al., 1995; Bogyo et al., 1998). A number of peptidyl vinyl sulphones 
exhibited a certain degree of specificity towards the chymotrypsin-like activity of proteasonles 
e. g. NLVS and NP-AAF-VS. 
One surprising observation from this study was the fact that peptidyl boronic acids with 
substantially different structures, exhibited Ki values for the I'%-er 20S proteasome 
chymotrypsin-like activity that were within an order of magnitude. For example Bz-Phe- 
boroLeu (17 nM), Cbz-nitroArg-boroLeu (pinacol ester) (39 nM), Cbz-Lys(boc)-boroLeu 
(pinacol ester) (116 nM) and Ph(CH2)6CO-Leu-boroLeu (pinacol ester) (116 n%l). This 
apparent low level of specificity may be related to the observed flexibility of the 20S 
proteasome. Addition of the proteasome substrate Cbz-LLE-N, -\P (0.4 rn%l) caused an 
increase in tile sedimentation coefficient of the 20S proteasome fi-om 17.7S to 19.7S (Djaballah 
et al., 19931). SIDS (0.01%) also caused an increase from 17.7S to '- I 22S and 50 nAl 
KCI 
caused a decrease to 13.9S. 26S proteasonies are known to degrade a wide variety ot'protein 
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substrates in a processive manner. The presence of multiple catalytic siteswrith a broad range 
of specificities and in particular chyrnotrypsin-like catalytic sites with a low level of substrate 
specificity, may ensure that all portions of the protein substrates are digested. 
It should be noted that most of the peptidyl boronic acids used in this study were synthesized 
as racenuc nuxtures containing a nuxture of R or SPI sidechains. The obvious exception is 
Bz-Phe-boroLeu that was synthesized as a chirally pure (P2 sidechain S, PI sidechain R) 
product. It is unlikely that both the R and S arrangements of the PI sidechain give rise to 
inhibitors of equal potency. It is probably the case that one of the two isomers is the active 
inhibitor and therefore the Ki values for chirally pure versions of these active isomers would 
be reduced by a factor of 2. 
More specific and effective inhibitors of the 20S proteasome LLVY activity may be produced 
by linking two peptidyl boronic acid functional groups together via a polar flexible linker. This 
bifunctional inhibitor would be capable of reacting with two catalytic sites at once. This 
approach has been attempted successfully using tripeptidyl aldehyde groups linked to both ends 
of a flexible nondegradable polyoxyethylene polymer of 19-25 monomers (Loidl et al., 1999a). 
An IC50 value of 17 nM was obtained against the chyrnotrypsin-like activity of yeast 20S 
proteasomes (Suc-LLVY-AMC substrate) using al-Nle-Leu-Leu-CO-(PEG)19-25-CO-Leu-Leu- 
Nle-al. The IC5o values for the trypsin-like activity (Bz-FVR-AMC substrate) or the PGPH 
activity (Cbz-LLE-NAP substrate) were greater than 100 W. In a similar manner al-Arg-Val- 
Arg-CO-(PEG)19ý-25-CO-Arg-Val-Arg-aI was the best inhibitor of the trypsin-like activity with 
an IC50 value of 71 nM. The heterobifunctional inhibitor al-Me-Leu-Leu-CO-(PEG)jq. 25-CO- 
Arg-Val-Arg-al was particularly interesting. The ICso values for the chymotrypsin-like and 
trypsin-like activities were 31 and 97 nM respectively. 
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6.4 - Tri-leucine peptidyl boronic acids vvere the most effective inhibitors of the 20S 
proteasome trypsin-like activity 
Cbz-Leu-Leu-boroLeu and the pinacol ester form of this inhibitor, were the most effective 
inhibitors of the liver 20S proteasome trypsin-like activity In a related study Bogyo and 
coworkers (1998) showed that Leu-Leu-Leu-Leu-vinyl sulphone and Bz-Phe-Leu-Leu-Leu- 
vinyl sulphone were the most effective vinyl sulphone inhibitors of the muscle 20S proteasome 
trypsin-like activity. Peptidyl boronic acids with a structure similar to leupeptin (Acetyl-Leu- 
Leu-Arg-al) may prove to be particularly specific inhibitors of the 20S proteasome trypsin-like 
activity (Savory & Rivett, 1993). One research group have developed a specific inhibitor, 
maleoyl-PAla-Val-Arg-al of the yeast 20S proteasome trypsin-like activity (Loidl et al , 
1999b). This inhibitor exhibited anIC50value of 0.5 ýM for the trypsin-I lke activity measured 
with the Bz-FVR-AMC substrate. Corresponding IC50 values for the chyrnotrypsm-like 
activity (Suc-LLVY-AMC substrate) and PGPH activity (Cbz-LLE-NAP substrate) were 
greater than 100 [tM. Crystals of yeast 20S proteasomes soaked with maleoyl-pAla-Val-Arg- 
al were prepared and analysed. The aldehyde functional group was only covalently bound to 
the P2/Pup I catalytic sites. In addition the maleoyl group was covalently linked via an S-C 
bond to Cysll8 ofthe -' subsite. S) This second covalent bond would make the inhibition 
practically irreversible. Asp-28 and Glu-53 appear to be particularly important specificity 
determinants in the SI subunit of the P2 catalytic site (Loidl et al., 1999b, Groll et al., 1997). 
The marnmalian subunits Z and NIIECL I are homologous to the yeast 02 subunit. The Z and 
MECL I subunits contain a Asp-53 and Glu-5 3 residue respeciveh, (Hisamatsu et al., 1996), 
Both subunits contain an Asp-28 residue. Spleen 220S proteasomes that predominantly contain 
MECL I suburflts, have a three times lower specific activity to 40 LN Boc-LSTR-ANIC, than 
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liver 20S proteasomes that contain approx. 50% Z and 50% MECL I subunits. The presence 
of the smaller Asp-53 residue in subunit Z may ease substrate binding leading to an increase 
in catalytic rate. The SI subsites of Z and MECL I contain other polar residues e. g. Cys-31 
and Ifis-3 5 and this polar environment would help to explain the poor inhibitory effect of Cbz- 
Leu-t-butylboroLeu on the liver 20S proteasome trypsin-like activity (section 4.2.3). The 
nature of the residues in the S2 and S3 subsites are also very important. This is Mustrated by 
the relative effectiveness of Cbz-Leu-Leu-boroLeu (pinacol ester) compared to Bz-Val(Ph)- 
boroLeu (pinacol ester) containing the large hydrophobic Val(Ph) P2 residue and PhSO2-Leu- 
boroLeu (pinacol ester) containing the polarS02as part of the group positioned in the S3 
subsite. 
6.5 - Bz-Phe-boroLeu is the best peptidyl boronic acid inhibitor of the liver 20S 
proteasome PGPH activity 
Bz-Phe-boroLeu (compound 1) was the most effective of the limited number of peptidyl 
boronic acids tested against the liver 20S proteasome PGPH activity. Of note was the fact that 
80 nM Bz-Phe-boroLeu caused significant (39%) inhibition of the liver 20S proteasome PGPH 
activity, whilest failing to inhibit the same activity of spleen 20S proteasomes. The 0 I/PRE3 
catalytic subunits of yeast 20S proteasomes are proposed to catalyse the PGPH activity (Dick 
et al., 1998). X-ray crystallographic studies on yeast 20S proteasomes suggested that six 
residues are major constituents of the PI subsite of 0 I/PRE3: Thr-20, Thr-3 1, Thr-3 5, Arg45, 
Ala-49,, Gln-53. The Arg-45 residue that is located at the bottom of the subsite is proposed 
to be a particularly important specificity determinant for these catalytic sites. The mammalian 
subunit homologs of 0 I/PRE3 are Y/6 and LNW2. The sIX important residues are conserved 
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in Y/8 but only AIa49 and Gin-53 are conserved in LNV2. The four changes are listed below 
ir) - Residue Y/5 LNT2 
20 Thr Val 
31 Thr Phe 
35 Thr Ser 
45 Arg Leu 
These changes will increase the hydrophobic nature of the LNV2 SI subsite. These and other 
changes in the S2 and S3 subsites may explain the decreased affinity of Bz-Phe-boroLeu for 
the PGPH catalytic sites of spleen 20S proteasomes. The increased hydrophobicity of the SI 
subsite will presumably inhibit the binding of the Glu residue in Cbz-LLE-NAP, thus helping 
to explain the decrease in specific activity of spleen 20S proteasomes compared to liver 20S 
proteasomes. 
6.6 - Peptidyl boronic acids are useful tools for studying biochemical processes that 
involve protein degradation 
A number of classes of proteasome inhibitor have been used in cell culture experiments. 
Peptidyl aldehydes e. g. Cbz-Leu-Leu-norVal-al and Cbz-Leu-Leu-Leu-al have been used to 
study the role of proteasomes in producing antigenic peptides for presentation on MHC class 
I molecules (Rock et al., 1994; Grant et al., 1995; Hughes et al., 1996; Vinitsky et al., 1997). 
They have also helped to elucidate the role of proteasome complexes in degrading IxBct and 
the role of the human cytornegalovirus protein US 11, in stimulating the degradation of MIFIC 
class I heavy chains by the 26S proteasomes (Alkalay et al., 1995; Wiertz et al., 1996b). The 
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degradation of the latter substrate was proposed to be performed on the cytosolic face of the 
encloplasmic reticulum. However, peptidyl aldehydes are readily reversible inhibitors that need 
to be used at micromolar concentrations in these cell culture experiments. They also inhibit 
calpains and lysosomal cysteine proteases e. g. cathepsin B (Rock et al., 1994). The 
streptomyces metabolite lactacystin inhibits cell cycle progression and the production of 
antigenic peptides (Fenteany et al., 1995; Craiu et al., 1997). Experiments using [H] 
lactacystin showed that the only radiolabelled cell components were proteasome complexes 
(Fenteany et al., 1995). Although lactacystin is cell permeable and apparently very specific, 
it is routinuely used at micromolar concentrations making the modification of other proteases 
more likely. For example a cathepsin A-like activity was significantly inhibited by 1-5 gM 
lactacystin (Ostrowska et al., 1997). This inhibition was dependent on the preincubation of 
lactacystin at pH 8.0 to allow production of the P-lactone species, before conducting the 
assays at pH 5.5. 
Peptidyl boronic acids will be a useful alternative to peptidyl aldehydes, lactacystin and 
peptidyl vinyl sulphones in cell culture experiments. These inhibitors cause significant 
inhibition of 20S and 26S proteasomes at nanomolar (e. g. 10-100 W) concentrations. Adams 
and coworkers (1998) detennined the Ki for inhibition of the 20S proteasome LLVY activity 
by 2-pyrazinylcarbonyl-Phe-boroLeu to be 0.62 nM. The corresponding Ki values for 
inhibition of the serine proteases human chymotrypsin and human cathepsin G were 320 and 
630 nN4 respectively. In this study, I have shown that proteasome complexes are the only tight- 
binding cellular target for 100 nN4 
[3 H] Phenacetyl-Leu-Leu-boroLeu. When using I ýtM [3 If] 
Phenacetyl-Leu-Leu-boroLeu, an additional small peak of radioactivity was observed in 
fraction 17 (Figure 5.3). This peak corresponded vvith a peak of Suc-LLVY-AMC hydrolysing 
activity, observed in assays conducted in the absence of SDS. The nature of these additional 
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target(s) was not investigated. One or more of these targets could be the ubiquitously 
expressed 4- and m-calpains. These Ca 2+ -dependent cysteine proteases have been proposed 
to play roles in integrin-mediated signal transduction and cell cycle control (Arthur et al., 
1998). Previous studies have shown that calpain inhibitor I (acetyl-Leu-Leu-Nle-al) and 
calpain inhibitor 11 (acetyl-Leu-Leu-Met-al) inhibit the chymotrypsin-like activity of 20S 
proteasomes (Vinitsky et al., 1992). Therefore inhibition of calpains by closely related peptidyl 
boronic acids is a likely occurrence in cells. Antibodies to ýt- and m-calpains are commercially 
available and these could be used to determine whether calpains are a target of ['H] 
Phenacetyl-Leu-Leu-boroLeu. 
Peptidyl boronic acids are useful for studying the degradation of individual proteins. The 
degradation of endogenously expressed glucocorticoid receptor has been shown to be 
inhibited by Bz-Phe-boroLeu in Rat-I fibroblast cells (Tavner, S. & Mason, G. G. F., 
unpublished observations). The nuclear localisation signal of the receptor is masked by the 
binding of the molecular chaperone HSP90. The binding of an appropriate steriod hormone 
causes the release of HSP90 and the exposure of the nuclear localisation signal. The steriod 
hormone-glucocorticoid receptor complex then translocates into the nucleus, to activate 
transcription of specific genes (Alberts et al., 1994). Bz-Phe-boroLeu caused a dose- 
dependent accumulation of the glucocorticoid receptor. The results in Table 5.4 show that a 
number of peptidyl boronic acids inhibit the production of P-amyloid in cultured cells. The Ki 
values for inhibition of the LLVY activity of purified 20S proteasomes compared well with the 
IC50 values for inhibition of 0-amyloid production and NF-KB activation in cultured cefls. 26S 
proteasomes are thought to stimulate the production of active p50-p65 NF-1KB complexes, 
through degrading the inhibitory IKB proteins and catalysing the co-translational processing 
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reaction required for the production of mature p50 subunits (Alkalay et al., 1995; Lin et al., 
1998b). Inhibition of proteasome complexes by peptidyl boronic acids is thought to directly 
or indirectly inhibit the y-secretase activity that is required for production of O-amyloid. The 
production of p3 by the ot- and y-secretases is also inhibited by the peptidyl boronic acids 
(Christie et al., 1999). In contrast the peptidyl boronic acids have little effect on the 
production of sAPPa produced by the a-secretase or the soluble APP protein produced by the 
P-secretase. 
6.7 - Determining the peptidyl boronic acid modified catalytic subunits of 20S 
proteasomes 
A number of experiments were carried out to attempt to determine which catalytic P-subunits 
were modified by Cbz-Leu-Leu-boroLeu and ['H] Phenacetyl-Leu-Leu-boroLeu. 
Unfortunately the association of these peptidyl boronic acids with the catalytic residues e. g. 
catalytic N-terminal threonine, did not survive the conditions required to separate the subunits 
by FIPLC or SDS-PAGE. However, competition experiments showed that Z-LLL-VS could 
block binding of [3 H] Phenacetyl-Leu-Leu-boroLeu to the chyrnotrypsin-like catalytic sites. 
Studies with a number of peptidyl vinyl sulphones showed that the catalytic subunits X/MB I 
and LNW7 predominantly hydrolyse the chymotrypsin-like substrates (Bogyo et al., 1998). 
PAL peptidyl boronic acids contain a reactive group e. g. phenylazide or benzophenone that 
is activated by U. V. light. The PAL peptidyl boronic acids were found to bind tightly to the 
chymotrypsin-like catalytic sites of 20S proteasomes, during dialysis experiments. UN. 
irradiation could be used to facilitate the production of a separate covalent bond between the 
PAL peptidyl boronic acid and the residues surrounding the catalytic site. This covalent bond 
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may survive HPLC separation of the 20S proteasome subunits. Catalytic subunits e. g. X/MB I 
or LUT7 could then be dialysed against a suitable buffer before digestion with trypsin. The 
tryptic fragments would then be separated using aC 18 HPLC column. A shift in the elution 
position of a peptide, when compared to the peptide map of an unmodified subunit, would 
indicate PAL peptidyl boronic acid modification of this peptide. Sequencing of the appropriate 
unmodified and modified peptides could then be used to identify the modified residue(s). 
These residues would not necessarily be the catalytic threonine because the photoactivatable 
group is located away from the boronic acid functional group. 
6.8 - Use of inhibitors to determine the roles of the various proteasome complexes in 
protein degradation 
Highly effective inhibitors of proteasomes may facilitate a greater understanding of how the 
various proteasome complexes operate together in cellular protein degradation. The PA28 
complex is known to stimulate the chymotrypsin-fike, trypsin-like and PGPH activities of 20S 
proteasomes (Kuehn & Dahimann, 1996). Binding of the PA28 complex to the 20S 
proteasome causes an increase in the diversity of peptides produced, during the digestion of 
synthetic 25 amino acid peptides (Groettrup et al., 1995). Very effective peptidyl boronic 
acids are useful tools because they open up the possibility of differentially inhibiting 
proteasome complexes. For example a number of peptidyl boronic acids may be very effective 
against the 20S proteasome and PA28-20S proteasome activities but not against the 26S 0 
proteasome. This will help investigators to determine whether the peptides produced by the 
26S proteasome, are often trimmed before being incorporated into MHC class I molecules. 
Specific inhibitors of hybrid proteasome activities would enable researchers to determine the 
role of this complex in protein degradation. A specific inhibitor of PA28-20S proteasome 
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activities e. g. chymotrypsin-like activity could also be used to ascertain whether any protein 
substrates are only degraded by the PA28-20S proteasome. This degradation would probably 
occur with the assistance of molecular chaperone molecules to unfold the protein before 
degradation. 
6.9 - Use of peptidyl boronic acids as therapeutic agents 
D- 
1%. ecently reported studies by scientists at Proscript Inc. (Palombella et al., 1998; Grisharn et 
al., 1999) showed that 2-pyrazinylcarbonyl-Phe-boroLeu (PS-341) and another dipeptidyl 
boronic acid named PS-273, could inhibit the degradation of IrBa and the activation of NF-KB 
in cultured cells. The expression of proinflammatory mediators such as cell surface adhesion 
molecules and cytokines could be blocked by either of these compounds. In further in vivo 
studies polyarthritis was induced in lewis rats by injection of a peptidoglycan/polysaccharide 
solution, derived from Group A streptococcal bacterial cell walls (Palombella et al., 1998). 
Rats received either 0 or 0.3 mg/kg 2-pyrazinylcarbonyi-Phe-boroLeu by oral administration 
each day from day one of the 28 day trial. The peptidyl boronic acid was shown to 
substantiafly reduce the redness, swelling and deformity ofjoints, even if the administration of 
the compound was delayed for 7 days. Histological analysis of the joints from untreated 
arthritic, 2-pyrazinylcarbonyl-Phe-boroLeu treated arthritic and normal healthy rats showed 
that the compound prevented many of the characteristic changes associated with the 
polyarthritis (Palombella et al., 1998). 
In a recent study, 10 pM Cbz-Leu-Leu-Leu-al was shown to promote the apoptosis of chronic 
lymphocytic leukemic (CLL) lymphocytes (Chandra et al., 1998). Significant increases in the 
rate of cell apoptosis were observed with CLL lymphocytes that (i) exhibited relatively high 
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basal levels of apoptosis, (ii) exhibited low basal apoptosis levels that were strongly increased 
in response to glucocorticoid treatment and (iii) exhibited low basal and low glucocorticold 
induced levels of apoptosis. Similar results were obtained with lactacystin. Further 
experiments showed that Cbz-Leu-Leu-Leu-al caused an increase in caspase activity. It was 
proposed that Cbz-Leu-Leu-Leu-al drastically reduced the production of active NF-YB by 
inhibiting the 26S proteasome. Lack of active NF-KB was suggested to lead to a reduction in 
mitochondrial membrane potential, release of cytochrome c and caspase activation. Cbz-Leu- 
Leu-Leu-al (10 ýM) was shown to cause a 2-fold lower level of apoptosis in normal 
lymphocytes with T-cells being most effected (Chandra et al., 1998). 20 ýiM Cbz-Leu-Leu- 
Leu-al was shown in a separate study to induce apoptosis in a prostate carcinoma ceU fine (Lin, 
et al., 1998a). 2-pyrazinylcarbonyl-Phe-boroLeu (PS-341) has recently been reported to 
possess antiturnour activity (Adams et al., 1999). This peptidyl boronic acid was shown to 
inhibit the growth of 60 different tumour cell fines at low e. g. 7 nM concentrations. Further 
studies suggested that PS-341 caused the accumulation of the cychn-dependent kinase inhibitor 
protein P21 , in the 
PC-3 prostate turnour cell line. This lead to the inhibition of cyclin- 
dependent kinase 4 and the arrest of the cell cycle at the G2-M transition. PS-341 was shown 
to stimulate caspase activity and apoptosis in growth-arrested tumour cells. Direct injection 
of PS-341 into the blood stream of tumour-bearing mice at a level of 1.0 mg/kg body weight, 
once weekly for 4 weeks caused an approximately 60% decrease in tumour volume. This 
level 
of PS-341 treatment was apparently well-tolerated by non-tumour cells with no adverse effects 
being noted. [14C] PS-341 was shown to concentrate in the adrenals, kidney cortex, liver, 
prostate and spleen. Low levels of radioactivity were observed in e. g. skin and muscle tissue 
with very little penetration of the radiolabelled inhibitor into 




Peptidyl boronic acids are important new drugs in the treatment of various forms of cancer and 
the effects of arthritis. Further studies on elucidatin-g, the exact mechan'sms by which tumour 
cells are stimulated to go into apoptosis or the symptoms of arthritis are elevated may guide 
scientists towards new strategies for treating these and other diseases. 
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